US20220056073A1 - Peptidomimetic proteasome inhibitors - Google Patents
Peptidomimetic proteasome inhibitors Download PDFInfo
- Publication number
- US20220056073A1 US20220056073A1 US17/521,328 US202117521328A US2022056073A1 US 20220056073 A1 US20220056073 A1 US 20220056073A1 US 202117521328 A US202117521328 A US 202117521328A US 2022056073 A1 US2022056073 A1 US 2022056073A1
- Authority
- US
- United States
- Prior art keywords
- monocyclic
- bicyclic
- alkyl
- ethyl
- cen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079156 Proteasome inhibitor Drugs 0.000 title description 20
- 239000003207 proteasome inhibitor Substances 0.000 title description 20
- 239000000816 peptidomimetic Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 233
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 20
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 230000036281 parasite infection Effects 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 13
- 208000035475 disorder Diseases 0.000 claims abstract description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 11
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 11
- 206010062016 Immunosuppression Diseases 0.000 claims abstract description 11
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 11
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 11
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 11
- 210000000056 organ Anatomy 0.000 claims abstract description 10
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 7
- 208000031888 Mycoses Diseases 0.000 claims abstract description 7
- 230000001900 immune effect Effects 0.000 claims abstract description 7
- 201000006938 muscular dystrophy Diseases 0.000 claims abstract description 7
- 125000002950 monocyclic group Chemical group 0.000 claims description 230
- 238000000034 method Methods 0.000 claims description 154
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 108
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 72
- 125000002619 bicyclic group Chemical group 0.000 claims description 60
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 59
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 50
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 150000002367 halogens Chemical class 0.000 claims description 50
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 48
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 41
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 41
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 25
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 24
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 24
- 229940002612 prodrug Drugs 0.000 claims description 24
- 239000000651 prodrug Substances 0.000 claims description 24
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims description 23
- 239000012453 solvate Substances 0.000 claims description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 14
- 125000003386 piperidinyl group Chemical group 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 11
- 201000004792 malaria Diseases 0.000 claims description 10
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 7
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 claims description 6
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 239000003098 androgen Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 claims description 6
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims description 3
- 241000239223 Arachnida Species 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000030002 adult glioblastoma Diseases 0.000 claims description 3
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 244000000013 helminth Species 0.000 claims description 3
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 244000000040 protozoan parasite Species 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000004881 Amebiasis Diseases 0.000 claims description 2
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 2
- 206010001980 Amoebiasis Diseases 0.000 claims description 2
- 208000024699 Chagas disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000008953 Cryptosporidiosis Diseases 0.000 claims description 2
- 206010011502 Cryptosporidiosis infection Diseases 0.000 claims description 2
- 206010061802 Cyclosporidium infection Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000004554 Leishmaniasis Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 241000243985 Onchocerca volvulus Species 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 2
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 201000002641 cyclosporiasis Diseases 0.000 claims description 2
- 201000006592 giardiasis Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 230000000527 lymphocytic effect Effects 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 208000003177 ocular onchocerciasis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 10
- 0 *C([1*])(C[Y]C[4*])N(C)C(=O)[W]C[3*] Chemical compound *C([1*])(C[Y]C[4*])N(C)C(=O)[W]C[3*] 0.000 description 306
- 238000002360 preparation method Methods 0.000 description 147
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 140
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 139
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 139
- -1 bicyclo[1.1.1]pentyl Chemical group 0.000 description 92
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 52
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 36
- 239000000243 solution Substances 0.000 description 36
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 30
- 150000001412 amines Chemical class 0.000 description 29
- 239000000203 mixture Substances 0.000 description 29
- 239000002904 solvent Substances 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000007821 HATU Substances 0.000 description 22
- 230000001404 mediated effect Effects 0.000 description 22
- 238000005859 coupling reaction Methods 0.000 description 21
- 230000008878 coupling Effects 0.000 description 20
- 238000010168 coupling process Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- 241000223960 Plasmodium falciparum Species 0.000 description 10
- 229930101531 artemisinin Natural products 0.000 description 10
- 229960001467 bortezomib Drugs 0.000 description 10
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 10
- 244000045947 parasite Species 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 7
- 229960004191 artemisinin Drugs 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- VSAHTKMEBXUMMR-JXFKEZNVSA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-N',N'-diethyl-2-(4-methylpentanoylamino)butanediamide Chemical compound C(N(C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(C=C1)F)CC)C VSAHTKMEBXUMMR-JXFKEZNVSA-N 0.000 description 6
- IIVWHGMLFGNMOW-UHFFFAOYSA-N C[C](C)C Chemical compound C[C](C)C IIVWHGMLFGNMOW-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000224016 Plasmodium Species 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- FDJDBBPBJMXWMT-LEDOBFOHSA-N (2S)-2-(benzylcarbamoylamino)-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-oxobutanamide Chemical compound C(C1=CC=CC=C1)NC(N[C@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)CC(=O)N1[C@H](CCCC1)CC)=O FDJDBBPBJMXWMT-LEDOBFOHSA-N 0.000 description 5
- HWASOVPEMZTDHW-KSNOWIBYSA-N (2S)-N-[(1S)-1-(1H-benzimidazol-2-yl)ethyl]-2-(3-methylbutylsulfonylamino)-4-oxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butanamide Chemical compound N1C(=NC2=C1C=CC=C2)[C@H](C)NC([C@H](CC(N1[C@H](CCC1)C1=CC=CC=C1)=O)NS(=O)(=O)CCC(C)C)=O HWASOVPEMZTDHW-KSNOWIBYSA-N 0.000 description 5
- MZGRUNZFTAAACM-FTRWYGJKSA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxo-2-[(3-propan-2-yl-1,2,4-oxadiazol-5-yl)amino]butanamide Chemical compound CC(C)C1=NOC(N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)N[C@@H](C)C2=NC=C(N2)C2=C(F)C=C(F)C=C2)=N1 MZGRUNZFTAAACM-FTRWYGJKSA-N 0.000 description 5
- PIWULMOLVXIGTP-WNPSOCMYSA-N 5-methyl-N-[(2S)-4-(2-methylpiperidin-1-yl)-1,4-dioxo-1-[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]butan-2-yl]-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCCC1C)NC(=O)C1=NOC(C)=C1)C1=NC=C(N1)C1=CC=CC=C1 PIWULMOLVXIGTP-WNPSOCMYSA-N 0.000 description 5
- NOUAWKFJOOOLIU-LEDOBFOHSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 NOUAWKFJOOOLIU-LEDOBFOHSA-N 0.000 description 5
- KCGBBBYBYMBRPE-SPEDKVCISA-N C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)OCC1=CC=CC=C1)C1=NC2=C(F)C=CC=C2N1 Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)OCC1=CC=CC=C1)C1=NC2=C(F)C=CC=C2N1 KCGBBBYBYMBRPE-SPEDKVCISA-N 0.000 description 5
- FRUVASLZOBXGQW-UEXGIBASSA-N N-[(2S)-1-[[(1R)-1-(1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4,4-dimethylpentanamide Chemical compound C[C@@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)CCC(C)(C)C)C1=NC2=CC=CC=C2N1 FRUVASLZOBXGQW-UEXGIBASSA-N 0.000 description 5
- KTUCEWAXZNUKAG-KSNOWIBYSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)N[C@@H](C)C1=NC2=CC=CC=C2N1 KTUCEWAXZNUKAG-KSNOWIBYSA-N 0.000 description 5
- BQBKRMRVYVQKHW-FTRWYGJKSA-N N-[(2S)-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-3,3-dimethylcyclobutane-1-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1CC(C)(C)C1)C1=NC2=C(F)C=CC=C2N1 BQBKRMRVYVQKHW-FTRWYGJKSA-N 0.000 description 5
- GZVCLEFJDGWKDN-ZWOKBUDYSA-N N-[(2S)-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4,4-dimethylpentanamide Chemical compound FC1=CC=CC=2NC(=NC=21)[C@H](C)NC(=O)[C@H](CC(=O)N1[C@H](CCCC1)C)NC(CCC(C)(C)C)=O GZVCLEFJDGWKDN-ZWOKBUDYSA-N 0.000 description 5
- LKCWUVPAIGIRAW-ZWOKBUDYSA-N N-[(2S)-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound FC1=CC=CC=2NC(=NC=21)[C@H](C)NC(=O)[C@H](CC(=O)N1[C@H](CCCC1)C)NC(CCC(C)C)=O LKCWUVPAIGIRAW-ZWOKBUDYSA-N 0.000 description 5
- IZVSPYDXLRBIHK-UVFQYZLESA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)c1cc(C)on1)c1ncc([nH]1)-c1ccc(F)cc1F IZVSPYDXLRBIHK-UVFQYZLESA-N 0.000 description 5
- PDTJXGMSWIWKRY-AVRDEDQJSA-N N-[(2S)-4-(azepan-1-yl)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCCCC1)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 PDTJXGMSWIWKRY-AVRDEDQJSA-N 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- UQXOYEZZEOEASY-QYWGDWMGSA-N (2S)-2-[(2-cyclopropylacetyl)amino]-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound C1(CC1)CC(=O)N[C@H](C(=O)N[C@@H](C)C=1NC(=CN=1)C1=C(C=C(C=C1)F)F)CC(=O)N1[C@H](CCCC1)C UQXOYEZZEOEASY-QYWGDWMGSA-N 0.000 description 4
- SXIOFHACCLTDLE-YDHSSHFGSA-N (2S)-2-[[benzyl(methyl)carbamoyl]amino]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound C(C1=CC=CC=C1)N(C(N[C@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)CC(=O)N1[C@H](CCCC1)C)=O)C SXIOFHACCLTDLE-YDHSSHFGSA-N 0.000 description 4
- UNRFEKFJCNCMJN-DCGLDWPTSA-N (2S)-2-amino-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound N[C@H](C(=O)N[C@@H](C)C=1NC(=CN=1)C1=C(C=C(C=C1)F)F)CC(=O)N1[C@H](CCCC1)C UNRFEKFJCNCMJN-DCGLDWPTSA-N 0.000 description 4
- PHTSPJMISUZXNG-WFXMLNOXSA-N (2S)-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-2-[[methyl(2-methylpropyl)carbamoyl]amino]-4-oxobutanamide Chemical compound C(C)[C@@H]1N(CCCC1)C(C[C@@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)NC(=O)N(C)CC(C)C)=O PHTSPJMISUZXNG-WFXMLNOXSA-N 0.000 description 4
- GWZVFWAXTCSSHR-BXWFABGCSA-N (2S)-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-oxo-2-[(3-propan-2-yl-1,2,4-oxadiazol-5-yl)amino]butanamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(=NO1)C(C)C)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 GWZVFWAXTCSSHR-BXWFABGCSA-N 0.000 description 4
- HWASOVPEMZTDHW-DCEDVJGZSA-N (2S)-N-[(1R)-1-(1H-benzimidazol-2-yl)ethyl]-2-(3-methylbutylsulfonylamino)-4-oxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butanamide Chemical compound N1C(=NC2=C1C=CC=C2)[C@@H](C)NC([C@H](CC(N1[C@H](CCC1)C1=CC=CC=C1)=O)NS(=O)(=O)CCC(C)C)=O HWASOVPEMZTDHW-DCEDVJGZSA-N 0.000 description 4
- ZANWOEPOJVJTCP-YDHSSHFGSA-N (2S)-N-[(1S)-1-(5-benzyl-1H-imidazol-2-yl)ethyl]-2-[(2-cyclopropylacetyl)amino]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound C(C1=CC=CC=C1)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NC(CC1CC1)=O)=O ZANWOEPOJVJTCP-YDHSSHFGSA-N 0.000 description 4
- WABFMAZIYIOGHT-FIKGOQFSSA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-2-[(3-methyl-2-oxobutyl)amino]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NCC(C(C)C)=O)=O WABFMAZIYIOGHT-FIKGOQFSSA-N 0.000 description 4
- VYILQPCOFCFSDG-JXQFQVJHSA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-2-[(4-methylphenyl)sulfonylamino]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NS(=O)(=O)C1=CC=C(C=C1)C)=O VYILQPCOFCFSDG-JXQFQVJHSA-N 0.000 description 4
- LDDNJGRFHCRAGY-FIKGOQFSSA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-2-(2-methylpropylsulfonylamino)-4-oxobutanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NS(=O)(=O)CC(C)C)=O LDDNJGRFHCRAGY-FIKGOQFSSA-N 0.000 description 4
- WZLARRJWSGOCQS-JXQFQVJHSA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxo-2-(phenacylamino)butanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NCC(C1=CC=CC=C1)=O)=O WZLARRJWSGOCQS-JXQFQVJHSA-N 0.000 description 4
- ZBRRGMDXKQPKAD-JXFKEZNVSA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-N'-methyl-2-(4-methylpentanoylamino)-N'-propan-2-ylbutanediamide Chemical compound CC(CCC(=O)N[C@@H](CC(=O)N(C(C)C)C)C(=O)N[C@@H](C)C1=NC=C(N1)C1=CC=C(C=C1F)F)C ZBRRGMDXKQPKAD-JXFKEZNVSA-N 0.000 description 4
- HWASOVPEMZTDHW-DUXSLQFZSA-N (2S)-N-[1-(1H-benzimidazol-2-yl)ethyl]-2-(3-methylbutylsulfonylamino)-4-oxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butanamide Chemical compound N1C(=NC2=C1C=CC=C2)C(C)NC([C@H](CC(N1[C@H](CCC1)C1=CC=CC=C1)=O)NS(=O)(=O)CCC(C)C)=O HWASOVPEMZTDHW-DUXSLQFZSA-N 0.000 description 4
- RHDDFONCBKNYCI-QUJCMNEKSA-N (2S,3R)-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-2-[3-(4-fluorophenyl)propanoylamino]-3-hydroxybutanamide Chemical compound FC1=CC=CC=2NC(=NC=21)[C@H](C)NC([C@H]([C@@H](C)O)NC(CCC1=CC=C(C=C1)F)=O)=O RHDDFONCBKNYCI-QUJCMNEKSA-N 0.000 description 4
- XNZBEYWUKUKCNX-FZMZJTMJSA-N (3S)-4-[[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid Chemical compound C(C)(C)(C)OC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C=1NC(=CN=1)C1=C(C=CC=C1)F XNZBEYWUKUKCNX-FZMZJTMJSA-N 0.000 description 4
- ZJUVCCVHIREGQR-ROUUACIJSA-N 3-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-1-(4,4-dimethylpentanoylamino)-1-[2-[(2S)-2-methylpiperidin-1-yl]-2-oxoethyl]urea Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC(=O)N(NC(CCC(C)(C)C)=O)CC(=O)N1[C@H](CCCC1)C ZJUVCCVHIREGQR-ROUUACIJSA-N 0.000 description 4
- JRXBVPBVHHAWFC-AJSBUHFISA-N 5,5,5-trifluoro-N-[(2S)-1-[[(1S)-1-(1-methylbenzimidazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]pentanamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=CC=CC=C2N1C JRXBVPBVHHAWFC-AJSBUHFISA-N 0.000 description 4
- YUKJTXBNNRPQHU-UHFFFAOYSA-N CC(C)C(C)C.CC(C)CC(=O)O.CC(C)CC(=O)OCC1=CC=CC=C1 Chemical compound CC(C)C(C)C.CC(C)CC(=O)O.CC(C)CC(=O)OCC1=CC=CC=C1 YUKJTXBNNRPQHU-UHFFFAOYSA-N 0.000 description 4
- LFSCEHVBOOZTNF-ZWOKBUDYSA-N CN(CCC(=O)N[C@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)CC(=O)N1[C@H](CCCC1)CC)C Chemical compound CN(CCC(=O)N[C@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)CC(=O)N1[C@H](CCCC1)CC)C LFSCEHVBOOZTNF-ZWOKBUDYSA-N 0.000 description 4
- UJVULQBSJGQYCG-OKILKGOBSA-N C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C1=NC2=C(F)C=CC=C2N1 Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C1=NC2=C(F)C=CC=C2N1 UJVULQBSJGQYCG-OKILKGOBSA-N 0.000 description 4
- MWADTQCJFZJHBG-MOPGFXCFSA-N C[C@H]1CCCCN1C(=O)CN(NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)CN(NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 MWADTQCJFZJHBG-MOPGFXCFSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- DQLJNLJFBOTJQT-IDZSKIIJSA-N FC1=C(CNC([C@H](C)N(C([C@H](CC(=O)N2C(CCCC2)C)NC(=O)C2=NOC(=C2)C)=O)C)=O)C=CC(=C1)F Chemical compound FC1=C(CNC([C@H](C)N(C([C@H](CC(=O)N2C(CCCC2)C)NC(=O)C2=NOC(=C2)C)=O)C)=O)C=CC(=C1)F DQLJNLJFBOTJQT-IDZSKIIJSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- SZMXSBGHLUQRFI-PXNSSMCTSA-N N-[(2S)-1-(1H-benzimidazol-2-ylmethylamino)-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)NCC1=NC2=CC=CC=C2N1 SZMXSBGHLUQRFI-PXNSSMCTSA-N 0.000 description 4
- KTUCEWAXZNUKAG-DUXSLQFZSA-N N-[(2S)-1-[1-(1H-benzimidazol-2-yl)ethylamino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)NC(C)C1=NC2=CC=CC=C2N1 KTUCEWAXZNUKAG-DUXSLQFZSA-N 0.000 description 4
- BYVNONMCPNXACM-MKXFTGRQSA-N N-[(2S)-1-[1-(1H-benzimidazol-2-yl)ethylamino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound CC(NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1=NOC(C)=C1)C1=NC2=CC=CC=C2N1 BYVNONMCPNXACM-MKXFTGRQSA-N 0.000 description 4
- KZNMEAZTJLUWIP-SXUUOERCSA-N N-[(2S)-1-[1-(1H-benzimidazol-2-yl)ethylamino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound CC(NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1=NOC(C)=C1)C1=NC2=CC=CC=C2N1 KZNMEAZTJLUWIP-SXUUOERCSA-N 0.000 description 4
- KTUCEWAXZNUKAG-DCEDVJGZSA-N N-[(2S)-1-[[(1R)-1-(1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)N[C@H](C)C1=NC2=CC=CC=C2N1 KTUCEWAXZNUKAG-DCEDVJGZSA-N 0.000 description 4
- TZPOFCNANWJIOI-YUXAGFNASA-N N-[(2S)-1-[[(1S)-1-(1,3-benzoxazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-5,5,5-trifluoropentanamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=CC=CC=C2O1 TZPOFCNANWJIOI-YUXAGFNASA-N 0.000 description 4
- ZSZHFLQXTZEGAG-KSNOWIBYSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-4,4-dimethylpentanamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCC(C)(C)C)C1=NC2=CC=CC=C2N1 ZSZHFLQXTZEGAG-KSNOWIBYSA-N 0.000 description 4
- FNBQQAPJLQSYMR-WFXMLNOXSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)N[C@@H](C)C1=NC2=CC=CC=C2N1 FNBQQAPJLQSYMR-WFXMLNOXSA-N 0.000 description 4
- AQOQQMKXPNYORK-MDKPJZGXSA-N N-[(2S)-1-[[(1S)-1-(4,6-difluoro-1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-ethylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)N[C@@H](C)C1=NC2=C(F)C=C(F)C=C2N1 AQOQQMKXPNYORK-MDKPJZGXSA-N 0.000 description 4
- WBQUIGNGXZSNQP-DMUIAEAWSA-N N-[(2S)-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-2-propan-2-ylcyclopropane-1-carboxamide Chemical compound CC(C)C1CC1C(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 WBQUIGNGXZSNQP-DMUIAEAWSA-N 0.000 description 4
- LZDSLZQSKVRQNC-FIKGOQFSSA-N N-[(2S)-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]spiro[3.3]heptane-2-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1CC2(CCC2)C1)C1=NC2=C(F)C=CC=C2N1 LZDSLZQSKVRQNC-FIKGOQFSSA-N 0.000 description 4
- LDPPMGNQTYLMTL-XUEUYAKLSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-1,4-dioxo-4-[(2R)-2-(trifluoromethyl)piperidin-1-yl]butan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C(F)(F)F)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 LDPPMGNQTYLMTL-XUEUYAKLSA-N 0.000 description 4
- ORYDTPFKKMHDQB-QFMFQJCFSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1=NOC(C)=C1)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 ORYDTPFKKMHDQB-QFMFQJCFSA-N 0.000 description 4
- BESIJTRUWYWFIC-LEDOBFOHSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-ethylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 BESIJTRUWYWFIC-LEDOBFOHSA-N 0.000 description 4
- SSHBVPFXCOKGLY-HOIFWPIMSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-3,3-dimethylcyclobutane-1-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1CC(C)(C)C1)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 SSHBVPFXCOKGLY-HOIFWPIMSA-N 0.000 description 4
- LQTSYCGLLHODCR-SPEDKVCISA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4,4-dimethylpentanamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)CCC(C)(C)C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 LQTSYCGLLHODCR-SPEDKVCISA-N 0.000 description 4
- GNLAMNWFQCZAOS-QYWGDWMGSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]cyclobutanecarboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1CCC1)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 GNLAMNWFQCZAOS-QYWGDWMGSA-N 0.000 description 4
- LJZBHZANXFASOK-FIKGOQFSSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(3S)-3-methylmorpholin-4-yl]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCOC[C@@H]1C)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 LJZBHZANXFASOK-FIKGOQFSSA-N 0.000 description 4
- FXCVMTOHHXATLP-KNBMTAEXSA-N N-[(2S)-1-[[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1=NOC(C)=C1)C1=NC=C(N1)C1=C(F)C=CC=C1 FXCVMTOHHXATLP-KNBMTAEXSA-N 0.000 description 4
- NCWYPRFZGNPVTE-MDKPJZGXSA-N N-[(2S)-4-[(2S)-2-ethylpiperidin-1-yl]-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]-3,3-dimethylcyclobutane-1-carboxamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 NCWYPRFZGNPVTE-MDKPJZGXSA-N 0.000 description 4
- ZJYFIQDCJQOIPO-WFXMLNOXSA-N N-[(2S)-4-[(2S)-2-ethylpiperidin-1-yl]-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]-4,4-dimethylpentanamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 ZJYFIQDCJQOIPO-WFXMLNOXSA-N 0.000 description 4
- OMALWNKWJHNTPD-BXWFABGCSA-N N-[(2S)-4-[(2S)-2-ethylpiperidin-1-yl]-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=NOC(C)=C1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 OMALWNKWJHNTPD-BXWFABGCSA-N 0.000 description 4
- YSCWCOLERSFISX-ZWOKBUDYSA-N N-[(2S)-4-[(2S)-2-ethylpiperidin-1-yl]-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]morpholine-4-carboxamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCOCC1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 YSCWCOLERSFISX-ZWOKBUDYSA-N 0.000 description 4
- LOYLTXQXZWVEMZ-WFXMLNOXSA-N N-[(2S)-4-[(2S)-2-ethylpiperidin-1-yl]-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]piperidine-1-carboxamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCCCC1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 LOYLTXQXZWVEMZ-WFXMLNOXSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000000078 anti-malarial effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- AXOOGGUQLYTQAX-UWJYYQICSA-N benzyl (3S)-4-[[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoate Chemical compound C(C)(C)(C)OC(=O)N[C@@H](CC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](C)C=1NC(=CN=1)C1=C(C=CC=C1)F AXOOGGUQLYTQAX-UWJYYQICSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- VUIOYOVWNBPXPH-ZETCQYMHSA-N (1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]ethanamine Chemical compound FC1=C(C=CC=C1)C1=CN=C(N1)[C@H](C)N VUIOYOVWNBPXPH-ZETCQYMHSA-N 0.000 description 3
- LPWHKHKVTKDHHE-YFKPBYRVSA-N (1s)-1-(4-fluoro-1h-benzimidazol-2-yl)ethanamine Chemical compound C1=CC(F)=C2NC([C@@H](N)C)=NC2=C1 LPWHKHKVTKDHHE-YFKPBYRVSA-N 0.000 description 3
- JCNDDYWSRQEGOF-FIKGOQFSSA-N (2S)-2-(1,3-benzothiazol-2-ylamino)-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-oxobutanamide Chemical compound S1C(=NC2=C1C=CC=C2)N[C@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)CC(=O)N1[C@H](CCCC1)CC JCNDDYWSRQEGOF-FIKGOQFSSA-N 0.000 description 3
- DYGSYESCHKJXCG-FIKGOQFSSA-N (2S)-2-(1,3-benzoxazol-2-ylamino)-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-oxobutanamide Chemical compound O1C(=NC2=C1C=CC=C2)N[C@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)CC(=O)N1[C@H](CCCC1)CC DYGSYESCHKJXCG-FIKGOQFSSA-N 0.000 description 3
- FXYLHBWFDTYHAJ-HOIFWPIMSA-N (2S)-2-(1,3-benzoxazol-2-ylamino)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound O1C(=NC2=C1C=CC=C2)N[C@H](C(=O)N[C@@H](C)C=1NC(=CN=1)C1=C(C=C(C=C1)F)F)CC(=O)N1[C@H](CCCC1)C FXYLHBWFDTYHAJ-HOIFWPIMSA-N 0.000 description 3
- XFOMLLRHTYLOQT-QOAWAWRESA-N (2S)-2-(1,3-benzoxazol-2-ylamino)-N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]ethyl]-4-oxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butanamide Chemical compound O1C(=NC2=C1C=CC=C2)N[C@H](C(=O)N[C@@H](C)C=1NC(=CN=1)C1=C(C=CC=C1)F)CC(N1[C@H](CCC1)C1=CC=CC=C1)=O XFOMLLRHTYLOQT-QOAWAWRESA-N 0.000 description 3
- NBWCYAOJTFOFNE-HOIFWPIMSA-N (2S)-2-(2-cyclopropylethylsulfonylamino)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound C1(CC1)CCS(=O)(=O)N[C@H](C(=O)N[C@@H](C)C=1NC(=CN=1)C1=C(C=C(C=C1)F)F)CC(=O)N1[C@H](CCCC1)C NBWCYAOJTFOFNE-HOIFWPIMSA-N 0.000 description 3
- ZRJUOVRHEWFRLW-BSRJHKFKSA-N (2S)-2-(benzenesulfonamido)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NS(=O)(=O)C1=CC=CC=C1)=O ZRJUOVRHEWFRLW-BSRJHKFKSA-N 0.000 description 3
- AKSGZBKWWMZKKW-JXQFQVJHSA-N (2S)-2-(benzylsulfonylamino)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NS(=O)(=O)CC1=CC=CC=C1)=O AKSGZBKWWMZKKW-JXQFQVJHSA-N 0.000 description 3
- HNEBQCIMUWMPIQ-FVJLSDCUSA-N (2S)-2-[[2-(3,3-dimethylcyclobutyl)acetyl]amino]-N-[(1R)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound CC1(CC(C1)CC(=O)N[C@H](C(=O)N[C@H](C)C1=NC2=C(N1)C=CC=C2F)CC(=O)N1[C@H](CCCC1)C)C HNEBQCIMUWMPIQ-FVJLSDCUSA-N 0.000 description 3
- AXALIBSCOQQNTE-PTLVVNQVSA-N (2S)-2-[[benzyl(methyl)carbamoyl]amino]-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-oxobutanamide Chemical compound C(C1=CC=CC=C1)N(C(N[C@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)CC(=O)N1[C@H](CCCC1)CC)=O)C AXALIBSCOQQNTE-PTLVVNQVSA-N 0.000 description 3
- JUBBAZKBHCWCTP-YDHLFZDLSA-N (2S)-2-amino-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-oxobutanamide Chemical compound N[C@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)CC(=O)N1[C@H](CCCC1)CC JUBBAZKBHCWCTP-YDHLFZDLSA-N 0.000 description 3
- QGYAPEVGBGZQPJ-XUEUYAKLSA-N (2S)-2-amino-N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]ethyl]-4-oxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butanamide Chemical compound N[C@H](C(=O)N[C@@H](C)C=1NC(=CN=1)C1=C(C=CC=C1)F)CC(N1[C@H](CCC1)C1=CC=CC=C1)=O QGYAPEVGBGZQPJ-XUEUYAKLSA-N 0.000 description 3
- XMOCDGSUCQHNEI-RYUDHWBXSA-N (2S)-4-[(2S)-2-ethylpiperidin-1-yl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)O)CC(=O)N1[C@H](CCCC1)CC XMOCDGSUCQHNEI-RYUDHWBXSA-N 0.000 description 3
- SORGEGJQNOVOHA-WFXMLNOXSA-N (2S)-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-2-(3-methylbutylsulfonylamino)-4-oxobutanamide Chemical compound C(C)[C@@H]1N(CCCC1)C(C[C@@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)NS(=O)(=O)CCC(C)C)=O SORGEGJQNOVOHA-WFXMLNOXSA-N 0.000 description 3
- BJFMHHWTMYHGSN-SPEDKVCISA-N (2S)-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-2-[(6-methyl-1,3-benzoxazol-2-yl)amino]-4-oxobutanamide Chemical compound C(C)[C@@H]1N(CCCC1)C(C[C@@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)NC=1OC2=C(N=1)C=CC(=C2)C)=O BJFMHHWTMYHGSN-SPEDKVCISA-N 0.000 description 3
- BUKSFDKVNUQFND-NYDSKATKSA-N (2S)-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-2-[[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]amino]-4-oxobutanamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(CC2=CC=C(F)C=C2)=NO1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 BUKSFDKVNUQFND-NYDSKATKSA-N 0.000 description 3
- UVIBTXMHGSUKBU-WATLYSKOSA-N (2S)-N-[(1S)-1-(5-benzyl-1H-imidazol-2-yl)ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-2-[[2-(oxan-4-yl)acetyl]amino]-4-oxobutanamide Chemical compound C(C1=CC=CC=C1)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NC(CC1CCOCC1)=O)=O UVIBTXMHGSUKBU-WATLYSKOSA-N 0.000 description 3
- WPCFDPIWBDXCAD-SPEDKVCISA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-2-(3-methylbutylsulfonylamino)-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NS(=O)(=O)CCC(C)C)=O WPCFDPIWBDXCAD-SPEDKVCISA-N 0.000 description 3
- ZBWBSOFNVMVAGZ-DOXZYTNZSA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-2-(ethylsulfonylamino)-4-[(2S)-2-methylpiperidin-1-yl]-4-oxobutanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NS(=O)(=O)CC)=O ZBWBSOFNVMVAGZ-DOXZYTNZSA-N 0.000 description 3
- ZTUZTBJCYAOAPM-BSRJHKFKSA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-2-[[2-(oxan-4-yl)acetyl]amino]-4-oxobutanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NC(CC1CCOCC1)=O)=O ZTUZTBJCYAOAPM-BSRJHKFKSA-N 0.000 description 3
- PZUOSSLEZTWBIY-JXQFQVJHSA-N (2S)-N-[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]-4-[(2S)-2-methylpiperidin-1-yl]-4-oxo-2-[(2-phenylacetyl)amino]butanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NC(CC1=CC=CC=C1)=O)=O PZUOSSLEZTWBIY-JXQFQVJHSA-N 0.000 description 3
- OEAPTBZSVQAEFP-AHIWAGSCSA-N (2S,3R)-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-3-hydroxy-2-[(4-methylphenyl)sulfonylamino]butanamide Chemical compound FC1=CC=CC2=C1NC(=N2)[C@H](C)NC([C@H]([C@@H](C)O)NS(=O)(=O)C1=CC=C(C=C1)C)=O OEAPTBZSVQAEFP-AHIWAGSCSA-N 0.000 description 3
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 3
- KYQIPNJPUWTWQJ-FTRWYGJKSA-N 2,2-difluoro-N-[(2S)-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]spiro[3.3]heptane-6-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(F)C=CC=C2N1 KYQIPNJPUWTWQJ-FTRWYGJKSA-N 0.000 description 3
- PIWULMOLVXIGTP-QRFRQXIXSA-N 5-methyl-N-[(2S)-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxo-1-[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]butan-2-yl]-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1=NOC(C)=C1)C1=NC=C(N1)C1=CC=CC=C1 PIWULMOLVXIGTP-QRFRQXIXSA-N 0.000 description 3
- YVNYLKUDTYZVSN-JLMWRMLUSA-N C(C)[C@@H]1N(CCCC1)C(C[C@@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)NC(=O)C1CC2(C1)CCC2)=O Chemical compound C(C)[C@@H]1N(CCCC1)C(C[C@@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)NC(=O)C1CC2(C1)CCC2)=O YVNYLKUDTYZVSN-JLMWRMLUSA-N 0.000 description 3
- HPMUARJUQJZKIX-HOIFWPIMSA-N C1(CC1)CCC(=O)N[C@H](C(=O)N[C@@H](C)C=1NC(=CN=1)C1=C(C=C(C=C1)F)F)CC(=O)N1[C@H](CCCC1)C Chemical compound C1(CC1)CCC(=O)N[C@H](C(=O)N[C@@H](C)C=1NC(=CN=1)C1=C(C=C(C=C1)F)F)CC(=O)N1[C@H](CCCC1)C HPMUARJUQJZKIX-HOIFWPIMSA-N 0.000 description 3
- DUVBLGKGSBVBKG-RXVVDRJESA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)CC/C1=N/C2=C(C=CC=C2)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)CC/C1=N/C2=C(C=CC=C2)N1 DUVBLGKGSBVBKG-RXVVDRJESA-N 0.000 description 3
- BFDWUHGDBSBKRZ-UHFFFAOYSA-N CC(C)c1cc(N2CCCC2)nc(C(C)C)n1 Chemical compound CC(C)c1cc(N2CCCC2)nc(C(C)C)n1 BFDWUHGDBSBKRZ-UHFFFAOYSA-N 0.000 description 3
- JBKQPNGRUDOMLD-WFYHXULLSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCCC2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCCC2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1 JBKQPNGRUDOMLD-WFYHXULLSA-N 0.000 description 3
- JBKQPNGRUDOMLD-LQWHRVPQSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1 JBKQPNGRUDOMLD-LQWHRVPQSA-N 0.000 description 3
- KAVIFZAHEZUAAO-ZWOKBUDYSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC(C)C)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC(C)C)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 KAVIFZAHEZUAAO-ZWOKBUDYSA-N 0.000 description 3
- XICISNCEJXXSCO-PLPOIYILSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 XICISNCEJXXSCO-PLPOIYILSA-N 0.000 description 3
- BMGAZXWGZAUAQH-BFMBIBTESA-N C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)OC(C)(C)C)C1=NC=C(N1)C1=C(F)C=CC=C1 Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)OC(C)(C)C)C1=NC=C(N1)C1=C(F)C=CC=C1 BMGAZXWGZAUAQH-BFMBIBTESA-N 0.000 description 3
- NNHLIJYRXCNBCS-UHFFFAOYSA-N C[C](C)c1cc(N2CCCC2)nc([C](C)C)n1 Chemical compound C[C](C)c1cc(N2CCCC2)nc([C](C)C)n1 NNHLIJYRXCNBCS-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DZFRPEMEDSXZLC-AVYPCKFXSA-N FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NC(=O)C1=CN=C(S1)C)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NC(=O)C1=CN=C(S1)C)=O DZFRPEMEDSXZLC-AVYPCKFXSA-N 0.000 description 3
- GDKWHJIODYRDOQ-FTRWYGJKSA-N FC1=CC=CC2=C1NC(=N2)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NC(=O)C1CC2(COC2)C1)=O Chemical compound FC1=CC=CC2=C1NC(=N2)[C@H](C)NC([C@H](CC(=O)N1[C@H](CCCC1)C)NC(=O)C1CC2(COC2)C1)=O GDKWHJIODYRDOQ-FTRWYGJKSA-N 0.000 description 3
- KTRCTAFKSSWCEZ-NWVWQQAFSA-N FC1=CC=CC2=C1NC(=N2)[C@H](C)NC([C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(=O)C1CC2(COC2)C1)=O Chemical compound FC1=CC=CC2=C1NC(=N2)[C@H](C)NC([C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(=O)C1CC2(COC2)C1)=O KTRCTAFKSSWCEZ-NWVWQQAFSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010065002 N-(4-morpholine)carbonyl-beta-(1-naphthyl)-alanyl-leucine boronic acid Proteins 0.000 description 3
- NHJDLVHFWAVMAP-AMZDPNTKSA-N N-[(2S)-1,4-dioxo-1-[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1=NOC(C)=C1)C1=NC=C(N1)C1=CC=CC=C1 NHJDLVHFWAVMAP-AMZDPNTKSA-N 0.000 description 3
- UFVDEOPJHQYWBU-OFGFBFBPSA-N N-[(2S)-1-[1-(1H-benzimidazol-2-yl)ethylamino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-3-methylcyclobutane-1-carboxamide Chemical compound CC(NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1CC(C)C1)C1=NC2=CC=CC=C2N1 UFVDEOPJHQYWBU-OFGFBFBPSA-N 0.000 description 3
- FNBQQAPJLQSYMR-UEXGIBASSA-N N-[(2S)-1-[[(1R)-1-(1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)N[C@H](C)C1=NC2=CC=CC=C2N1 FNBQQAPJLQSYMR-UEXGIBASSA-N 0.000 description 3
- BYVNONMCPNXACM-JKFKMHIGSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1=NOC(C)=C1)C1=NC2=CC=CC=C2N1 BYVNONMCPNXACM-JKFKMHIGSA-N 0.000 description 3
- GMLIQVRNGXYMMV-IPJJNNNSSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-ethylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4,4-dimethylpentanamide Chemical compound N1C(=NC2=C1C=CC=C2)[C@H](C)NC(=O)[C@H](CC(=O)N1[C@H](CCCC1)CC)NC(CCC(C)(C)C)=O GMLIQVRNGXYMMV-IPJJNNNSSA-N 0.000 description 3
- KZNMEAZTJLUWIP-QOKNQOGYSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1=NOC(C)=C1)C1=NC2=CC=CC=C2N1 KZNMEAZTJLUWIP-QOKNQOGYSA-N 0.000 description 3
- BPZKJLNRYXSQTC-ZWOKBUDYSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpyrrolidin-1-yl]-1,4-dioxobutan-2-yl]-4,4-dimethylpentanamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C)NC(=O)CCC(C)(C)C)c1nc2ccccc2[nH]1 BPZKJLNRYXSQTC-ZWOKBUDYSA-N 0.000 description 3
- CUGYXFAQZQPNLL-DEYYWGMASA-N N-[(2S)-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1=CN=C(C)S1)C1=NC2=C(F)C=CC=C2N1 CUGYXFAQZQPNLL-DEYYWGMASA-N 0.000 description 3
- HLQSTNLHTWANIS-VSGQMKJSSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-1,4-dioxo-4-(2-propan-2-ylpiperidin-1-yl)butan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCCC1C(C)C)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 HLQSTNLHTWANIS-VSGQMKJSSA-N 0.000 description 3
- BKGPCYHPTMTMBE-UWJYYQICSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-1,4-dioxo-4-piperidin-1-ylbutan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCCC1)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 BKGPCYHPTMTMBE-UWJYYQICSA-N 0.000 description 3
- GUJBBMJXEZHEKO-JXFKEZNVSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-1,4-dioxo-4-pyrrolidin-1-ylbutan-2-yl]-4,4-dimethylpentanamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC1)NC(=O)CCC(C)(C)C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 GUJBBMJXEZHEKO-JXFKEZNVSA-N 0.000 description 3
- IPLMHFSZTXWVKX-JXFKEZNVSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-1,4-dioxo-4-pyrrolidin-1-ylbutan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC1)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 IPLMHFSZTXWVKX-JXFKEZNVSA-N 0.000 description 3
- PGQJMDGELAJMCC-KSSFIOAISA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-1,4-dioxo-4-pyrrolidin-1-ylbutan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC1)NC(=O)C1=NOC(C)=C1)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 PGQJMDGELAJMCC-KSSFIOAISA-N 0.000 description 3
- RCWMUJBTAMQTOD-FGSXEWAUSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2R)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@H]1C)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 RCWMUJBTAMQTOD-FGSXEWAUSA-N 0.000 description 3
- SSXCWVSMNBDTSU-OFUSPXKRSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-2-propan-2-ylcyclopropane-1-carboxamide Chemical compound CC(C)C1CC1C(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 SSXCWVSMNBDTSU-OFUSPXKRSA-N 0.000 description 3
- KYSUEPWILKTYPX-FPDDQMOCSA-N N-[(2S)-1-[[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1=NOC(C)=C1)C1=NC=C(N1)C1=C(F)C=CC=C1 KYSUEPWILKTYPX-FPDDQMOCSA-N 0.000 description 3
- NDVYSMHKZQCTEA-KNBMTAEXSA-N N-[(2S)-1-[[(1S)-1-[5-(4-fluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1=NOC(C)=C1)C1=NC=C(N1)C1=CC=C(F)C=C1 NDVYSMHKZQCTEA-KNBMTAEXSA-N 0.000 description 3
- GKISWOAKVIBMDA-XABNSEFBSA-N N-[(2S)-4-(2-cyclopropylpyrrolidin-1-yl)-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]-2,2-difluorospiro[3.3]heptane-6-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=CC=CC(F)=C2N1 GKISWOAKVIBMDA-XABNSEFBSA-N 0.000 description 3
- LTRULYUWXXAPEF-XABNSEFBSA-N N-[(2S)-4-(2-cyclopropylpyrrolidin-1-yl)-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]-2-oxaspiro[3.3]heptane-6-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(COC2)C1)C1=NC2=CC=CC(F)=C2N1 LTRULYUWXXAPEF-XABNSEFBSA-N 0.000 description 3
- WWZDHKHXVUTOSP-MPGHIAIKSA-N N-[(2S)-4-[(2S)-2-ethylpiperidin-1-yl]-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]-1,3-thiazole-5-carboxamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 WWZDHKHXVUTOSP-MPGHIAIKSA-N 0.000 description 3
- YSONTQYUWVCLPT-QOKNQOGYSA-N N-[(2S)-4-[(2S)-2-ethylpiperidin-1-yl]-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 YSONTQYUWVCLPT-QOKNQOGYSA-N 0.000 description 3
- BZAMYNUFGGGMPB-DPPDIKPLSA-N N-[(2S)-4-[(2S)-2-ethylpiperidin-1-yl]-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]-2-propan-2-ylcyclopropane-1-carboxamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC1C(C)C)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 BZAMYNUFGGGMPB-DPPDIKPLSA-N 0.000 description 3
- FTIBIGOVUHZWEP-WFXMLNOXSA-N N-[(2S)-4-[(2S)-2-ethylpiperidin-1-yl]-1-[[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 FTIBIGOVUHZWEP-WFXMLNOXSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- MQMHIOPMTAJOHV-SFTDATJTSA-N [(1r)-3-methyl-1-[[(2s)-2-(morpholine-4-carbonylamino)-3-naphthalen-1-ylpropanoyl]amino]butyl]boronic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2C=CC=1)C(=O)N[C@@H](CC(C)C)B(O)O)C(=O)N1CCOCC1 MQMHIOPMTAJOHV-SFTDATJTSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- GKLYVKAVLLUXKL-OALUTQOASA-N benzyl (2S)-4-[(2S)-2-ethylpiperidin-1-yl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoate Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)OCC1=CC=CC=C1)CC(=O)N1[C@H](CCCC1)CC GKLYVKAVLLUXKL-OALUTQOASA-N 0.000 description 3
- YWJXSRRTCSHUAU-AWEZNQCLSA-N benzyl n-[(2s)-1-oxo-1-(phenacylamino)propan-2-yl]carbamate Chemical compound N([C@@H](C)C(=O)NCC(=O)C=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 YWJXSRRTCSHUAU-AWEZNQCLSA-N 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000007960 cellular response to stress Effects 0.000 description 3
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 3
- 238000006264 debenzylation reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- OOJNDQDDEOVXLH-QMMMGPOBSA-N tert-butyl n-[(2s)-1-(2-amino-3-fluoroanilino)-1-oxopropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)C(=O)NC1=CC=CC(F)=C1N OOJNDQDDEOVXLH-QMMMGPOBSA-N 0.000 description 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 3
- CBDHCRRAMPPZCM-VIFPVBQESA-N (1S)-1-(5-benzyl-1H-imidazol-2-yl)ethanamine Chemical compound C(C1=CC=CC=C1)C1=CN=C(N1)[C@H](C)N CBDHCRRAMPPZCM-VIFPVBQESA-N 0.000 description 2
- BMOGYIPGXDAZCK-LURJTMIESA-N (1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethanamine Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)N BMOGYIPGXDAZCK-LURJTMIESA-N 0.000 description 2
- XQFMQMXJXWTGON-QMMMGPOBSA-N (1s)-1-(5-phenyl-1h-imidazol-2-yl)ethanamine Chemical compound N1C([C@@H](N)C)=NC=C1C1=CC=CC=C1 XQFMQMXJXWTGON-QMMMGPOBSA-N 0.000 description 2
- BZQHDPSKUBNQPA-ZETCQYMHSA-N (1s)-1-[5-(4-fluorophenyl)-1h-imidazol-2-yl]ethanamine Chemical compound N1C([C@@H](N)C)=NC=C1C1=CC=C(F)C=C1 BZQHDPSKUBNQPA-ZETCQYMHSA-N 0.000 description 2
- NCCQAFWGVALMTR-KNBMTAEXSA-N (2S)-2-[(2-cyclopropylacetyl)amino]-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-oxobutanamide Chemical compound C1(CC1)CC(=O)N[C@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)CC(=O)N1[C@H](CCCC1)CC NCCQAFWGVALMTR-KNBMTAEXSA-N 0.000 description 2
- MAVQZQNPYIFUAB-PTLVVNQVSA-N (2S)-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-oxo-2-(3-phenylpropanoylamino)butanamide Chemical compound C(C)[C@@H]1N(CCCC1)C(C[C@@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)NC(CCC1=CC=CC=C1)=O)=O MAVQZQNPYIFUAB-PTLVVNQVSA-N 0.000 description 2
- ZXBKCQNIWAUWNF-NJTBCWBZSA-N (2S)-N-[(1S)-1-(5-benzyl-1H-imidazol-2-yl)ethyl]-2-[(2-cyclopropylacetyl)amino]-4-oxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butanamide Chemical compound C(C1=CC=CC=C1)C1=CN=C(N1)[C@H](C)NC([C@H](CC(N1[C@H](CCC1)C1=CC=CC=C1)=O)NC(CC1CC1)=O)=O ZXBKCQNIWAUWNF-NJTBCWBZSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 2
- PBOADZMUTXWNOR-UHFFFAOYSA-N 3-(2-oxo-3h-[1,2,4]triazolo[1,5-a]pyridin-6-yl)propanoic acid Chemical compound C1=C(CCC(=O)O)C=CC2=NC(O)=NN21 PBOADZMUTXWNOR-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- BNMPIJWVMVNSRD-UHFFFAOYSA-N 5-methyl-1,2-oxazole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NO1 BNMPIJWVMVNSRD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- JRFNFPRHZOMBEV-ZQIUZPCESA-N C(C)[C@@H]1N(CCCC1)C(C[C@@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)NC(CC(F)(F)F)=O)=O Chemical compound C(C)[C@@H]1N(CCCC1)C(C[C@@H](C(=O)N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)NC(CC(F)(F)F)=O)=O JRFNFPRHZOMBEV-ZQIUZPCESA-N 0.000 description 2
- FXKNIESJEVJYNO-BGERDNNASA-N C1(CC1)C1N(CCC1)C(C[C@@H](C(=O)NC1(CC1)C1=NC2=C(N1)C(=CC=C2)F)NC(=O)C1CC2(C1)CC(C2)(F)F)=O Chemical compound C1(CC1)C1N(CCC1)C(C[C@@H](C(=O)NC1(CC1)C1=NC2=C(N1)C(=CC=C2)F)NC(=O)C1CC2(C1)CC(C2)(F)F)=O FXKNIESJEVJYNO-BGERDNNASA-N 0.000 description 2
- IQZCIEOEGLMUFB-UHFFFAOYSA-N CC(=O)CC(C)C.CC(C)C(C)C.CC(C)CC(=O)OCC1=CC=CC=C1 Chemical compound CC(=O)CC(C)C.CC(C)C(C)C.CC(C)CC(=O)OCC1=CC=CC=C1 IQZCIEOEGLMUFB-UHFFFAOYSA-N 0.000 description 2
- IIKRULLTCMSQCL-UHFFFAOYSA-N CC(C)C(=O)C1=CN(C)C=N1.CC(C)C(=O)C1CC2(C1)CC(F)(F)C2.CC(C)C(=O)C1CC2(COC2)C1.CC(C)C(=O)C1CCC1.CC(C)C(=O)CC1=CC=CC=C1.CC(C)C(=O)CC1CC(C)(C)C1.CC(C)C(=O)CC1CCOCC1.CC(C)C(=O)CCC1=CC=C(F)C=C1.CC(C)C(=O)CCC1CC1.CC(C)C(=O)CCCC(F)(F)F.CC(C)C(=O)N(C)CC1=CC=CC=C1.CC(C)C1=NC(CC2=CC=C(F)C=C2)=NO1.CC(C)C1=NOC(C(C)C)=N1.CC(C)CC(=O)C(C)C.CC(C)CC(=O)C1=CC=CC=C1.CC(C)CS(=O)(=O)C(C)C.CC(C)S(=O)(=O)C1=CC=CC=C1.CC(C)S(=O)(=O)CC1=CC=CC=C1.CC(C)S(=O)(=O)CCC1CC1.CC1=CC=C(S(=O)(=O)C(C)C)C=C1.CC1CC(C(=O)C(C)C)C1.CCS(=O)(=O)C(C)C Chemical compound CC(C)C(=O)C1=CN(C)C=N1.CC(C)C(=O)C1CC2(C1)CC(F)(F)C2.CC(C)C(=O)C1CC2(COC2)C1.CC(C)C(=O)C1CCC1.CC(C)C(=O)CC1=CC=CC=C1.CC(C)C(=O)CC1CC(C)(C)C1.CC(C)C(=O)CC1CCOCC1.CC(C)C(=O)CCC1=CC=C(F)C=C1.CC(C)C(=O)CCC1CC1.CC(C)C(=O)CCCC(F)(F)F.CC(C)C(=O)N(C)CC1=CC=CC=C1.CC(C)C1=NC(CC2=CC=C(F)C=C2)=NO1.CC(C)C1=NOC(C(C)C)=N1.CC(C)CC(=O)C(C)C.CC(C)CC(=O)C1=CC=CC=C1.CC(C)CS(=O)(=O)C(C)C.CC(C)S(=O)(=O)C1=CC=CC=C1.CC(C)S(=O)(=O)CC1=CC=CC=C1.CC(C)S(=O)(=O)CCC1CC1.CC1=CC=C(S(=O)(=O)C(C)C)C=C1.CC1CC(C(=O)C(C)C)C1.CCS(=O)(=O)C(C)C IIKRULLTCMSQCL-UHFFFAOYSA-N 0.000 description 2
- SDASXXBVWSLZHC-FYDQXMQDSA-N CC(C)C(=O)C1=CN=CS1.CC(C)C(=O)C1CC(C)(C)C1.CC(C)C(=O)C1CC1C(C)C.CC(C)C(=O)C1CC2(CCC2)C1.CC(C)C(=O)CC(F)(F)F.CC(C)C(=O)CC1CC1.CC(C)C(=O)CCC(C)(C)C.CC(C)C(=O)CCC1=CC=CC=C1.CC(C)C(=O)CCN(C)C.CC(C)C(=O)N1CCCCC1.CC(C)C(=O)N1CCOCC1.CC(C)C(=O)NCC1=CC=CC=C1.CC(C)C(=O)OCC1=CC=CC=C1.CC(C)C(=O)[C@H]1C[C@@H]1C1=CC=CC=C1.CC(C)C1=NC2=C(C=CC=C2)O1.CC(C)C1=NC2=C(C=CC=C2)S1.CC(C)C1=NOC(C(C)C)=N1.CC(C)CCC(=O)C(C)C.CC(C)CCS(=O)(=O)C(C)C.CC(C)CN(C)C(=O)C(C)C.CC(C)COC(=O)C(C)C.CC1=CC(C(=O)C(C)C)=NO1.CC1=CC2=C(C=C1)N=C(C(C)C)O2.CC1=NC=C(C(=O)C(C)C)S1 Chemical compound CC(C)C(=O)C1=CN=CS1.CC(C)C(=O)C1CC(C)(C)C1.CC(C)C(=O)C1CC1C(C)C.CC(C)C(=O)C1CC2(CCC2)C1.CC(C)C(=O)CC(F)(F)F.CC(C)C(=O)CC1CC1.CC(C)C(=O)CCC(C)(C)C.CC(C)C(=O)CCC1=CC=CC=C1.CC(C)C(=O)CCN(C)C.CC(C)C(=O)N1CCCCC1.CC(C)C(=O)N1CCOCC1.CC(C)C(=O)NCC1=CC=CC=C1.CC(C)C(=O)OCC1=CC=CC=C1.CC(C)C(=O)[C@H]1C[C@@H]1C1=CC=CC=C1.CC(C)C1=NC2=C(C=CC=C2)O1.CC(C)C1=NC2=C(C=CC=C2)S1.CC(C)C1=NOC(C(C)C)=N1.CC(C)CCC(=O)C(C)C.CC(C)CCS(=O)(=O)C(C)C.CC(C)CN(C)C(=O)C(C)C.CC(C)COC(=O)C(C)C.CC1=CC(C(=O)C(C)C)=NO1.CC1=CC2=C(C=C1)N=C(C(C)C)O2.CC1=NC=C(C(=O)C(C)C)S1 SDASXXBVWSLZHC-FYDQXMQDSA-N 0.000 description 2
- KWATVVWEMGOYHB-FGSXEWAUSA-N CC(C)C(=O)CN[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound CC(C)C(=O)CN[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 KWATVVWEMGOYHB-FGSXEWAUSA-N 0.000 description 2
- MZDBFRNGSHUCKD-OFUSPXKRSA-N CC(C)C(C1)C1C(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@@H](C)C1=NCC(c(c(F)c2)ccc2F)=N1)=O)=O Chemical compound CC(C)C(C1)C1C(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@@H](C)C1=NCC(c(c(F)c2)ccc2F)=N1)=O)=O MZDBFRNGSHUCKD-OFUSPXKRSA-N 0.000 description 2
- BVMJVJBCLGHIPY-UHFFFAOYSA-N CC(C)C1(C(C)C)CC1 Chemical compound CC(C)C1(C(C)C)CC1 BVMJVJBCLGHIPY-UHFFFAOYSA-N 0.000 description 2
- DFIBQTBBPHGQLG-QQMNAOGKSA-N CC(C)C1=NOC(N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)N[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3F)C2)=N1 Chemical compound CC(C)C1=NOC(N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)N[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3F)C2)=N1 DFIBQTBBPHGQLG-QQMNAOGKSA-N 0.000 description 2
- BFGXAAKTVAZBMX-RFGXYLLOSA-N CC(C)C1CC1C(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC(C)C1CC1C(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 BFGXAAKTVAZBMX-RFGXYLLOSA-N 0.000 description 2
- IIZPSBPIVHKGFQ-UHFFFAOYSA-N CC(C)C1CCCC1C(C)C Chemical compound CC(C)C1CCCC1C(C)C IIZPSBPIVHKGFQ-UHFFFAOYSA-N 0.000 description 2
- HVJKZICIMIWFCP-UHFFFAOYSA-N CC(C)CC(OCc1ccccc1)=O Chemical compound CC(C)CC(OCc1ccccc1)=O HVJKZICIMIWFCP-UHFFFAOYSA-N 0.000 description 2
- RAUZJYPMFXRDSW-UTKZUKDTSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 RAUZJYPMFXRDSW-UTKZUKDTSA-N 0.000 description 2
- PSADJVXCCQOKCC-GCJKJVERSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCCC1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCCC1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 PSADJVXCCQOKCC-GCJKJVERSA-N 0.000 description 2
- MDZUCYUGDQCSAL-LLHWJCAFSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCCC1C(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCCC1C(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 MDZUCYUGDQCSAL-LLHWJCAFSA-N 0.000 description 2
- GIUSLAFLZNDUGC-XXBNENTESA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCCCC1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCCCC1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 GIUSLAFLZNDUGC-XXBNENTESA-N 0.000 description 2
- XSLMIBBOOOUIDW-QATBIIFWSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C(F)(F)F)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C(F)(F)F)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 XSLMIBBOOOUIDW-QATBIIFWSA-N 0.000 description 2
- UNVANHIEJYRDLP-MSYCTHLASA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 UNVANHIEJYRDLP-MSYCTHLASA-N 0.000 description 2
- NTGSPCMJOPZFLO-IPJJNNNSSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@H](C)/C1=N/C2=C(C=CC=C2)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@H](C)/C1=N/C2=C(C=CC=C2)N1 NTGSPCMJOPZFLO-IPJJNNNSSA-N 0.000 description 2
- UNVANHIEJYRDLP-PWHSHALESA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 UNVANHIEJYRDLP-PWHSHALESA-N 0.000 description 2
- AGZXPRXVEZOWLA-FGSXEWAUSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCOC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCOC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 AGZXPRXVEZOWLA-FGSXEWAUSA-N 0.000 description 2
- PCFOFRWVTQGRJS-VSGQMKJSSA-N CC(C)CCC(N[C@@H](CC(N(CCCC1)C1C(C)C)=O)C(N[C@@H](C)C1=NCC(c(ccc(F)c2)c2F)=N1)=O)=O Chemical compound CC(C)CCC(N[C@@H](CC(N(CCCC1)C1C(C)C)=O)C(N[C@@H](C)C1=NCC(c(ccc(F)c2)c2F)=N1)=O)=O PCFOFRWVTQGRJS-VSGQMKJSSA-N 0.000 description 2
- LWKBSUZQQVYLNE-UEXGIBASSA-N CC(C)CCC(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@H](C)C1=NC2=CC=CCC2=N1)=O)=O Chemical compound CC(C)CCC(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@H](C)C1=NC2=CC=CCC2=N1)=O)=O LWKBSUZQQVYLNE-UEXGIBASSA-N 0.000 description 2
- ZEVDYFBLOPKOMR-QGZVFWFLSA-N CC(C)CCNc1nc(C(=O)C[C@@H](C)C(=O)NCc2ccc(F)cc2F)cc(N2CCCC2)n1 Chemical compound CC(C)CCNc1nc(C(=O)C[C@@H](C)C(=O)NCc2ccc(F)cc2F)cc(N2CCCC2)n1 ZEVDYFBLOPKOMR-QGZVFWFLSA-N 0.000 description 2
- KBKXYBJGAIROPO-UHFFFAOYSA-N CC(C)CCS(=O)(=O)C(C)C Chemical compound CC(C)CCS(=O)(=O)C(C)C KBKXYBJGAIROPO-UHFFFAOYSA-N 0.000 description 2
- HSSHQUCNFWFZKO-MSYCTHLASA-N CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 HSSHQUCNFWFZKO-MSYCTHLASA-N 0.000 description 2
- BEKQQZSBKDSBNX-FGSXEWAUSA-N CC(C)CS(=O)(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC(C)CS(=O)(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 BEKQQZSBKDSBNX-FGSXEWAUSA-N 0.000 description 2
- WXAHIMBXSQEQKP-NKQQYQHASA-N CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3)C2)=NO1 Chemical compound CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3)C2)=NO1 WXAHIMBXSQEQKP-NKQQYQHASA-N 0.000 description 2
- ASDQZFJXFYDIRO-DCABOPQKSA-N CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(CC3=CC=CC=C3)C2)=NO1 Chemical compound CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(CC3=CC=CC=C3)C2)=NO1 ASDQZFJXFYDIRO-DCABOPQKSA-N 0.000 description 2
- WGCDQNKHPYSQCL-LQGBDCMISA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)CC(C)/C2=N/C3=C(C=CC=C3)N2)=NO1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)CC(C)/C2=N/C3=C(C=CC=C3)N2)=NO1 WGCDQNKHPYSQCL-LQGBDCMISA-N 0.000 description 2
- WGCDQNKHPYSQCL-GUXCAODWSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)/C2=N/C3=C(C=CC=C3)N2)=NO1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)/C2=N/C3=C(C=CC=C3)N2)=NO1 WGCDQNKHPYSQCL-GUXCAODWSA-N 0.000 description 2
- JZUWHICVCHXGIN-XFQAVAEZSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)=NO1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)=NO1 JZUWHICVCHXGIN-XFQAVAEZSA-N 0.000 description 2
- LQGWDEORPHYTJC-WWMYMODYSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=CC=C3)N2)=NO1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=CC=C3)N2)=NO1 LQGWDEORPHYTJC-WWMYMODYSA-N 0.000 description 2
- ARGRKBQKNXJARU-WWMYMODYSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3)N2)=NO1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3)N2)=NO1 ARGRKBQKNXJARU-WWMYMODYSA-N 0.000 description 2
- CRPATCPMVXFTFL-LJQANCHMSA-N CC1=CC=C(S(=O)(=O)C[C@@H](CC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)C3)CC2)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)C[C@@H](CC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)C3)CC2)C=C1 CRPATCPMVXFTFL-LJQANCHMSA-N 0.000 description 2
- ZWHZVRQQPPETBN-RNHFSVANSA-N CC1=CC=C(S(=O)(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)C=C1 ZWHZVRQQPPETBN-RNHFSVANSA-N 0.000 description 2
- IPEJDVKYVHLZJJ-VCBZYWHSSA-N CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)/C2=N/C3=C(C=CC=C3F)N2)S1 Chemical compound CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)/C2=N/C3=C(C=CC=C3F)N2)S1 IPEJDVKYVHLZJJ-VCBZYWHSSA-N 0.000 description 2
- PMZXNBNRCODQBS-XFQAVAEZSA-N CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)S1 Chemical compound CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)S1 PMZXNBNRCODQBS-XFQAVAEZSA-N 0.000 description 2
- GGBWPJLCWBXEIG-GUXCAODWSA-N CCS(=O)(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CCS(=O)(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 GGBWPJLCWBXEIG-GUXCAODWSA-N 0.000 description 2
- QLNYEJHMMYFZRL-MABOMDMHSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(C1CCCCC1)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(C1CCCCC1)=O)=O QLNYEJHMMYFZRL-MABOMDMHSA-N 0.000 description 2
- XQXBEJGBLJIEAB-CGPMYILUSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(CC1CC1)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(CC1CC1)=O)=O XQXBEJGBLJIEAB-CGPMYILUSA-N 0.000 description 2
- QTVXQLKGXCYXNL-SPYBRQBASA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(OCC(C)C)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(OCC(C)C)=O)=O QTVXQLKGXCYXNL-SPYBRQBASA-N 0.000 description 2
- DDQCXHKLDXCBDM-OSUJBIHNSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(OCc1ccccc1)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(OCc1ccccc1)=O)=O DDQCXHKLDXCBDM-OSUJBIHNSA-N 0.000 description 2
- PUQNLAADJJQRMK-LWVXSWFQSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C1N=C2C(F)=CC=CC2=N1)=O)Nc1nc(C(C)C)n[o]1)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C1N=C2C(F)=CC=CC2=N1)=O)Nc1nc(C(C)C)n[o]1)=O PUQNLAADJJQRMK-LWVXSWFQSA-N 0.000 description 2
- WFSZHGWAURVRQQ-JLMWRMLUSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)c([nH]c1ccc2)nc1c2F)=O)NC(C1CCCCC1)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)c([nH]c1ccc2)nc1c2F)=O)NC(C1CCCCC1)=O)=O WFSZHGWAURVRQQ-JLMWRMLUSA-N 0.000 description 2
- HRLZUMWOMNXKDZ-YCPHGPKFSA-N CC[C@H]1CCCCN1C(=O)C[C@H](N)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](N)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 HRLZUMWOMNXKDZ-YCPHGPKFSA-N 0.000 description 2
- RWEAKCYOLJNXQO-SYNHAJSKSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=C(C)S1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=C(C)S1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 RWEAKCYOLJNXQO-SYNHAJSKSA-N 0.000 description 2
- PPEPAMIXRWWCFR-GJYPPUQNSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 PPEPAMIXRWWCFR-GJYPPUQNSA-N 0.000 description 2
- GYCGPYZVRZETLW-SYNHAJSKSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=NOC(C)=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=NOC(C)=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 GYCGPYZVRZETLW-SYNHAJSKSA-N 0.000 description 2
- VPJDCDNXEVRYNQ-LZNRXBQRSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 VPJDCDNXEVRYNQ-LZNRXBQRSA-N 0.000 description 2
- XGUZPJPZDHXBRK-ZWNSVPMJSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC1C(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC1C(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 XGUZPJPZDHXBRK-ZWNSVPMJSA-N 0.000 description 2
- CSQDDHSDHSAEDM-RFWXGWTQSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 CSQDDHSDHSAEDM-RFWXGWTQSA-N 0.000 description 2
- BYJYCLUCBFKTNF-VKJFTORMSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC(F)(F)F)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC(F)(F)F)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 BYJYCLUCBFKTNF-VKJFTORMSA-N 0.000 description 2
- GCOQKZMSHFRDRU-MMOPVJDHSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC2=C(N1)C(F)=CC=C2 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC2=C(N1)C(F)=CC=C2 GCOQKZMSHFRDRU-MMOPVJDHSA-N 0.000 description 2
- IZYKDHXDFJEHFC-QTEQDKRBSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2)N1 IZYKDHXDFJEHFC-QTEQDKRBSA-N 0.000 description 2
- CJKLLYOYBGRBEV-DXIQSLLYSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 CJKLLYOYBGRBEV-DXIQSLLYSA-N 0.000 description 2
- JLMFLPIFJGWFFQ-QTEQDKRBSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2)N1 JLMFLPIFJGWFFQ-QTEQDKRBSA-N 0.000 description 2
- WUMLPSABVQDTTD-DXIQSLLYSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 WUMLPSABVQDTTD-DXIQSLLYSA-N 0.000 description 2
- OSUPZBFJENDENT-IZIIKQMZSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 OSUPZBFJENDENT-IZIIKQMZSA-N 0.000 description 2
- PATOUSIRSJXJQF-KJWPAHLWSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 PATOUSIRSJXJQF-KJWPAHLWSA-N 0.000 description 2
- OAIOSOGUSXUICT-LQWHRVPQSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCN(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCN(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 OAIOSOGUSXUICT-LQWHRVPQSA-N 0.000 description 2
- LIYLEYTTWXMLSZ-DXIQSLLYSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 LIYLEYTTWXMLSZ-DXIQSLLYSA-N 0.000 description 2
- RLRPQGUEVRJQQQ-KJWPAHLWSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 RLRPQGUEVRJQQQ-KJWPAHLWSA-N 0.000 description 2
- QVWITYUEGZBUBW-DXIQSLLYSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCCCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCCCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 QVWITYUEGZBUBW-DXIQSLLYSA-N 0.000 description 2
- MISWGXFHHIVMBS-LQWHRVPQSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCOCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCOCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 MISWGXFHHIVMBS-LQWHRVPQSA-N 0.000 description 2
- UPYNSPQAWOZWBA-IZIIKQMZSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)NCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)NCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 UPYNSPQAWOZWBA-IZIIKQMZSA-N 0.000 description 2
- FYXYAIWNWJVNIK-BXWFABGCSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C1=NC2=C(F)C=CC=C2N1 FYXYAIWNWJVNIK-BXWFABGCSA-N 0.000 description 2
- NPESAJDRTKDWQC-LQWHRVPQSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 NPESAJDRTKDWQC-LQWHRVPQSA-N 0.000 description 2
- MGGGTEDGMLPNCN-IZIIKQMZSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 MGGGTEDGMLPNCN-IZIIKQMZSA-N 0.000 description 2
- RQQKRGMBRPGRAP-ZIUBFTGCSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 RQQKRGMBRPGRAP-ZIUBFTGCSA-N 0.000 description 2
- VRFWEASDAZYVEZ-MDKPJZGXSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(C(C)C)=NO1)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)C1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(C(C)C)=NO1)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)C1 VRFWEASDAZYVEZ-MDKPJZGXSA-N 0.000 description 2
- BCZMNYYGNLSSGK-PZGSVQSZSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(CC2=CC=C(F)C=C2)=NO1)C(=O)N[C@@H](C)/C1=N/C2=C(C=CC=C2F)C1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(CC2=CC=C(F)C=C2)=NO1)C(=O)N[C@@H](C)/C1=N/C2=C(C=CC=C2F)C1 BCZMNYYGNLSSGK-PZGSVQSZSA-N 0.000 description 2
- QISFFAAZEUGWQF-DXIQSLLYSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)CCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)CCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 QISFFAAZEUGWQF-DXIQSLLYSA-N 0.000 description 2
- DWBCLRWZKSMJPQ-ZENTWMBTSA-N CC[C@H]1CCCCN1C(=O)N[C@H](NC1=NC2=C(C=C(C)C=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)N[C@H](NC1=NC2=C(C=C(C)C=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 DWBCLRWZKSMJPQ-ZENTWMBTSA-N 0.000 description 2
- JAGBDGUCHVCDFO-VXIBIUTKSA-N C[C@@H](C(N=C12)=NC1=CC=CC2F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(C1CC(C)(C)C1)=O)=O Chemical compound C[C@@H](C(N=C12)=NC1=CC=CC2F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(C1CC(C)(C)C1)=O)=O JAGBDGUCHVCDFO-VXIBIUTKSA-N 0.000 description 2
- DEWKMTQUXXICDK-ZDKQUTPJSA-N C[C@@H](C(N=C12)=NC1=CC=CC2F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(OCc1ccccc1)=O)=O Chemical compound C[C@@H](C(N=C12)=NC1=CC=CC2F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(OCc1ccccc1)=O)=O DEWKMTQUXXICDK-ZDKQUTPJSA-N 0.000 description 2
- APYVFBLORVZPCD-UTKZUKDTSA-N C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1)NC(=O)CCC(C)(C)C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1)NC(=O)CCC(C)(C)C)C1=NC=C(C2=CC=C(F)C=C2F)N1 APYVFBLORVZPCD-UTKZUKDTSA-N 0.000 description 2
- XMLCHSHJTCIHAG-DCEDVJGZSA-N C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(/C=C\C=C/2)O1 Chemical compound C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(/C=C\C=C/2)O1 XMLCHSHJTCIHAG-DCEDVJGZSA-N 0.000 description 2
- ZHLOIRLLDMNUIK-KKVCJECGSA-N C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CC1CC1)C1=NC=C(CC2=CC=CC=C2)N1 Chemical compound C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CC1CC1)C1=NC=C(CC2=CC=CC=C2)N1 ZHLOIRLLDMNUIK-KKVCJECGSA-N 0.000 description 2
- DKUMEDFVAXFYRL-WTIAFYNJSA-N C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)/C1=N/C2=C(C=CC=C2)S1 Chemical compound C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)/C1=N/C2=C(C=CC=C2)S1 DKUMEDFVAXFYRL-WTIAFYNJSA-N 0.000 description 2
- ANBAKKGQKFYYSW-MOPGFXCFSA-N C[C@H]1CCCCN1C(=O)CN(NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C(=O)NCc1ccc(F)cc1F Chemical compound C[C@H]1CCCCN1C(=O)CN(NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C(=O)NCc1ccc(F)cc1F ANBAKKGQKFYYSW-MOPGFXCFSA-N 0.000 description 2
- LCFOHJUUYLHZKH-SJORKVTESA-N C[C@H]1CCCCN1C(=O)CN(NC(=O)OC(C)(C)C)C(=O)C[C@@H](C)C(=O)NCc1ccc(F)cc1F Chemical compound C[C@H]1CCCCN1C(=O)CN(NC(=O)OC(C)(C)C)C(=O)C[C@@H](C)C(=O)NCc1ccc(F)cc1F LCFOHJUUYLHZKH-SJORKVTESA-N 0.000 description 2
- FNMWZRYNFZFVMW-WATLYSKOSA-N C[C@H]1CCCCN1C(=O)C[C@@H](C(=O)N[C@@H](C)C(=O)NCC2=CC(=CC=C2)N)NC(=O)CCC3=CC=CC=C3 Chemical compound C[C@H]1CCCCN1C(=O)C[C@@H](C(=O)N[C@@H](C)C(=O)NCC2=CC(=CC=C2)N)NC(=O)CCC3=CC=CC=C3 FNMWZRYNFZFVMW-WATLYSKOSA-N 0.000 description 2
- USIMFQSNOMLSSM-WWMYMODYSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN(C)C=N1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN(C)C=N1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 USIMFQSNOMLSSM-WWMYMODYSA-N 0.000 description 2
- YOZMUILZTKVOKZ-GUXCAODWSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 YOZMUILZTKVOKZ-GUXCAODWSA-N 0.000 description 2
- CUBHDVSEIOIFBU-JLHGSKIFSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CCC1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CCC1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 CUBHDVSEIOIFBU-JLHGSKIFSA-N 0.000 description 2
- REWFUSQCMSQKSV-RNHFSVANSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 REWFUSQCMSQKSV-RNHFSVANSA-N 0.000 description 2
- XJHGAIYJJXPXMO-JLHGSKIFSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 XJHGAIYJJXPXMO-JLHGSKIFSA-N 0.000 description 2
- LPBRGCXVPJBXIG-NMMYMHLASA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1 LPBRGCXVPJBXIG-NMMYMHLASA-N 0.000 description 2
- QLJFVSCJTVHMHK-IMWIBFENSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CCOCC1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CCOCC1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 QLJFVSCJTVHMHK-IMWIBFENSA-N 0.000 description 2
- FKCVVXOVNUKFAT-UFPGJGBJSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CCOCC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CCOCC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1 FKCVVXOVNUKFAT-UFPGJGBJSA-N 0.000 description 2
- VOTFFAPVOFOOCM-MSYCTHLASA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 VOTFFAPVOFOOCM-MSYCTHLASA-N 0.000 description 2
- NRZYXMBNUPZKDB-STSQHVNTSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC1CC1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC1CC1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 NRZYXMBNUPZKDB-STSQHVNTSA-N 0.000 description 2
- USOANEIYMBNKAL-YIIWZEITSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCc1ccccc1)C(=O)C[C@@H](C)C(=O)NCc1cccc(CC(=O)OC(C)(C)C)c1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCc1ccccc1)C(=O)C[C@@H](C)C(=O)NCc1cccc(CC(=O)OC(C)(C)C)c1 USOANEIYMBNKAL-YIIWZEITSA-N 0.000 description 2
- JTTBBCYOQKXBTQ-UFPGJGBJSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCc1ccccc1)C(=O)C[C@@H](C)C(=O)NCc1cccc(N)c1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCc1ccccc1)C(=O)C[C@@H](C)C(=O)NCc1cccc(N)c1 JTTBBCYOQKXBTQ-UFPGJGBJSA-N 0.000 description 2
- KWPPTMMDTCBWMX-RNHFSVANSA-N C[C@H]1CCCCN1C(=O)C[C@H](NCC(=O)C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NCC(=O)C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 KWPPTMMDTCBWMX-RNHFSVANSA-N 0.000 description 2
- DKKOQBOOBSVUKP-IMWIBFENSA-N C[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 DKKOQBOOBSVUKP-IMWIBFENSA-N 0.000 description 2
- BIWOCCSUIFXSLF-RNHFSVANSA-N C[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 BIWOCCSUIFXSLF-RNHFSVANSA-N 0.000 description 2
- GEESGPDOCKIVAW-STSQHVNTSA-N C[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)CCC1CC1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)CCC1CC1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 GEESGPDOCKIVAW-STSQHVNTSA-N 0.000 description 2
- WGYJOEXKOYNVTH-LQWHRVPQSA-N C[C@H]1CCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2)N1 Chemical compound C[C@H]1CCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2)N1 WGYJOEXKOYNVTH-LQWHRVPQSA-N 0.000 description 2
- CVGQDRGTGVAQBJ-FGSXEWAUSA-N C[C@H]1CCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H]1CCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 CVGQDRGTGVAQBJ-FGSXEWAUSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000002476 Falciparum Malaria Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000224467 Giardia intestinalis Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- UHKXMXJLVRANQJ-INIZCTEOSA-N N-[(2S)-1-[(2,4-difluorophenyl)methylamino]-1-oxopropan-2-yl]-2-(3-methylbutylamino)-6-pyrrolidin-1-ylpyrimidine-4-carboxamide Chemical compound FC1=C(C=CC(=C1)F)CNC([C@H](C)NC(=O)C1=NC(=NC(=C1)N1CCCC1)NCCC(C)C)=O UHKXMXJLVRANQJ-INIZCTEOSA-N 0.000 description 2
- SMHFTXQRWKFSID-YUXAGFNASA-N N-[(2S)-1-[[(1S)-1-(1,3-benzothiazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-5,5,5-trifluoropentanamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=CC=CC=C2S1 SMHFTXQRWKFSID-YUXAGFNASA-N 0.000 description 2
- NLSPWZUKCVDDFZ-WDJPJFJCSA-N N-[(2S)-1-[[(1S)-1-(1,3-benzoxazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-2,2-difluorospiro[3.3]heptane-6-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=CC=CC=C2O1 NLSPWZUKCVDDFZ-WDJPJFJCSA-N 0.000 description 2
- BBHCDQRFNMLWRP-IPJJNNNSSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-4-[(2S)-2-ethylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound N1C(=NC2=C1C=CC=C2)[C@H](C)NC(=O)[C@H](CC(=O)N1[C@H](CCCC1)CC)NC(CCC(C)C)=O BBHCDQRFNMLWRP-IPJJNNNSSA-N 0.000 description 2
- RBQGXMXRHXSXFM-IDNYDCHQSA-N N-[(2S)-1-[[(1S)-1-(5-benzyl-1H-imidazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2R)-2-phenylpyrrolidin-1-yl]butan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1=NOC(C)=C1)C1=NC=C(CC2=CC=CC=C2)N1 RBQGXMXRHXSXFM-IDNYDCHQSA-N 0.000 description 2
- YAJMMSBHADBYCQ-DOXZYTNZSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-1,3-thiazole-5-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1=CN=CS1)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 YAJMMSBHADBYCQ-DOXZYTNZSA-N 0.000 description 2
- NMBHQXJBXLYYGM-FTRWYGJKSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-1-methylimidazole-4-carboxamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)C1=CN(C)C=N1)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 NMBHQXJBXLYYGM-FTRWYGJKSA-N 0.000 description 2
- RCWMUJBTAMQTOD-SPEDKVCISA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4-methylpentanamide Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)N[C@@H](C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 RCWMUJBTAMQTOD-SPEDKVCISA-N 0.000 description 2
- YXVCTZKSFWUMJM-FIKGOQFSSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2S)-2-methylpyrrolidin-1-yl]-1,4-dioxobutan-2-yl]-4,4-dimethylpentanamide Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C)NC(=O)CCC(C)(C)C)C1=NC=C(N1)C1=C(F)C=C(F)C=C1 YXVCTZKSFWUMJM-FIKGOQFSSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241001220313 Syngamus trachea Species 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- IWDPWKLTLCLZLA-AWEZNQCLSA-N benzyl n-[(1s)-1-(5-phenyl-1h-imidazol-2-yl)ethyl]carbamate Chemical compound N([C@@H](C)C=1NC(=CN=1)C=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 IWDPWKLTLCLZLA-AWEZNQCLSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
- 229960002438 carfilzomib Drugs 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 108700002672 epoxomicin Proteins 0.000 description 2
- DOGIDQKFVLKMLQ-JTHVHQAWSA-N epoxomicin Chemical compound CC[C@H](C)[C@H](N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 DOGIDQKFVLKMLQ-JTHVHQAWSA-N 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 230000000646 gametocidal effect Effects 0.000 description 2
- 210000000973 gametocyte Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-N isocaproic acid Chemical compound CC(C)CCC(O)=O FGKJLKRYENPLQH-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960003648 ixazomib Drugs 0.000 description 2
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YSVAYZCFQNXNTH-HOTGVXAUSA-N tert-butyl N-[[(2S)-1-[(2,4-difluorophenyl)methylamino]-1-oxopropan-2-yl]carbamoyl-[2-[(2S)-2-methylpiperidin-1-yl]-2-oxoethyl]amino]carbamate Chemical compound FC1=C(CNC([C@H](C)NC(=O)N(NC(=O)OC(C)(C)C)CC(=O)N2[C@H](CCCC2)C)=O)C=CC(=C1)F YSVAYZCFQNXNTH-HOTGVXAUSA-N 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- AHDDRJBFJBDEPW-BDAKNGLRSA-N (1s,2s)-2-phenylcyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1 AHDDRJBFJBDEPW-BDAKNGLRSA-N 0.000 description 1
- MKOLWAGYWWWXDK-SPEDKVCISA-N (2S)-4-[(2S)-2-ethylpiperidin-1-yl]-N-[(1S)-1-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-2-[(5-methyl-1,3-benzoxazol-2-yl)amino]-4-oxobutanamide Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](Nc1nc2cc(C)ccc2o1)C(=O)N[C@@H](C)c1nc2c(F)cccc2[nH]1 MKOLWAGYWWWXDK-SPEDKVCISA-N 0.000 description 1
- AKKKYSLSCDVDMR-IBGZPJMESA-N (2S)-N'-tert-butyl-N-[1-(4-fluoro-1H-benzimidazol-2-yl)cyclopropyl]-2-[(4-methylphenyl)sulfonylamino]butanediamide Chemical compound C(C)(C)(C)NC(C[C@@H](C(=O)NC1(CC1)C1=NC2=C(N1)C=CC=C2F)NS(=O)(=O)C1=CC=C(C=C1)C)=O AKKKYSLSCDVDMR-IBGZPJMESA-N 0.000 description 1
- IOWZVYRNSVHLNR-FQEVSTJZSA-N (2S)-N'-tert-butyl-N-[1-(4-fluoro-1H-benzimidazol-2-yl)cyclopropyl]-2-[(4-methylphenyl)sulfonylamino]pentanediamide Chemical compound C(C)(C)(C)NC(CC[C@@H](C(=O)NC1(CC1)C1=NC2=C(N1)C=CC=C2F)NS(=O)(=O)C1=CC=C(C=C1)C)=O IOWZVYRNSVHLNR-FQEVSTJZSA-N 0.000 description 1
- WHQNSJDTHMMFRV-NRFANRHFSA-N (2S)-N'-tert-butyl-N-[1-(4-fluoro-1H-benzimidazol-2-yl)cyclopropyl]-2-[3-(4-fluorophenyl)propanoylamino]pentanediamide Chemical compound CC(NC(=O)CC[C@@H](C(=O)NC1(C2=NC3=C(N2)C(F)=CC=C3)CC1)NC(=O)CCC1=CC=C(F)C=C1)(C)C WHQNSJDTHMMFRV-NRFANRHFSA-N 0.000 description 1
- SPTVHFUSMUYJKI-CVDCTZTESA-N (2S)-N-[(2S)-1-(1H-indazol-7-ylmethylamino)-1-oxopropan-2-yl]-4-oxo-2-(3-phenylpropanoylamino)-4-pyrrolidin-1-ylbutanamide Chemical compound N1N=CC2=CC=CC(=C12)CNC([C@H](C)NC([C@H](CC(N1CCCC1)=O)NC(CCC1=CC=CC=C1)=O)=O)=O SPTVHFUSMUYJKI-CVDCTZTESA-N 0.000 description 1
- FLXVOOSWBFOFBS-RDPSFJRHSA-N (2S)-N-[(2S)-1-(1H-indol-7-ylmethylamino)-1-oxopropan-2-yl]-4-oxo-2-(3-phenylpropanoylamino)-4-pyrrolidin-1-ylbutanamide Chemical compound N1C=CC2=CC=CC(=C12)CNC([C@H](C)NC([C@H](CC(N1CCCC1)=O)NC(CCC1=CC=CC=C1)=O)=O)=O FLXVOOSWBFOFBS-RDPSFJRHSA-N 0.000 description 1
- JUTDHSGANMHVIC-SNVBAGLBSA-N (2r)-2-phenylpyrrolidine Chemical compound C1CCN[C@H]1C1=CC=CC=C1 JUTDHSGANMHVIC-SNVBAGLBSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- SOHLZANWVLCPHK-LBPRGKRZSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-phenylmethoxybutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(=O)OCC1=CC=CC=C1 SOHLZANWVLCPHK-LBPRGKRZSA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- MFXAGCQVWGPEJH-LRSLUSHPSA-N (2s)-2-[[(2s)-4-amino-2-[[(3r)-3-hydroxydodecanoyl]amino]-4-oxobutanoyl]amino]-n-[(2s)-4-methyl-1-oxopentan-2-yl]pentanediamide Chemical compound CCCCCCCCC[C@@H](O)CC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C=O MFXAGCQVWGPEJH-LRSLUSHPSA-N 0.000 description 1
- HFEDNVOKYCDBFD-FJXQXJEOSA-N (2s)-2-ethylpiperidine;hydrochloride Chemical compound Cl.CC[C@H]1CCCCN1 HFEDNVOKYCDBFD-FJXQXJEOSA-N 0.000 description 1
- LDRWTKQWSXGSTM-LBPRGKRZSA-N (3s)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-phenylmethoxybutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CC(O)=O)C(=O)OCC1=CC=CC=C1 LDRWTKQWSXGSTM-LBPRGKRZSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- YZVFSQQHQPPKNX-UHFFFAOYSA-N 1,3-thiazole-5-carboxylic acid Chemical compound OC(=O)C1=CN=CS1 YZVFSQQHQPPKNX-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- BVXJATDAUGZNFT-JXFKEZNVSA-N 2,2-difluoro-N-[(2S)-1-[[1-(4-fluoro-1H-benzimidazol-2-yl)cyclopropyl]amino]-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]spiro[3.3]heptane-6-carboxamide Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)NC1(CC1)C1=NC2=CC=CC(F)=C2N1 BVXJATDAUGZNFT-JXFKEZNVSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- BLDFSDCBQJUWFG-UHFFFAOYSA-N 2-(methylamino)-1,2-diphenylethanol Chemical compound C=1C=CC=CC=1C(NC)C(O)C1=CC=CC=C1 BLDFSDCBQJUWFG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BSQLQMLFTHJVKS-UHFFFAOYSA-N 2-chloro-1,3-benzothiazole Chemical compound C1=CC=C2SC(Cl)=NC2=C1 BSQLQMLFTHJVKS-UHFFFAOYSA-N 0.000 description 1
- BBVQDWDBTWSGHQ-UHFFFAOYSA-N 2-chloro-1,3-benzoxazole Chemical compound C1=CC=C2OC(Cl)=NC2=C1 BBVQDWDBTWSGHQ-UHFFFAOYSA-N 0.000 description 1
- CLEOKTJHYLXEKQ-UHFFFAOYSA-N 2-chloro-6-methyl-1,3-benzoxazole Chemical compound CC1=CC=C2N=C(Cl)OC2=C1 CLEOKTJHYLXEKQ-UHFFFAOYSA-N 0.000 description 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- QCXCIYPOMMIBHO-UHFFFAOYSA-N 2-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NC=C(C(O)=O)S1 QCXCIYPOMMIBHO-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- HBYCKISMJZSUDJ-UHFFFAOYSA-N 2-propan-2-ylcyclopropane-1-carboxylic acid Chemical compound CC(C)C1CC1C(O)=O HBYCKISMJZSUDJ-UHFFFAOYSA-N 0.000 description 1
- 229940126695 20S proteasome inhibitor Drugs 0.000 description 1
- KSNKQSPJFRQSEI-UHFFFAOYSA-N 3,3,3-trifluoropropanoic acid Chemical compound OC(=O)CC(F)(F)F KSNKQSPJFRQSEI-UHFFFAOYSA-N 0.000 description 1
- UWOAWSLEKWLDNR-UHFFFAOYSA-N 3,3-dimethylcyclobutane-1-carboxylic acid Chemical compound CC1(C)CC(C(O)=O)C1 UWOAWSLEKWLDNR-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- OJSCBKGRGMBEEW-UHFFFAOYSA-N 3-fluorobenzene-1,2-diamine Chemical compound NC1=CC=CC(F)=C1N OJSCBKGRGMBEEW-UHFFFAOYSA-N 0.000 description 1
- CAOXTJCSAJIUGW-UHFFFAOYSA-N 3-methylbutane-1-sulfonyl chloride Chemical compound CC(C)CCS(Cl)(=O)=O CAOXTJCSAJIUGW-UHFFFAOYSA-N 0.000 description 1
- HMMSZUQCCUWXRA-UHFFFAOYSA-N 4,4-dimethyl valeric acid Chemical compound CC(C)(C)CCC(O)=O HMMSZUQCCUWXRA-UHFFFAOYSA-N 0.000 description 1
- QUGADGXAROHCKR-UHFFFAOYSA-N 4-methyl-1,2-oxazole-3-carboxamide Chemical compound CC1=CON=C1C(N)=O QUGADGXAROHCKR-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000001819 4H-chromenyl group Chemical group O1C(=CCC2=CC=CC=C12)* 0.000 description 1
- SOSVJYSDQKQTHL-UHFFFAOYSA-N 5-chloro-3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazole Chemical compound C1=CC(F)=CC=C1CC1=NOC(Cl)=N1 SOSVJYSDQKQTHL-UHFFFAOYSA-N 0.000 description 1
- FBIASHIOEXPRSD-UHFFFAOYSA-N 5-chloro-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(Cl)=N1 FBIASHIOEXPRSD-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000498253 Ancylostoma duodenale Species 0.000 description 1
- 241000244188 Ascaris suum Species 0.000 description 1
- 241001455947 Babesia divergens Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001235572 Balantioides coli Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- XICISNCEJXXSCO-HLPFYSDJSA-N C(C)[C@@H]1N(CCCC1)C(C[C@@H](C(N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)=O)NC(=O)[C@@H]1[C@@H](C1)C1=CC=CC=C1)=O Chemical compound C(C)[C@@H]1N(CCCC1)C(C[C@@H](C(N[C@@H](C)C1=NC2=C(N1)C=CC=C2F)=O)NC(=O)[C@@H]1[C@@H](C1)C1=CC=CC=C1)=O XICISNCEJXXSCO-HLPFYSDJSA-N 0.000 description 1
- VJKQXJCBUKJYCF-JLMWRMLUSA-N C(C1=CC=CC=C1)C1=CN=C(N1)[C@H](C)NC(=O)[C@H](CC(=O)N1[C@H](CCCC1)C)NC(=O)C1=NOC(=C1)C Chemical compound C(C1=CC=CC=C1)C1=CN=C(N1)[C@H](C)NC(=O)[C@H](CC(=O)N1[C@H](CCCC1)C)NC(=O)C1=NOC(=C1)C VJKQXJCBUKJYCF-JLMWRMLUSA-N 0.000 description 1
- RBQGXMXRHXSXFM-NOOLENRPSA-N C(C1=CC=CC=C1)C1=CN=C(N1)[C@H](C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(=O)C1=NOC(=C1)C Chemical compound C(C1=CC=CC=C1)C1=CN=C(N1)[C@H](C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(=O)C1=NOC(=C1)C RBQGXMXRHXSXFM-NOOLENRPSA-N 0.000 description 1
- ZXBKCQNIWAUWNF-PUUVEUEGSA-N C(C1=CC=CC=C1)C1=CN=C(N1)[C@H](C)NC([C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(CC1CC1)=O)=O Chemical compound C(C1=CC=CC=C1)C1=CN=C(N1)[C@H](C)NC([C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(CC1CC1)=O)=O ZXBKCQNIWAUWNF-PUUVEUEGSA-N 0.000 description 1
- GGVOHQVJTKRIPQ-UHFFFAOYSA-N C1=CC2=C(C=C1)OCO2.COC1=CC=CC=C1 Chemical compound C1=CC2=C(C=C1)OCO2.COC1=CC=CC=C1 GGVOHQVJTKRIPQ-UHFFFAOYSA-N 0.000 description 1
- IACRFLDIMGKZEJ-UHFFFAOYSA-N C=C(CC(C)C)N1CCCCC1.C=C(CC(C)C)N1CCCCCC1.CC(=O)CC(C)C.CC(C)C(C)C.CC(C)CC(=O)N(C)C(C)C.CC(C)CC(=O)N1CCCC1.CC(C)CC(=O)N1CCCC1C.CC(C)CC(=O)N1CCCC1C1=CC=CC=C1.CC(C)CC(=O)N1CCCC1C1CC1.CC(C)CC(=O)N1CCCCC1C.CC(C)CC(=O)N1CCCCC1C(C)(F)F.CC(C)CC(=O)N1CCCCC1C(C)C.CC(C)CC(=O)N1CCOCC1C.CC(C)CC(=O)NC(C)(C)C.CC(C)CC(=O)OCC1=CC=CC=C1.CC(C)CCC(=O)NC(C)(C)C.CC(C)CCC(=O)NC(C)(C)C.CCC1CCCCN1C(=O)CC(C)C.CCN(CC)C(=O)CC(C)C Chemical compound C=C(CC(C)C)N1CCCCC1.C=C(CC(C)C)N1CCCCCC1.CC(=O)CC(C)C.CC(C)C(C)C.CC(C)CC(=O)N(C)C(C)C.CC(C)CC(=O)N1CCCC1.CC(C)CC(=O)N1CCCC1C.CC(C)CC(=O)N1CCCC1C1=CC=CC=C1.CC(C)CC(=O)N1CCCC1C1CC1.CC(C)CC(=O)N1CCCCC1C.CC(C)CC(=O)N1CCCCC1C(C)(F)F.CC(C)CC(=O)N1CCCCC1C(C)C.CC(C)CC(=O)N1CCOCC1C.CC(C)CC(=O)NC(C)(C)C.CC(C)CC(=O)OCC1=CC=CC=C1.CC(C)CCC(=O)NC(C)(C)C.CC(C)CCC(=O)NC(C)(C)C.CCC1CCCCN1C(=O)CC(C)C.CCN(CC)C(=O)CC(C)C IACRFLDIMGKZEJ-UHFFFAOYSA-N 0.000 description 1
- RYZZDYBNXQXBNN-UHFFFAOYSA-N C=C(CC(C)C)N1CCCCC1.C=C(CC(C)C)N1CCCCCC1.CC(C)CC(=O)N1CCCCC1C(C)(F)F.CC(C)CC(=O)N1CCCCC1C(C)C.CC(C)CC(=O)N1CCOCC1C Chemical compound C=C(CC(C)C)N1CCCCC1.C=C(CC(C)C)N1CCCCCC1.CC(C)CC(=O)N1CCCCC1C(C)(F)F.CC(C)CC(=O)N1CCCCC1C(C)C.CC(C)CC(=O)N1CCOCC1C RYZZDYBNXQXBNN-UHFFFAOYSA-N 0.000 description 1
- YNMUXWBQHZFOOI-UHFFFAOYSA-N CC(C)(C)CCC1=CC=CC=C1.CC(C)CC1=CC=CC=C1.CC(C)CCCC1=CC=CC=C1 Chemical compound CC(C)(C)CCC1=CC=CC=C1.CC(C)CC1=CC=CC=C1.CC(C)CCCC1=CC=CC=C1 YNMUXWBQHZFOOI-UHFFFAOYSA-N 0.000 description 1
- BIIQBQSVNXSPSO-HXUWFJFHSA-N CC(C)(C)NC(=O)CC[C@H](CC(=O)CCC1=CC=C(F)C=C1)C(=O)NC1(/C2=N/C3=CC=CC(F)=C3C2)CC1 Chemical compound CC(C)(C)NC(=O)CC[C@H](CC(=O)CCC1=CC=C(F)C=C1)C(=O)NC1(/C2=N/C3=CC=CC(F)=C3C2)CC1 BIIQBQSVNXSPSO-HXUWFJFHSA-N 0.000 description 1
- ZVEUHRBIXCHLOZ-QHCPKHFHSA-N CC(C)(C)NC(=O)CC[C@H](NC(=O)CCC1=CC=C(F)C=C1)C(=O)NC1(C2=NC3=CC=CC(F)=C3C2)CC1 Chemical compound CC(C)(C)NC(=O)CC[C@H](NC(=O)CCC1=CC=C(F)C=C1)C(=O)NC1(C2=NC3=CC=CC(F)=C3C2)CC1 ZVEUHRBIXCHLOZ-QHCPKHFHSA-N 0.000 description 1
- QLKNJHNFIJKVJH-UHFFFAOYSA-N CC(C)/C1=N/C2=C(C=CC=C2)N1.CC(C)/C1=N/C2=C(C=CC=C2)N1C(C)C.CC(C)/C1=N/C2=C(C=CC=C2)O1.CC(C)/C1=N/C2=C(C=CC=C2)S1.CC(C)C.CC(C)C.CC(C)C.CC(C)C1=CN=C(C(C)C)N1 Chemical compound CC(C)/C1=N/C2=C(C=CC=C2)N1.CC(C)/C1=N/C2=C(C=CC=C2)N1C(C)C.CC(C)/C1=N/C2=C(C=CC=C2)O1.CC(C)/C1=N/C2=C(C=CC=C2)S1.CC(C)C.CC(C)C.CC(C)C.CC(C)C1=CN=C(C(C)C)N1 QLKNJHNFIJKVJH-UHFFFAOYSA-N 0.000 description 1
- BQHRITWXPXRXBE-UHFFFAOYSA-N CC(C)C(C)O.CC(C)CC(=O)N(C)C(C)C.CC(C)CC(=O)N1CCCC1.CC(C)CC(=O)N1CCCC1C.CC(C)CC(=O)N1CCCC1C1=CC=CC=C1.CC(C)CC(=O)N1CCCC1C1CC1.CC(C)CC(=O)N1CCCCC1C.CC(C)CC(=O)NC(C)(C)C.CC(C)CC(=O)O.CC(C)CC(=O)OCC1=CC=CC=C1.CC(C)CCC(=O)NC(C)(C)C.CC(C)CCC(=O)NC(C)(C)C.CCC1CCCCN1C(=O)CC(C)C.CCN(CC)C(=O)CC(C)C Chemical compound CC(C)C(C)O.CC(C)CC(=O)N(C)C(C)C.CC(C)CC(=O)N1CCCC1.CC(C)CC(=O)N1CCCC1C.CC(C)CC(=O)N1CCCC1C1=CC=CC=C1.CC(C)CC(=O)N1CCCC1C1CC1.CC(C)CC(=O)N1CCCCC1C.CC(C)CC(=O)NC(C)(C)C.CC(C)CC(=O)O.CC(C)CC(=O)OCC1=CC=CC=C1.CC(C)CCC(=O)NC(C)(C)C.CC(C)CCC(=O)NC(C)(C)C.CCC1CCCCN1C(=O)CC(C)C.CCN(CC)C(=O)CC(C)C BQHRITWXPXRXBE-UHFFFAOYSA-N 0.000 description 1
- RFWHNLDCUHZBTQ-ZJIJYXDWSA-N CC(C)C(C1)C1C(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)=O Chemical compound CC(C)C(C1)C1C(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)=O RFWHNLDCUHZBTQ-ZJIJYXDWSA-N 0.000 description 1
- KGCZQDICLUAJTO-UHFFFAOYSA-N CC(C)C.CC(C)C.CC(C)C.CC(C)C1=CC=CC2=C1N/C=C\2.CC(C)C1=CC=CC2=C1N/N=C\2.CC(C)C1=CC=CC=C1 Chemical compound CC(C)C.CC(C)C.CC(C)C.CC(C)C1=CC=CC2=C1N/C=C\2.CC(C)C1=CC=CC2=C1N/N=C\2.CC(C)C1=CC=CC=C1 KGCZQDICLUAJTO-UHFFFAOYSA-N 0.000 description 1
- ABQYORNLWCYGOR-UHFFFAOYSA-N CC(C)C.CC(C)C.CC(C)C.CC(C)C1=CN=C(C(C)C)N1.CC(C)C1=NC2=C(C=CC=C2)N1.CC(C)C1=NC2=C(C=CC=C2)N1C(C)C.CC(C)C1=NC2=C(C=CC=C2)O1.CC(C)C1=NC2=C(C=CC=C2)S1.CC(C)NC(=O)C(C)C Chemical compound CC(C)C.CC(C)C.CC(C)C.CC(C)C1=CN=C(C(C)C)N1.CC(C)C1=NC2=C(C=CC=C2)N1.CC(C)C1=NC2=C(C=CC=C2)N1C(C)C.CC(C)C1=NC2=C(C=CC=C2)O1.CC(C)C1=NC2=C(C=CC=C2)S1.CC(C)NC(=O)C(C)C ABQYORNLWCYGOR-UHFFFAOYSA-N 0.000 description 1
- GUZJBFUYVOFAPT-UHFFFAOYSA-N CC(C)C.CC(C)C.CC(C)C1=CC=CC2=C1NC=C2.CC(C)C1=CC=CC2=C1NN=C2 Chemical compound CC(C)C.CC(C)C.CC(C)C1=CC=CC2=C1NC=C2.CC(C)C1=CC=CC2=C1NN=C2 GUZJBFUYVOFAPT-UHFFFAOYSA-N 0.000 description 1
- VUFSLUBVLWQERW-UHFFFAOYSA-N CC(C)C.CC(C)C1=CC=CC=C1 Chemical compound CC(C)C.CC(C)C1=CC=CC=C1 VUFSLUBVLWQERW-UHFFFAOYSA-N 0.000 description 1
- OVCBFYUKZQEEGZ-IBIIDCDHSA-N CC(C)C1CC1C(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC(C)C1CC1C(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 OVCBFYUKZQEEGZ-IBIIDCDHSA-N 0.000 description 1
- JUMWUGMTACUIMJ-VGRQQRRBSA-N CC(C)C1CC1C(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC3=C(C=CC=C3)N2)=NO1.C[C@@H](CC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)CCC(C)(C)C)C1=NC2=C(C=CC=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 Chemical compound CC(C)C1CC1C(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC3=C(C=CC=C3)N2)=NO1.C[C@@H](CC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)CCC(C)(C)C)C1=NC2=C(C=CC=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 JUMWUGMTACUIMJ-VGRQQRRBSA-N 0.000 description 1
- ATTYATPJKKXZAX-WEALKAMMSA-N CC(C)C1CC1C(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2F)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2F)N1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC3=C(C=CC=C3)N2)=NO1.C[C@@H](CC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)CCC(C)(C)C)C1=NC2=C(C=CC=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1 Chemical compound CC(C)C1CC1C(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2F)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2F)N1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC3=C(C=CC=C3)N2)=NO1.C[C@@H](CC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)CCC(C)(C)C)C1=NC2=C(C=CC=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1 ATTYATPJKKXZAX-WEALKAMMSA-N 0.000 description 1
- BGUPSURWSIZOGF-ODOWMPGOSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)CCC1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC3=C(C=CC=C3F)N2)S1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(CC2=CC=C(F)C=C2)=NO1)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)C1.CC[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2C)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)CCC1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC3=C(C=CC=C3F)N2)S1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(CC2=CC=C(F)C=C2)=NO1)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)C1.CC[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2C)N1 BGUPSURWSIZOGF-ODOWMPGOSA-N 0.000 description 1
- NTGSPCMJOPZFLO-DXIQSLLYSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2)N1 NTGSPCMJOPZFLO-DXIQSLLYSA-N 0.000 description 1
- XKNWEGJDKKARRF-LYFZHLORSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)NCC1=NC2=C(C=CC=C2)N1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)CC(C)/C2=N/C3=C(C=CC=C3)N2)=NO1.CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC3=C(C=CC=C3F)N2)S1.C[C@H]1CCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)NCC1=NC2=C(C=CC=C2)N1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)CC(C)/C2=N/C3=C(C=CC=C3)N2)=NO1.CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC3=C(C=CC=C3F)N2)S1.C[C@H]1CCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1 XKNWEGJDKKARRF-LYFZHLORSA-N 0.000 description 1
- IIFJZRGVBDHQNJ-LQWHRVPQSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 IIFJZRGVBDHQNJ-LQWHRVPQSA-N 0.000 description 1
- RLZNPIJOTNJUTI-PBTPRMJDSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1 RLZNPIJOTNJUTI-PBTPRMJDSA-N 0.000 description 1
- FKIIUPQPMVQIGT-CEVDQSQBSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)=NO1.CC1CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)C1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=C(C)C=C2F)N1.C[C@@H](CC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)OCC1=CC=CC=C1)C1=NC2=C(C=CC=C2F)N1.C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(COC2)C1)C1=NC2=C(N1)C(F)=CC=C2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(COC2)C1)C(=O)C[C@@H](C)C1=NC2=C(N1)C(F)=CC=C2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)=NO1.CC1CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)C1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=C(C)C=C2F)N1.C[C@@H](CC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)OCC1=CC=CC=C1)C1=NC2=C(C=CC=C2F)N1.C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(COC2)C1)C1=NC2=C(N1)C(F)=CC=C2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(COC2)C1)C(=O)C[C@@H](C)C1=NC2=C(N1)C(F)=CC=C2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 FKIIUPQPMVQIGT-CEVDQSQBSA-N 0.000 description 1
- STKBCXWTZONYRZ-LQBCJMIYSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(COC2)C1)/C1=N/C2=C(N1)C(F)=CC=C2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(COC2)C1)/C1=N/C2=C(N1)C(F)=CC=C2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 STKBCXWTZONYRZ-LQBCJMIYSA-N 0.000 description 1
- YHKLYBBKEWAYCQ-YBSZAXQISA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1.CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1.CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)=NO1.CC1=CC=CC2=C1CC(C1(NC(=O)[C@@H](CC(=O)N3CCCC[C@H]3C)NC(=O)C3CC4(C3)CC(F)(F)C4)CC1)N2.C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(N1)C(F)=CC=C2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)C[C@@H](C)C1=NC2=C(N1)C(F)=CC=C2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1.CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1.CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)=NO1.CC1=CC=CC2=C1CC(C1(NC(=O)[C@@H](CC(=O)N3CCCC[C@H]3C)NC(=O)C3CC4(C3)CC(F)(F)C4)CC1)N2.C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(N1)C(F)=CC=C2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)C[C@@H](C)C1=NC2=C(N1)C(F)=CC=C2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 YHKLYBBKEWAYCQ-YBSZAXQISA-N 0.000 description 1
- RLZNPIJOTNJUTI-QGUKFAFCSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1 RLZNPIJOTNJUTI-QGUKFAFCSA-N 0.000 description 1
- RLZNPIJOTNJUTI-OUIFVKKZSA-N CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1 Chemical compound CC(C)CCC(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1 RLZNPIJOTNJUTI-OUIFVKKZSA-N 0.000 description 1
- UWNADWZGEHDQAB-UHFFFAOYSA-N CC(C)CCC(C)C Chemical compound CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 1
- WTYPKXUOWPSIBQ-DUXSLQFZSA-N CC(C)CCC(N[C@@H](CC(N(CCC1)[C@H]1c1ccccc1)=O)C(NC(C)C1=NC2=CC=CCC2=N1)=O)=O Chemical compound CC(C)CCC(N[C@@H](CC(N(CCC1)[C@H]1c1ccccc1)=O)C(NC(C)C1=NC2=CC=CCC2=N1)=O)=O WTYPKXUOWPSIBQ-DUXSLQFZSA-N 0.000 description 1
- RNFRKDCTOLTDGJ-JWNTYJGQSA-N CC(C)CCC(N[C@@H](CC(N(CCCC1)[C@H]1C(F)(F)F)=O)C(N[C@@H](C)c1nc(-c(c(F)c2)ccc2F)c[n]1C)=O)=O Chemical compound CC(C)CCC(N[C@@H](CC(N(CCCC1)[C@H]1C(F)(F)F)=O)C(N[C@@H](C)c1nc(-c(c(F)c2)ccc2F)c[n]1C)=O)=O RNFRKDCTOLTDGJ-JWNTYJGQSA-N 0.000 description 1
- QFHFGANOBLFXLG-JERZPMBSSA-N CC(C)CCC(N[C@@H](CC(N1CCCCCC1)=O)C(N[C@@H](C)C1=NCC(C(C=CC(F)=C2)C2=[F])=N1)=O)=O Chemical compound CC(C)CCC(N[C@@H](CC(N1CCCCCC1)=O)C(N[C@@H](C)C1=NCC(C(C=CC(F)=C2)C2=[F])=N1)=O)=O QFHFGANOBLFXLG-JERZPMBSSA-N 0.000 description 1
- XOMSMBZLGAZXLQ-SPEDKVCISA-N CC(C)CCC(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@@H](C)C1=NCC(c(ccc(F)c2)c2F)=N1)=O)=O Chemical compound CC(C)CCC(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@@H](C)C1=NCC(c(ccc(F)c2)c2F)=N1)=O)=O XOMSMBZLGAZXLQ-SPEDKVCISA-N 0.000 description 1
- HTZQSLDXANTUGO-VHRCFOOQSA-N CC(C)CCC(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@H](C)C1=NC(C=CC=C2)C2=N1)=O)=O Chemical compound CC(C)CCC(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@H](C)C1=NC(C=CC=C2)C2=N1)=O)=O HTZQSLDXANTUGO-VHRCFOOQSA-N 0.000 description 1
- BKUUSEFMVWDIEX-MSYCTHLASA-N CC(C)CCC(N[C@@H](CC(N1[C@H](C)CCCC1)=O)C(N[C@@H](C)c1nc(-c(c(F)c2)ccc2F)c[n]1C)=O)=O Chemical compound CC(C)CCC(N[C@@H](CC(N1[C@H](C)CCCC1)=O)C(N[C@@H](C)c1nc(-c(c(F)c2)ccc2F)c[n]1C)=O)=O BKUUSEFMVWDIEX-MSYCTHLASA-N 0.000 description 1
- HRNQRAAKORRRQT-FETYVJPBSA-N CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)/C1=N/C2=C(C=CC=C2)N1.CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2)N1.CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(N1)/C(F)=C\C=C/2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 Chemical compound CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)/C1=N/C2=C(C=CC=C2)N1.CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2)N1.CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1.C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(N1)/C(F)=C\C=C/2.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 HRNQRAAKORRRQT-FETYVJPBSA-N 0.000 description 1
- IULHUQBMPCJWRH-PBTPRMJDSA-N CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1 Chemical compound CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)CC(C)C1=NC2=C(C=CC=C2)N1 IULHUQBMPCJWRH-PBTPRMJDSA-N 0.000 description 1
- IULHUQBMPCJWRH-QGUKFAFCSA-N CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1 Chemical compound CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1 IULHUQBMPCJWRH-QGUKFAFCSA-N 0.000 description 1
- IULHUQBMPCJWRH-OUIFVKKZSA-N CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1 Chemical compound CC(C)CCS(=O)(=O)N[C@@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C(=O)C[C@H](C)C1=NC2=C(C=CC=C2)N1 IULHUQBMPCJWRH-OUIFVKKZSA-N 0.000 description 1
- TUFJDQAUSXNOLP-UHFFFAOYSA-N CC(C)CCS(C(C)C)(=N)=O Chemical compound CC(C)CCS(C(C)C)(=N)=O TUFJDQAUSXNOLP-UHFFFAOYSA-N 0.000 description 1
- IETMUJIZBYAPDI-DUXSLQFZSA-N CC(C)CCS(N[C@@H](CC(N(CCC1)[C@H]1c1ccccc1)=O)C(NC(C)C1=NC2=CC=CCC2=N1)=O)(=O)=O Chemical compound CC(C)CCS(N[C@@H](CC(N(CCC1)[C@H]1c1ccccc1)=O)C(NC(C)C1=NC2=CC=CCC2=N1)=O)(=O)=O IETMUJIZBYAPDI-DUXSLQFZSA-N 0.000 description 1
- UXUUHOINYQUTAW-LHGHHUKDSA-N CC(C)CCS(N[C@@H](CC(N(CCC1)[C@H]1c1ccccc1)=O)C(N[C@H](C)C1=NC(C=CC=C2)C2=N1)=O)(=O)=O Chemical compound CC(C)CCS(N[C@@H](CC(N(CCC1)[C@H]1c1ccccc1)=O)C(N[C@H](C)C1=NC(C=CC=C2)C2=N1)=O)(=O)=O UXUUHOINYQUTAW-LHGHHUKDSA-N 0.000 description 1
- GMWCPZKHFXKMDT-HZGQRYOBSA-N CC(C)CS(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@@H](C)C(NC1C2CCCCCCC2)NC1c(ccc(F)c1)c1F)=O)(=O)=O Chemical compound CC(C)CS(N[C@@H](CC(N1[C@@H](C)CCCC1)=O)C(N[C@@H](C)C(NC1C2CCCCCCC2)NC1c(ccc(F)c1)c1F)=O)(=O)=O GMWCPZKHFXKMDT-HZGQRYOBSA-N 0.000 description 1
- IGZDXYHMGWRJAZ-UHFFFAOYSA-N CC(C)NC(=O)C(C)C Chemical compound CC(C)NC(=O)C(C)C IGZDXYHMGWRJAZ-UHFFFAOYSA-N 0.000 description 1
- JSQVPZMUPFJPDA-FTRWYGJKSA-N CC(C)c1n[o]c(N[C@@H](CC(N2[C@@H](C)CCCC2)=O)C(N[C@@H](C)C2=NCC(c(ccc(F)c3)c3F)=N2)=O)n1 Chemical compound CC(C)c1n[o]c(N[C@@H](CC(N2[C@@H](C)CCCC2)=O)C(N[C@@H](C)C2=NCC(c(ccc(F)c3)c3F)=N2)=O)n1 JSQVPZMUPFJPDA-FTRWYGJKSA-N 0.000 description 1
- TYTIAXVEDYPXLA-SNLKNMPISA-N CC1=C2CC(C3(NC(=O)[C@H](CCC(=O)NC(C)(C)C)CC(=O)CCC4=CC=C(F)C=C4)CC3)=NC2=CC=C1.CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3F)C2)=NO1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC3)NC(=O)CCC(C)C)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)NC(=O)[C@H](CC(=O)N(C)C(C)C)NC(=O)CCC(C)C)N2)C=C1.CCN(CC)C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)N[C@@H](C)C1=NC=C(C2=C(F)C=C(C)C=C2)N1.CN[C@@H](CC(=O)O)C(=O)C[C@@H](C)C1=NC=C(C2=CC=CC=C2F)N1.C[C@H](CC(=O)[C@H](CC(=O)OCC1=CC=CC=C1)NC(=O)OC(C)(C)C)C1=NC=C(C2=CC=CC=C2F)N1.C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCCC[C@@H]1C)C1=NC=C(C2=C(F)C=C(F)C=C2)C1.C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C1=NC=C(C2=C(F)C=CC=C2)C1.C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)OC(C)(C)C)C1=NC=C(C2=C(F)C=CC=C2)C1 Chemical compound CC1=C2CC(C3(NC(=O)[C@H](CCC(=O)NC(C)(C)C)CC(=O)CCC4=CC=C(F)C=C4)CC3)=NC2=CC=C1.CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3F)C2)=NO1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC3)NC(=O)CCC(C)C)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)NC(=O)[C@H](CC(=O)N(C)C(C)C)NC(=O)CCC(C)C)N2)C=C1.CCN(CC)C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)N[C@@H](C)C1=NC=C(C2=C(F)C=C(C)C=C2)N1.CN[C@@H](CC(=O)O)C(=O)C[C@@H](C)C1=NC=C(C2=CC=CC=C2F)N1.C[C@H](CC(=O)[C@H](CC(=O)OCC1=CC=CC=C1)NC(=O)OC(C)(C)C)C1=NC=C(C2=CC=CC=C2F)N1.C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCCC[C@@H]1C)C1=NC=C(C2=C(F)C=C(F)C=C2)C1.C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C1=NC=C(C2=C(F)C=CC=C2)C1.C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)OC(C)(C)C)C1=NC=C(C2=C(F)C=CC=C2)C1 TYTIAXVEDYPXLA-SNLKNMPISA-N 0.000 description 1
- PAOFCGFSBIRIOM-OECDRGGWSA-N CC1=C2NC(C3(NC(=O)[C@H](CCC(=O)NC(C)(C)C)NC(=O)CCC4=CC=C(F)C=C4)CC3)=NC2=CC=C1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3F)N2)=NO1.CN[C@@H](CC(=O)O)C(=O)N[C@@H](C)C1=NC=C(C2=CC=CC=C2F)N1.C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCCC[C@@H]1C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1.C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C1=NC=C(C2=C(F)C=CC=C2)N1.C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)OC(C)(C)C)C1=NC=C(C2=C(F)C=CC=C2)N1.C[C@H](NC(=O)[C@H](CC(=O)OCC1=CC=CC=C1)NC(=O)OC(C)(C)C)C1=NC=C(C2=CC=CC=C2F)N1 Chemical compound CC1=C2NC(C3(NC(=O)[C@H](CCC(=O)NC(C)(C)C)NC(=O)CCC4=CC=C(F)C=C4)CC3)=NC2=CC=C1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3F)N2)=NO1.CN[C@@H](CC(=O)O)C(=O)N[C@@H](C)C1=NC=C(C2=CC=CC=C2F)N1.C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCCC[C@@H]1C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1.C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C1=NC=C(C2=C(F)C=CC=C2)N1.C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)OC(C)(C)C)C1=NC=C(C2=C(F)C=CC=C2)N1.C[C@H](NC(=O)[C@H](CC(=O)OCC1=CC=CC=C1)NC(=O)OC(C)(C)C)C1=NC=C(C2=CC=CC=C2F)N1 PAOFCGFSBIRIOM-OECDRGGWSA-N 0.000 description 1
- RKEKABPRAJNGHB-HUOGWEQVSA-N CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3F)C2)=NO1 Chemical compound CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3F)C2)=NO1 RKEKABPRAJNGHB-HUOGWEQVSA-N 0.000 description 1
- RHILKEMHJRBGPE-BYUYDETGSA-N CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3)C2)=NO1.CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(CC3=CC=CC=C3)C2)=NO1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CC1CC1)C1=NC=C(CC2=CC=CC=C2)N1.C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC1=NC2=C(C=CC=C2)O1)C1=NC=C(C2=CC=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CCOCC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1 Chemical compound CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3)C2)=NO1.CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(CC3=CC=CC=C3)C2)=NO1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CC1CC1)C1=NC=C(CC2=CC=CC=C2)N1.C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC1=NC2=C(C=CC=C2)O1)C1=NC=C(C2=CC=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CCOCC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1 RHILKEMHJRBGPE-BYUYDETGSA-N 0.000 description 1
- IKFCFPPQLMPVQU-BGWZLZDWSA-N CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3)C2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCCC2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1.CC1=CC=C(C2=CN=C([C@H](C)NC(=O)[C@@H](CC(=O)C3=NOC(C)=C3)CC(=O)N3CCC[C@@H]3C3=CC=CC=C3)C2)C(F)=C1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CC1CC1)C1=NC=C(CC2=CC=CC=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CCOCC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1 Chemical compound CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3)C2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCCC2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1.CC1=CC=C(C2=CN=C([C@H](C)NC(=O)[C@@H](CC(=O)C3=NOC(C)=C3)CC(=O)N3CCC[C@@H]3C3=CC=CC=C3)C2)C(F)=C1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CC1CC1)C1=NC=C(CC2=CC=CC=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CCOCC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1 IKFCFPPQLMPVQU-BGWZLZDWSA-N 0.000 description 1
- BVVHPXCPQGZKHV-HKLKAILGSA-N CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3F)C2)=NO1 Chemical compound CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=CC=C3F)C2)=NO1 BVVHPXCPQGZKHV-HKLKAILGSA-N 0.000 description 1
- SDXNUVVVWAGZQU-DWCCUSHNSA-N CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(CC3=CC=CC=C3)C2)=NO1.C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C/C1=N/C2=C(C=CC=C2)O1)C1=NC=C(C2=CC=CC=C2F)C1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1 Chemical compound CC1=CC(C(=O)C[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)N[C@@H](C)C2=NC=C(CC3=CC=CC=C3)C2)=NO1.C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C/C1=N/C2=C(C=CC=C2)O1)C1=NC=C(C2=CC=CC=C2F)C1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC=C(CC2=CC=CC=C2)N1 SDXNUVVVWAGZQU-DWCCUSHNSA-N 0.000 description 1
- CUZSYRJIGZGRHU-KUHUBIRLSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC2)C(=O)C[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3F)N2)=NO1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC2)C(=O)C[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3F)N2)=NO1 CUZSYRJIGZGRHU-KUHUBIRLSA-N 0.000 description 1
- GRZQQOPKMOXYKT-XYUCKWBGSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC2)C(=O)C[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3F)N2)=NO1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC3)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCCCC3)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3CC3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC3CC3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NCC(=O)C(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCC[C@@H]3C)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CCS(=O)(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(C)C=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CCC1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC2)C(=O)C[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3F)N2)=NO1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC3)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCCCC3)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3CC3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC3CC3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NCC(=O)C(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCC[C@@H]3C)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CCS(=O)(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(C)C=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CCC1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 GRZQQOPKMOXYKT-XYUCKWBGSA-N 0.000 description 1
- YTGIVHDXVIDCRR-MZGSFOEGSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3F)N2)=NO1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC3)NC(=O)CCC(C)C)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)NC(=O)[C@H](CC(=O)N(C)C(C)C)NC(=O)CCC(C)C)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3CC3)N2)C(F)=C1.CCN(C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)N[C@@H](C)C1=NC=C(C2=CC=C(C)C=C2F)N1)C(C)C.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CCC1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC2)C(=O)N[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3F)N2)=NO1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC3)NC(=O)CCC(C)C)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)NC(=O)[C@H](CC(=O)N(C)C(C)C)NC(=O)CCC(C)C)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3CC3)N2)C(F)=C1.CCN(C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)N[C@@H](C)C1=NC=C(C2=CC=C(C)C=C2F)N1)C(C)C.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CCC1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 YTGIVHDXVIDCRR-MZGSFOEGSA-N 0.000 description 1
- OZDDIDFDBJRSSS-FERNYGBRSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCCC2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1.CC1=CC=C(C2=CN=C([C@H](C)NC(=O)[C@@H](CC(=O)C3=NOC(C)=C3)CC(=O)N3CCC[C@@H]3C3=CC=CC=C3)C2)C(F)=C1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCCC2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=C(F)C=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=CC=CC=C3)N2)=NO1.CC1=CC=C(C2=CN=C([C@H](C)NC(=O)[C@@H](CC(=O)C3=NOC(C)=C3)CC(=O)N3CCC[C@@H]3C3=CC=CC=C3)C2)C(F)=C1 OZDDIDFDBJRSSS-FERNYGBRSA-N 0.000 description 1
- NHTZMYICFAOQNR-VJFJWILXSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)=NO1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)C3CC3C(C)C)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3=CC=CC=C3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCOC[C@@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)NC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC3=NC(C(C)C)=NO3)C2)C(F)=C1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(C)C=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN(C)C=N1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)=NO1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)C3CC3C(C)C)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3=CC=CC=C3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCOC[C@@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)NC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC3=NC(C(C)C)=NO3)C2)C(F)=C1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(C)C=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN(C)C=N1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 NHTZMYICFAOQNR-VJFJWILXSA-N 0.000 description 1
- YHFGUSMXKRLICR-CVEXFGIFSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)=NO1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCCCC3)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCOC[C@@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)NC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC3=NC(C(C)C)=NO3)N2)C(F)=C1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN(C)C=N1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)=NO1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCCCC3)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCOC[C@@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)NC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC3=NC(C(C)C)=NO3)N2)C(F)=C1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN(C)C=N1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 YHFGUSMXKRLICR-CVEXFGIFSA-N 0.000 description 1
- XBJKRRAHVJMLDI-OYHZEJGOSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)=NO1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)=NO1 XBJKRRAHVJMLDI-OYHZEJGOSA-N 0.000 description 1
- KKIIKVXIIGXIMU-MFDWLUCJSA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)C[C@@H](C)C2=NC3=C(/C=C\C=C/3)N2)=NO1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCC(C)(C)C)C1=NC2=C(C=CC=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)=NO1.CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)C[C@@H](C)C2=NC3=C(/C=C\C=C/3)N2)=NO1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCC(C)(C)C)C1=NC2=C(C=CC=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 KKIIKVXIIGXIMU-MFDWLUCJSA-N 0.000 description 1
- XBJKRRAHVJMLDI-FMNCTDSISA-N CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)C[C@@H](C)C2=NC3=C(C=CC=C3)N2)=NO1 Chemical compound CC1=CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)C[C@@H](C)C2=NC3=C(C=CC=C3)N2)=NO1 XBJKRRAHVJMLDI-FMNCTDSISA-N 0.000 description 1
- ACGULSIVJAWPAH-DUEXAWGRSA-N CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)C3CC3C(C)C)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3=CC=CC=C3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)N[C@@H](C)C1=NC=C(C2=CC=C(C)C=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)C3CC3C(C)C)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3=CC=CC=C3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)N[C@@H](C)C1=NC=C(C2=CC=C(C)C=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 ACGULSIVJAWPAH-DUEXAWGRSA-N 0.000 description 1
- IKNDSWIQPKPTGC-KMANIZMESA-N CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CC(C)C)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CC3=CC=CC=C3)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CCC(C)C)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CCC3CC3)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCCC3C(C)C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C(F)(F)F)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3CCOCC3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NCC(=O)C3=CC=CC=C3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](NC(=O)N3CCCC[C@@H]3C)N/C3=N/C4=C(C=CC=C4)O3)N2)C(F)=C1.CC1=CC=C(S(=O)(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)C=C1.CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)S1.C[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CC(C)C)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CC3=CC=CC=C3)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CCC(C)C)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CCC3CC3)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCCC3C(C)C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C(F)(F)F)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3CCOCC3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NCC(=O)C3=CC=CC=C3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](NC(=O)N3CCCC[C@@H]3C)N/C3=N/C4=C(C=CC=C4)O3)N2)C(F)=C1.CC1=CC=C(S(=O)(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)C=C1.CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)S1.C[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 IKNDSWIQPKPTGC-KMANIZMESA-N 0.000 description 1
- UWYOTSRFUIBVQK-RWSQAYACSA-N CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CC(C)C)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CCC3CC3)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCCC3C(C)C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3CCOCC3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NCC(=O)C3=CC=CC=C3)N2)C(F)=C1.CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)S1 Chemical compound CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CC(C)C)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CCC3CC3)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCCC3C(C)C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CC3CCOCC3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NCC(=O)C3=CC=CC=C3)N2)C(F)=C1.CC1=NC=C(C(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)S1 UWYOTSRFUIBVQK-RWSQAYACSA-N 0.000 description 1
- KUDUALNMYQGVQC-QAKBZTOZSA-N CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CC3=CC=CC=C3)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CCC(C)C)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C(F)(F)F)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC3=NC4=C(C=CC=C4)O3)N2)C(F)=C1.CC1=CC=C(S(=O)(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)C=C1.C[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CC3=CC=CC=C3)N2)C=C1.CC1=CC(F)=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NS(=O)(=O)CCC(C)C)N2)C=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C(F)(F)F)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC3=NC4=C(C=CC=C4)O3)N2)C(F)=C1.CC1=CC=C(S(=O)(=O)N[C@@H](CC(=O)N2CCCC[C@@H]2C)C(=O)C[C@@H](C)C2=NC=C(C3=C(F)C=C(F)C=C3)N2)C=C1.C[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 KUDUALNMYQGVQC-QAKBZTOZSA-N 0.000 description 1
- OPCBPRQFIBRUIF-RTWAWAEBSA-N CC1=CC=C(C2=CN=C([C@H](C)CC(=O)N(CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)(C)C)N2)C(F)=C1 Chemical compound CC1=CC=C(C2=CN=C([C@H](C)CC(=O)N(CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)(C)C)N2)C(F)=C1 OPCBPRQFIBRUIF-RTWAWAEBSA-N 0.000 description 1
- ZSNBTYUWZRMWJW-XUSRKODNSA-N CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC3)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCCC3)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC3CC3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NCC(=O)C(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCC[C@@H]3C)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CCS(=O)(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(C)C=C2)N1 Chemical compound CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC3)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCCC3)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NC(=O)CCC3CC3)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCCC[C@@H]3C)NCC(=O)C(C)C)N2)C(F)=C1.CC1=CC=C(C2=CN=C([C@H](C)CC(=O)[C@H](CC(=O)N3CCC[C@@H]3C)NC(=O)CCC(C)(C)C)N2)C(F)=C1.CCS(=O)(=O)N[C@@H](CC(=O)N1CCCC[C@@H]1C)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(C)C=C2)N1 ZSNBTYUWZRMWJW-XUSRKODNSA-N 0.000 description 1
- QCCXFNRZNCDLQN-VZECBTOASA-N CC1=CC=C(S(=O)(=O)C[C@@H](CC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)C3)CC2)C=C1.CC1=CC=C(S(=O)(=O)C[C@@H](CCC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)C3)CC2)C=C1.CC1=CC=C(S(=O)(=O)C[C@H](C(=O)N[C@@H](C)C2=NC3=CC=CC(C)=C3C2)[C@@H](C)O)C=C1.CC1=CC=CC2=C1NC(C1(CC(=O)[C@H](CC(=O)N3CCCC3C3CC3)NC(=O)C3CC4(C3)CC(F)(F)C4)CC1)=N2.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(C=CC=C2)O1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)N1C.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)O1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)S1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@H]1C1=CC=CC=C1)NC(=O)C1CC2(COC2)C1)C1=NC2=C(N1)C(F)=CC=C2.C[C@H](NC(=O)[C@@H](CC(=O)CCC1=CC=C(F)C=C1)[C@@H](C)O)C1=NC2=C(C=CC=C2F)C1 Chemical compound CC1=CC=C(S(=O)(=O)C[C@@H](CC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)C3)CC2)C=C1.CC1=CC=C(S(=O)(=O)C[C@@H](CCC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)C3)CC2)C=C1.CC1=CC=C(S(=O)(=O)C[C@H](C(=O)N[C@@H](C)C2=NC3=CC=CC(C)=C3C2)[C@@H](C)O)C=C1.CC1=CC=CC2=C1NC(C1(CC(=O)[C@H](CC(=O)N3CCCC3C3CC3)NC(=O)C3CC4(C3)CC(F)(F)C4)CC1)=N2.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(C=CC=C2)O1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)N1C.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)O1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)S1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@H]1C1=CC=CC=C1)NC(=O)C1CC2(COC2)C1)C1=NC2=C(N1)C(F)=CC=C2.C[C@H](NC(=O)[C@@H](CC(=O)CCC1=CC=C(F)C=C1)[C@@H](C)O)C1=NC2=C(C=CC=C2F)C1 QCCXFNRZNCDLQN-VZECBTOASA-N 0.000 description 1
- UGXNNUVGUQKNPR-HXUWFJFHSA-N CC1=CC=C(S(=O)(=O)C[C@@H](CCC(=O)NC(C)(C)C)C(=O)NC2(/C3=N/C4=C(C=CC=C4F)C3)CC2)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)C[C@@H](CCC(=O)NC(C)(C)C)C(=O)NC2(/C3=N/C4=C(C=CC=C4F)C3)CC2)C=C1 UGXNNUVGUQKNPR-HXUWFJFHSA-N 0.000 description 1
- PFPRCRHRCHSULD-DAYGRLMNSA-N CC1=CC=C(S(=O)(=O)C[C@H](C(=O)N[C@@H](C)/C2=N/C3=CC=CC(F)=C3C2)[C@@H](C)O)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)C[C@H](C(=O)N[C@@H](C)/C2=N/C3=CC=CC(F)=C3C2)[C@@H](C)O)C=C1 PFPRCRHRCHSULD-DAYGRLMNSA-N 0.000 description 1
- HABYSSQGEMYZAM-VABDDOAWSA-N CC1=CC=C(S(=O)(=O)N[C@@H](CC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)N3)CC2)C=C1.CC1=CC=C(S(=O)(=O)N[C@@H](CCC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)N3)CC2)C=C1.CC1=CC=C(S(=O)(=O)N[C@H](C(=O)N[C@@H](C)/C2=N/C3=CC=CC(C)=C3N2)[C@@H](C)O)C=C1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(/C=C\C=C/2)O1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)S1.C[C@H](NC(=O)[C@@H](NC(=O)CCC1=CC=C(F)C=C1)[C@@H](C)O)/C1=N/C2=C(F)C=CC=C2N1 Chemical compound CC1=CC=C(S(=O)(=O)N[C@@H](CC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)N3)CC2)C=C1.CC1=CC=C(S(=O)(=O)N[C@@H](CCC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)N3)CC2)C=C1.CC1=CC=C(S(=O)(=O)N[C@H](C(=O)N[C@@H](C)/C2=N/C3=CC=CC(C)=C3N2)[C@@H](C)O)C=C1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(/C=C\C=C/2)O1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)S1.C[C@H](NC(=O)[C@@H](NC(=O)CCC1=CC=C(F)C=C1)[C@@H](C)O)/C1=N/C2=C(F)C=CC=C2N1 HABYSSQGEMYZAM-VABDDOAWSA-N 0.000 description 1
- NYEWEWBNGRNFBC-NRFANRHFSA-N CC1=CC=C(S(=O)(=O)N[C@@H](CCC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)C3)CC2)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)N[C@@H](CCC(=O)NC(C)(C)C)C(=O)NC2(C3=NC4=C(C=CC=C4F)C3)CC2)C=C1 NYEWEWBNGRNFBC-NRFANRHFSA-N 0.000 description 1
- FPPNRPMTDJCEKR-MNVSYLFESA-N CC1=CC=C(S(=O)(=O)N[C@H](C(=O)N[C@@H](C)C2=NC3=CC=CC(F)=C3C2)[C@@H](C)O)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)N[C@H](C(=O)N[C@@H](C)C2=NC3=CC=CC(F)=C3C2)[C@@H](C)O)C=C1 FPPNRPMTDJCEKR-MNVSYLFESA-N 0.000 description 1
- UHINXQPMXTXLRH-ZHBXJDIXSA-N CC1=CC=CC2=C1NC(C1(CC(=O)[C@H](CC(=O)N3CCCC3C3CC3)NC(=O)C3CC4(C3)CC(F)(F)C4)CC1)=N2.CC1=CC=CC2=C1NC(C1(NC(=O)[C@@H](CC(=O)N3CCCC[C@H]3C)NC(=O)C3CC4(C3)CC(F)(F)C4)CC1)=N2.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)N1C.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)O1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@H]1C1=CC=CC=C1)NC(=O)C1CC2(COC2)C1)C1=NC2=C(N1)C(F)=CC=C2 Chemical compound CC1=CC=CC2=C1NC(C1(CC(=O)[C@H](CC(=O)N3CCCC3C3CC3)NC(=O)C3CC4(C3)CC(F)(F)C4)CC1)=N2.CC1=CC=CC2=C1NC(C1(NC(=O)[C@@H](CC(=O)N3CCCC[C@H]3C)NC(=O)C3CC4(C3)CC(F)(F)C4)CC1)=N2.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)N1C.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)O1.C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@H]1C1=CC=CC=C1)NC(=O)C1CC2(COC2)C1)C1=NC2=C(N1)C(F)=CC=C2 UHINXQPMXTXLRH-ZHBXJDIXSA-N 0.000 description 1
- QAERWGDUPFKNKZ-WXXMXEFLSA-N CC1CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)C1 Chemical compound CC1CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)C1 QAERWGDUPFKNKZ-WXXMXEFLSA-N 0.000 description 1
- FHQDZFQNFYHXAU-BOWFOJTHSA-N CC1CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)C1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=C(C)C=C2F)N1.C[C@@H](CC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)CC1CC(C)(C)C1)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(COC2)C1)C(=O)C[C@@H](C)/C1=N/C2=C(N1)C(F)=CC=C2 Chemical compound CC1CC(C(=O)N[C@@H](CC(=O)N2CCC[C@@H]2C2=CC=CC=C2)C(=O)CC(C)C2=NC3=C(C=CC=C3)N2)C1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=C(C)C=C2F)N1.C[C@@H](CC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)CC1CC(C)(C)C1)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(COC2)C1)C(=O)C[C@@H](C)/C1=N/C2=C(N1)C(F)=CC=C2 FHQDZFQNFYHXAU-BOWFOJTHSA-N 0.000 description 1
- PIJFIKTUEVTADB-XZOYJPPVSA-N CCC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)c1nc(c(F)ccc2)c2[nH]1)=O)Nc1nc(Cc(cc2)ccc2F)n[o]1)=O Chemical compound CCC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)c1nc(c(F)ccc2)c2[nH]1)=O)Nc1nc(Cc(cc2)ccc2F)n[o]1)=O PIJFIKTUEVTADB-XZOYJPPVSA-N 0.000 description 1
- WUPVMBIXEDMGFI-ISQHHOFKSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(CCC(C)C)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(CCC(C)C)=O)=O WUPVMBIXEDMGFI-ISQHHOFKSA-N 0.000 description 1
- SXKKGZZRSUFWTB-AJYLMXJNSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(CCc1ccccc1)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(CCc1ccccc1)=O)=O SXKKGZZRSUFWTB-AJYLMXJNSA-N 0.000 description 1
- JLJYJTRXRCDWFT-ISQHHOFKSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(N(C)CC(C)C)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(N(C)CC(C)C)=O)=O JLJYJTRXRCDWFT-ISQHHOFKSA-N 0.000 description 1
- OFMZMUYACZORAH-AJYLMXJNSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(N(C)Cc1ccccc1)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(N(C)Cc1ccccc1)=O)=O OFMZMUYACZORAH-AJYLMXJNSA-N 0.000 description 1
- SAYHRODQJVBXQT-SPYBRQBASA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(N1CCOCC1)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(N1CCOCC1)=O)=O SAYHRODQJVBXQT-SPYBRQBASA-N 0.000 description 1
- ZZANLXTYVUJTAQ-OSUJBIHNSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(NCc1ccccc1)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(NCc1ccccc1)=O)=O ZZANLXTYVUJTAQ-OSUJBIHNSA-N 0.000 description 1
- SUCKKSGLDPCRQF-UCPGQXKASA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC([C@H](C1)[C@@H]1c1ccccc1)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC([C@H](C1)[C@@H]1c1ccccc1)=O)=O SUCKKSGLDPCRQF-UCPGQXKASA-N 0.000 description 1
- IHMADLOTCWQNCL-LNTMXCLISA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)Nc1nc(cc(C)cc2)c2[o]1)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)Nc1nc(cc(C)cc2)c2[o]1)=O IHMADLOTCWQNCL-LNTMXCLISA-N 0.000 description 1
- VIRCAHUUXDUUKF-LNTMXCLISA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)Nc1nc(ccc(C)c2)c2[o]1)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)Nc1nc(ccc(C)c2)c2[o]1)=O VIRCAHUUXDUUKF-LNTMXCLISA-N 0.000 description 1
- YSSWDHDHITYMGW-HOIFWPIMSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C1C=C2F)=NC1=CC2=[F])=O)NC(CCC(C)C)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C(N=C1C=C2F)=NC1=CC2=[F])=O)NC(CCC(C)C)=O)=O YSSWDHDHITYMGW-HOIFWPIMSA-N 0.000 description 1
- BKRCIUSMPWCAEA-RZTUXSPFSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C1=NC(C=CC=C2)C2=N1)=O)NC(CCC(C)C)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)C1=NC(C=CC=C2)C2=N1)=O)NC(CCC(C)C)=O)=O BKRCIUSMPWCAEA-RZTUXSPFSA-N 0.000 description 1
- GIEASLIXODRFEU-LLYLOPHFSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)c([nH]c1ccc2)nc1c2F)=O)NC([C@@H]1[C@@H](C)C1)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)c([nH]c1ccc2)nc1c2F)=O)NC([C@@H]1[C@@H](C)C1)=O)=O GIEASLIXODRFEU-LLYLOPHFSA-N 0.000 description 1
- RWJFWSZBFOWTRD-ONTIZHBOSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)c1nc(cccc2)c2[n]1C)=O)NC(CCC(C)C)=O)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)c1nc(cccc2)c2[n]1C)=O)NC(CCC(C)C)=O)=O RWJFWSZBFOWTRD-ONTIZHBOSA-N 0.000 description 1
- QHVPGZIGDLLAFX-QFAJGFAJSA-N CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)c1nc(cccc2F)c2[nH]1)=O)NC1ON=C(Cc(cc2)ccc2F)N1)=O Chemical compound CC[C@@H](CCCC1)N1C(C[C@@H](C(N[C@@H](C)c1nc(cccc2F)c2[nH]1)=O)NC1ON=C(Cc(cc2)ccc2F)N1)=O QHVPGZIGDLLAFX-QFAJGFAJSA-N 0.000 description 1
- YDRUVFRHYFKDAG-UAVUOLJFSA-N CC[C@@H](CCCC1)N1C(N[C@@H](C(N[C@@H](C)c([nH]c1ccc2)nc1c2F)=O)Nc1nc(ccc(C)c2)c2[o]1)=O Chemical compound CC[C@@H](CCCC1)N1C(N[C@@H](C(N[C@@H](C)c([nH]c1ccc2)nc1c2F)=O)Nc1nc(ccc(C)c2)c2[o]1)=O YDRUVFRHYFKDAG-UAVUOLJFSA-N 0.000 description 1
- JJOUJTMCRHSOPE-KXNSMUHISA-N CC[C@@H](CCCC1)N1C(N[C@@H](C(N[C@@H](C)c([nH]c1ccc2)nc1c2F)=O)Nc1nc(cccc2)c2[s]1)=O Chemical compound CC[C@@H](CCCC1)N1C(N[C@@H](C(N[C@@H](C)c([nH]c1ccc2)nc1c2F)=O)Nc1nc(cccc2)c2[s]1)=O JJOUJTMCRHSOPE-KXNSMUHISA-N 0.000 description 1
- VBEXPEGEWHCJSU-CYIINTKFSA-N CC[C@H]1CCCCN1C(=O)C[C@H](N)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=NOC(C)=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC1C(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC(F)(F)F)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2C)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2C)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCN(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCCCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(C(C)C)=NO1)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)C1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](N)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=NOC(C)=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC1C(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC(F)(F)F)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2C)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2C)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCN(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCCCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(C(C)C)=NO1)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)C1 VBEXPEGEWHCJSU-CYIINTKFSA-N 0.000 description 1
- UCDIWPMUFNPWOH-VNIPCALWSA-N CC[C@H]1CCCCN1C(=O)C[C@H](N)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2C)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCN(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](N)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2C)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCN(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 UCDIWPMUFNPWOH-VNIPCALWSA-N 0.000 description 1
- KDLDRGUDEPNMFZ-VZGBAENTSA-N CC[C@H]1CCCCN1C(=O)C[C@H](N/C1=N/C2=C(C=C(C)C=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=C(C)S1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)NCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC2=C(C=CC=C2)S1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](N/C1=N/C2=C(C=C(C)C=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=C(C)S1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)NCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC2=C(C=CC=C2)S1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 KDLDRGUDEPNMFZ-VZGBAENTSA-N 0.000 description 1
- GCYHZPUBTQRDJB-CDHXOCGDSA-N CC[C@H]1CCCCN1C(=O)C[C@H](N/C1=N/C2=C(C=CC(C)=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](N/C1=N/C2=C(C=CC=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](N/C1=[SH]/C2=C(C=CC=C2)N1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=C(C)S1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCOCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)NCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](N/C1=N/C2=C(C=CC(C)=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](N/C1=N/C2=C(C=CC=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](N/C1=[SH]/C2=C(C=CC=C2)N1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=C(C)S1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCOCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)NCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 GCYHZPUBTQRDJB-CDHXOCGDSA-N 0.000 description 1
- JURUWYWEYRWTHK-ATZQQQBMSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=NOC(C)=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC1C(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC(F)(F)F)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2C)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(C(C)C)=NO1)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=CN=CS1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1=NOC(C)=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC1C(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC(F)(F)F)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2C)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(C(C)C)=NO1)C(=O)N[C@@H](C)C1=NC2=C(C=CC=C2F)N1 JURUWYWEYRWTHK-ATZQQQBMSA-N 0.000 description 1
- VSXDZQWOPGWBAR-RYGIKFPVSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)/C1=N/C2=C(F)C=CC=C2N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCCCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCOCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC2=C(C=CC=C2)O1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)/C1=N/C2=C(F)C=CC=C2N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCCCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N1CCOCC1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC2=C(C=CC=C2)O1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 VSXDZQWOPGWBAR-RYGIKFPVSA-N 0.000 description 1
- PRILSFHKAZMVKD-HUHIMMNNSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(CC2=CC=C(F)C=C2)=NO1)C(=O)N[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)CCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2C)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NC1=NC(CC2=CC=C(F)C=C2)=NO1)C(=O)N[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1.CC[C@H]1CCCCN1C(=O)C[C@H](NS(=O)(=O)CCC(C)C)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2C)N1 PRILSFHKAZMVKD-HUHIMMNNSA-N 0.000 description 1
- BQOJARLRIGMTTI-LMNJBCLMSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=C(F)C=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=C(F)C=C2F)N1 BQOJARLRIGMTTI-LMNJBCLMSA-N 0.000 description 1
- FPUAQAVKSLEIDI-UWVAXJGDSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 FPUAQAVKSLEIDI-UWVAXJGDSA-N 0.000 description 1
- KURGJDKHLSLHQE-RFWXGWTQSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC1=CC2=C(C=CC=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC1=CC2=C(C=CC=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 KURGJDKHLSLHQE-RFWXGWTQSA-N 0.000 description 1
- APQRXWAPHOMMCW-RFWXGWTQSA-N CC[C@H]1CCCCN1C(=O)C[C@H](NC1=CC2=C(C=CC=C2)S1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)C[C@H](NC1=CC2=C(C=CC=C2)S1)C(=O)C[C@@H](C)/C1=N/C2=C(C=CC=C2F)N1 APQRXWAPHOMMCW-RFWXGWTQSA-N 0.000 description 1
- MAEVMWILAACYSW-YPBQGGFRSA-N CC[C@H]1CCCCN1C(=O)N[C@H](N/C1=N/C2=C(C=CC=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)N[C@H](N/C1=N/C2=C(C=CC=C2)O1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 MAEVMWILAACYSW-YPBQGGFRSA-N 0.000 description 1
- ZKAKUQUGQYJZDS-YPBQGGFRSA-N CC[C@H]1CCCCN1C(=O)N[C@H](N/C1=N/C2=C(C=CC=C2)S1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound CC[C@H]1CCCCN1C(=O)N[C@H](N/C1=N/C2=C(C=CC=C2)S1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 ZKAKUQUGQYJZDS-YPBQGGFRSA-N 0.000 description 1
- IGBHTEKXXXSNSX-UHFFFAOYSA-N CCc1nc(cccc2)c2[n]1CC Chemical compound CCc1nc(cccc2)c2[n]1CC IGBHTEKXXXSNSX-UHFFFAOYSA-N 0.000 description 1
- ZWLPDRBWANQMGQ-VWWSICORSA-N C[C@@H](C(N=C1)N=C1c(ccc(F)c1)c1F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(CC1CCOCC1)=O)=O Chemical compound C[C@@H](C(N=C1)N=C1c(ccc(F)c1)c1F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(CC1CCOCC1)=O)=O ZWLPDRBWANQMGQ-VWWSICORSA-N 0.000 description 1
- SQJHSOJADKRJHL-XUIGNXMTSA-N C[C@@H](C(N=C12)=NC1=CC=CC2F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(C1CCCCC1)=O)=O Chemical compound C[C@@H](C(N=C12)=NC1=CC=CC2F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(C1CCCCC1)=O)=O SQJHSOJADKRJHL-XUIGNXMTSA-N 0.000 description 1
- OPQLDDWMAVFDFE-BNNMJTAPSA-N C[C@@H](C(N=C12)=NC1=CC=CC2F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(N(C)Cc1ccccc1)=O)=O Chemical compound C[C@@H](C(N=C12)=NC1=CC=CC2F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(N(C)Cc1ccccc1)=O)=O OPQLDDWMAVFDFE-BNNMJTAPSA-N 0.000 description 1
- NUIHAYJPKKRIGH-SPYBRQBASA-N C[C@@H](C(N=C12)=NC1=CC=CC2F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(N1CCCCC1)=O)=O Chemical compound C[C@@H](C(N=C12)=NC1=CC=CC2F)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(N1CCCCC1)=O)=O NUIHAYJPKKRIGH-SPYBRQBASA-N 0.000 description 1
- JZDRLXUGXNBRTQ-IOILQMDJSA-N C[C@@H](C(NC1)NC1(CC1CCCCC1)C1CCCCCC1)NC([C@H](CC(N(CCC1)[C@H]1C1CCCCC1)=O)NC(C1(C2CCCCCCC2)NOC(C)C1)=O)=O Chemical compound C[C@@H](C(NC1)NC1(CC1CCCCC1)C1CCCCCC1)NC([C@H](CC(N(CCC1)[C@H]1C1CCCCC1)=O)NC(C1(C2CCCCCCC2)NOC(C)C1)=O)=O JZDRLXUGXNBRTQ-IOILQMDJSA-N 0.000 description 1
- FMQVWYHWQLZLBF-AWTLISATSA-N C[C@@H](C(NC1)NC1c(cccc1)c1F)NC([C@H](CC(N(CCC1)[C@H]1c1ccccc1)O)NC(C1NOC(C)C1)=O)=O Chemical compound C[C@@H](C(NC1)NC1c(cccc1)c1F)NC([C@H](CC(N(CCC1)[C@H]1c1ccccc1)O)NC(C1NOC(C)C1)=O)=O FMQVWYHWQLZLBF-AWTLISATSA-N 0.000 description 1
- DHPOZMMKJFGDRJ-QJTINKPMSA-N C[C@@H](C(NC1)NC1c1ccccc1F)NC([C@H](CC(N(CCC1)[C@H]1c1ccccc1)=O)NC(C1NOC(C)C1)=O)=O Chemical compound C[C@@H](C(NC1)NC1c1ccccc1F)NC([C@H](CC(N(CCC1)[C@H]1c1ccccc1)=O)NC(C1NOC(C)C1)=O)=O DHPOZMMKJFGDRJ-QJTINKPMSA-N 0.000 description 1
- PMKISHWPYZONBH-PXTRNLTBSA-N C[C@@H](C(NCC1C2=NC=CC2=CC=C1)=O)NC([C@H](CC(N1CCCC1)=O)NC(CCc1ccccc1)=O)=O Chemical compound C[C@@H](C(NCC1C2=NC=CC2=CC=C1)=O)NC([C@H](CC(N1CCCC1)=O)NC(CCc1ccccc1)=O)=O PMKISHWPYZONBH-PXTRNLTBSA-N 0.000 description 1
- HBEJCFXQHONVGR-ROUUACIJSA-N C[C@@H](C(NCc(ccc(F)c1)c1F)=O)NC(N(CC(N1[C@@H](C)CCCC1)=O)NC(CCC(C)(C)C)=O)=O Chemical compound C[C@@H](C(NCc(ccc(F)c1)c1F)=O)NC(N(CC(N1[C@@H](C)CCCC1)=O)NC(CCC(C)(C)C)=O)=O HBEJCFXQHONVGR-ROUUACIJSA-N 0.000 description 1
- BDSXHMUJLWZUFB-IWDFNABXSA-N C[C@@H](C1(C2CCCCCCCCC2)NC(CC2CCCCC2)CN1)NC([C@H](CC(N(CCC1)[C@H]1C1CCCCC1)=O)NC(C(C1)NOC1(C)C1CCCCCC1)=O)=O Chemical compound C[C@@H](C1(C2CCCCCCCCC2)NC(CC2CCCCC2)CN1)NC([C@H](CC(N(CCC1)[C@H]1C1CCCCC1)=O)NC(C(C1)NOC1(C)C1CCCCCC1)=O)=O BDSXHMUJLWZUFB-IWDFNABXSA-N 0.000 description 1
- RVEXDHALGWQHKL-BYURATGHSA-N C[C@@H](C1=NC(C=CC=C2)C2=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O Chemical compound C[C@@H](C1=NC(C=CC=C2)C2=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O RVEXDHALGWQHKL-BYURATGHSA-N 0.000 description 1
- AXJKNPXQNPQXQQ-KSNOWIBYSA-N C[C@@H](C1=NC2=CC=CCC2=N1)NC([C@H](CC(N(CCC1)[C@H]1c1ccccc1)=O)NC(CCC(C)(C)C)=O)=O Chemical compound C[C@@H](C1=NC2=CC=CCC2=N1)NC([C@H](CC(N(CCC1)[C@H]1c1ccccc1)=O)NC(CCC(C)(C)C)=O)=O AXJKNPXQNPQXQQ-KSNOWIBYSA-N 0.000 description 1
- AJEYHPGNYBQMQQ-WFXMLNOXSA-N C[C@@H](C1=NC2=CC=CCC2=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(CCC(C)(C)C)=O)=O Chemical compound C[C@@H](C1=NC2=CC=CCC2=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(CCC(C)(C)C)=O)=O AJEYHPGNYBQMQQ-WFXMLNOXSA-N 0.000 description 1
- DLUOZZYVRHJHHF-QOKNQOGYSA-N C[C@@H](C1=NC2=CC=CCC2=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O Chemical compound C[C@@H](C1=NC2=CC=CCC2=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O DLUOZZYVRHJHHF-QOKNQOGYSA-N 0.000 description 1
- ZEBIQMIMMGGYLP-SKPFHBQLSA-N C[C@@H](C1=NCC(Cc2ccccc2)=N1)NC([C@H](CCC(N1[C@@H](C)CCCC1)=O)NC(CC1CC1)=O)=O Chemical compound C[C@@H](C1=NCC(Cc2ccccc2)=N1)NC([C@H](CCC(N1[C@@H](C)CCCC1)=O)NC(CC1CC1)=O)=O ZEBIQMIMMGGYLP-SKPFHBQLSA-N 0.000 description 1
- SRZLZIJCXVKYJR-ROUUACIJSA-N C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC(N(CC(N1[C@@H](C)CCCC1)=O)NC(CCC(C)(C)C)=O)=O Chemical compound C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC(N(CC(N1[C@@H](C)CCCC1)=O)NC(CCC(C)(C)C)=O)=O SRZLZIJCXVKYJR-ROUUACIJSA-N 0.000 description 1
- RPBGWEUQCQDIHL-KSSFIOAISA-N C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O Chemical compound C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O RPBGWEUQCQDIHL-KSSFIOAISA-N 0.000 description 1
- MIRHNQQSEKIFEQ-FIKGOQFSSA-N C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCC1)=O)NC(CCC(C)(C)C)=O)=O Chemical compound C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCC1)=O)NC(CCC(C)(C)C)=O)=O MIRHNQQSEKIFEQ-FIKGOQFSSA-N 0.000 description 1
- SZIUBFNXCWSGMJ-HOIFWPIMSA-N C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(C1CC(C)(C)C1)=O)=O Chemical compound C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(C1CC(C)(C)C1)=O)=O SZIUBFNXCWSGMJ-HOIFWPIMSA-N 0.000 description 1
- SSEZJTWVVHKBKJ-HOIFWPIMSA-N C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(CCC1CC1)=O)=O Chemical compound C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(CCC1CC1)=O)=O SSEZJTWVVHKBKJ-HOIFWPIMSA-N 0.000 description 1
- BZZCCVKPGUWTET-UVFQYZLESA-N C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O Chemical compound C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O BZZCCVKPGUWTET-UVFQYZLESA-N 0.000 description 1
- PCMDSCYSMOXPLT-OYGZYKIASA-N C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC1[O]2(CCCCCCC2)c2ccccc2N1)=O Chemical compound C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC1[O]2(CCCCCCC2)c2ccccc2N1)=O PCMDSCYSMOXPLT-OYGZYKIASA-N 0.000 description 1
- AKMZGSZQQBIPFM-JXQFQVJHSA-N C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NCC(c1ccccc1)=O)=O Chemical compound C[C@@H](C1=NCC(c(c(F)c2)ccc2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NCC(c1ccccc1)=O)=O AKMZGSZQQBIPFM-JXQFQVJHSA-N 0.000 description 1
- HSXZGZRYDAPUOW-JXFKEZNVSA-N C[C@@H](C1=NCC(c(ccc(F)c2)c2F)=N1)NC([C@H](CC(N1CCCC1)=O)NC(CCC(C)(C)C)=O)=O Chemical compound C[C@@H](C1=NCC(c(ccc(F)c2)c2F)=N1)NC([C@H](CC(N1CCCC1)=O)NC(CCC(C)(C)C)=O)=O HSXZGZRYDAPUOW-JXFKEZNVSA-N 0.000 description 1
- ANWZVWNXLOJWNR-SPEDKVCISA-N C[C@@H](C1=NCC(c(ccc(F)c2)c2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(CCC(C)(C)C)=O)=O Chemical compound C[C@@H](C1=NCC(c(ccc(F)c2)c2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(CCC(C)(C)C)=O)=O ANWZVWNXLOJWNR-SPEDKVCISA-N 0.000 description 1
- HSLUXVLVYVJWFC-YWTKSJFSSA-N C[C@@H](C1=NCC(c(ccc(F)c2)c2F)=N1)NC([C@H](NC(N1[C@@H](C)CCCC1)=O)Nc1nc2ccccc2[o]1)=O Chemical compound C[C@@H](C1=NCC(c(ccc(F)c2)c2F)=N1)NC([C@H](NC(N1[C@@H](C)CCCC1)=O)Nc1nc2ccccc2[o]1)=O HSLUXVLVYVJWFC-YWTKSJFSSA-N 0.000 description 1
- NGRLYFQDSNNQFO-KNBMTAEXSA-N C[C@@H](C1=NCC(c(cccc2)c2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O Chemical compound C[C@@H](C1=NCC(c(cccc2)c2F)=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O NGRLYFQDSNNQFO-KNBMTAEXSA-N 0.000 description 1
- YXPQJLDTFYWSMK-WNPSOCMYSA-N C[C@@H](C1=NCC(c2ccccc2)=N1)NC([C@H](CC(N1C(C)CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O Chemical compound C[C@@H](C1=NCC(c2ccccc2)=N1)NC([C@H](CC(N1C(C)CCCC1)=O)NC(c1n[o]c(C)c1)=O)=O YXPQJLDTFYWSMK-WNPSOCMYSA-N 0.000 description 1
- XTOLIPKPLZBEBX-QBBZHMSDSA-N C[C@@H](C1N(C2CCCCCCCC2)c(c(F)ccc2)c2N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC([C@@H](C1)[C@H]1c1ccccc1)=O)=O Chemical compound C[C@@H](C1N(C2CCCCCCCC2)c(c(F)ccc2)c2N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC([C@@H](C1)[C@H]1c1ccccc1)=O)=O XTOLIPKPLZBEBX-QBBZHMSDSA-N 0.000 description 1
- BLIXQVGINCINAM-WDTIMJDQSA-N C[C@@H](C1N=C(Cc2ccccc2)C=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(CC1CCOCC1)=O)=O Chemical compound C[C@@H](C1N=C(Cc2ccccc2)C=N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(CC1CCOCC1)=O)=O BLIXQVGINCINAM-WDTIMJDQSA-N 0.000 description 1
- CRLIQBOJCDOJLS-HDPZSBONSA-N C[C@@H](C1N=CC(c(c(F)c2)ccc2F)N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NS(c1ccccc1)(=O)=O)=O Chemical compound C[C@@H](C1N=CC(c(c(F)c2)ccc2F)N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NS(c1ccccc1)(=O)=O)=O CRLIQBOJCDOJLS-HDPZSBONSA-N 0.000 description 1
- HPRFXKSCJXSTRJ-RWXIPMJASA-N C[C@@H](C1Nc(c(F)ccc2)c2N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC([C@H](C1)[C@@H]1c1ccccc1)=O)=O Chemical compound C[C@@H](C1Nc(c(F)ccc2)c2N1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC([C@H](C1)[C@@H]1c1ccccc1)=O)=O HPRFXKSCJXSTRJ-RWXIPMJASA-N 0.000 description 1
- FYBXJQVNEHXJQP-IPJJNNNSSA-N C[C@@H](CC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)CCC(C)(C)C)C1=NC2=C(C=CC=C2)N1 Chemical compound C[C@@H](CC(=O)[C@H](CC(=O)N1CCCC[C@@H]1C)NC(=O)CCC(C)(C)C)C1=NC2=C(C=CC=C2)N1 FYBXJQVNEHXJQP-IPJJNNNSSA-N 0.000 description 1
- QIQFKSMSRVMNLI-PXNSSMCTSA-N C[C@@H](CCCC1)N1C(C[C@@H](C(NCC1=NC2=CC=CCC2=N1)=O)NC(CCC(C)(C)C)=O)=O Chemical compound C[C@@H](CCCC1)N1C(C[C@@H](C(NCC1=NC2=CC=CCC2=N1)=O)NC(CCC(C)(C)C)=O)=O QIQFKSMSRVMNLI-PXNSSMCTSA-N 0.000 description 1
- GAHULKWEYRJKIE-FTRWYGJKSA-N C[C@@H](c1nc(c(F)ccc2)c2[nH]1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(C(CC1)CCC1(F)F)=O)=O Chemical compound C[C@@H](c1nc(c(F)ccc2)c2[nH]1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(C(CC1)CCC1(F)F)=O)=O GAHULKWEYRJKIE-FTRWYGJKSA-N 0.000 description 1
- UJFQNURPDSNDDP-NWVWQQAFSA-N C[C@@H](c1nc2cccc(F)c2[nH]1)NC([C@H](CC(N(CCC1)[C@@H]1c1ccccc1)=O)NC(C1CCOCC1)=O)=O Chemical compound C[C@@H](c1nc2cccc(F)c2[nH]1)NC([C@H](CC(N(CCC1)[C@@H]1c1ccccc1)=O)NC(C1CCOCC1)=O)=O UJFQNURPDSNDDP-NWVWQQAFSA-N 0.000 description 1
- QMEBXPJBMSKQGM-FTRWYGJKSA-N C[C@@H](c1nc2cccc(F)c2[nH]1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(C1CCOCC1)=O)=O Chemical compound C[C@@H](c1nc2cccc(F)c2[nH]1)NC([C@H](CC(N1[C@@H](C)CCCC1)=O)NC(C1CCOCC1)=O)=O QMEBXPJBMSKQGM-FTRWYGJKSA-N 0.000 description 1
- VDJHCURQDIDLMW-YWTKSJFSSA-N C[C@@H](c1ncc(-c(ccc(F)c2)c2F)[nH]1)NC([C@H](NC(N1[C@@H](C)CCCC1)=O)Nc1nc2ccccc2[o]1)=O Chemical compound C[C@@H](c1ncc(-c(ccc(F)c2)c2F)[nH]1)NC([C@H](NC(N1[C@@H](C)CCCC1)=O)Nc1nc2ccccc2[o]1)=O VDJHCURQDIDLMW-YWTKSJFSSA-N 0.000 description 1
- AFZKZKIGMWBSPD-SPEDKVCISA-N C[C@@H](c1ncc(Cc2ccccc2)[nH]1)NC([C@H](CC(N1[C@@H](C)CCC1)=O)NC(CC1CC1)=O)=O Chemical compound C[C@@H](c1ncc(Cc2ccccc2)[nH]1)NC([C@H](CC(N1[C@@H](C)CCC1)=O)NC(CC1CC1)=O)=O AFZKZKIGMWBSPD-SPEDKVCISA-N 0.000 description 1
- LINDKWXDQOMRIY-VGOFRKELSA-N C[C@@H]1CCCCN1C(=O)C[C@@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)NC1(/C2=N/C3=C(C2)C(F)=CC=C3)CC1 Chemical compound C[C@@H]1CCCCN1C(=O)C[C@@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)NC1(/C2=N/C3=C(C2)C(F)=CC=C3)CC1 LINDKWXDQOMRIY-VGOFRKELSA-N 0.000 description 1
- BVXJATDAUGZNFT-OXQOHEQNSA-N C[C@@H]1CCCCN1C(=O)C[C@@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)NC1(C2=NC3=C(N2)C(F)=CC=C3)CC1 Chemical compound C[C@@H]1CCCCN1C(=O)C[C@@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)NC1(C2=NC3=C(N2)C(F)=CC=C3)CC1 BVXJATDAUGZNFT-OXQOHEQNSA-N 0.000 description 1
- VMCCQTODQKIKRG-NKWVPACGSA-N C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(N1)C(F)=CC=C2 Chemical compound C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(C1)CC(F)(F)C2)C1=NC2=C(N1)C(F)=CC=C2 VMCCQTODQKIKRG-NKWVPACGSA-N 0.000 description 1
- SAGYMWPMRVZYHH-NKWVPACGSA-N C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(COC2)C1)C1=NC2=C(N1)C(F)=CC=C2 Chemical compound C[C@H](CC(=O)[C@H](CC(=O)N1CCCC1C1CC1)NC(=O)C1CC2(COC2)C1)C1=NC2=C(N1)C(F)=CC=C2 SAGYMWPMRVZYHH-NKWVPACGSA-N 0.000 description 1
- GLAIOZXUZYQNRG-BQQUOAEZSA-N C[C@H](CC(=O)[C@H](CC(=O)N1CCCC[C@H]1C1=CC=CC=C1)NC(=O)C1CC2(COC2)C1)C1=NC2=C(N1)C(F)=CC=C2 Chemical compound C[C@H](CC(=O)[C@H](CC(=O)N1CCCC[C@H]1C1=CC=CC=C1)NC(=O)C1CC2(COC2)C1)C1=NC2=C(N1)C(F)=CC=C2 GLAIOZXUZYQNRG-BQQUOAEZSA-N 0.000 description 1
- PKACSQSVKMXBOK-QGUKFAFCSA-N C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCC(C)(C)C)C1=NC2=C(C=CC=C2)N1 Chemical compound C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCC(C)(C)C)C1=NC2=C(C=CC=C2)N1 PKACSQSVKMXBOK-QGUKFAFCSA-N 0.000 description 1
- ZPPATUZVHAKOIP-FGCOXFRFSA-N C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)N1C Chemical compound C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)N1C ZPPATUZVHAKOIP-FGCOXFRFSA-N 0.000 description 1
- IKUICXSKBRQOGN-WTIAFYNJSA-N C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)O1 Chemical compound C[C@H](CC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)NC(=O)CCCC(F)(F)F)C1=NC2=C(C=CC=C2)O1 IKUICXSKBRQOGN-WTIAFYNJSA-N 0.000 description 1
- HMVMQJIZRWNTLH-LURJTMIESA-N C[C@H](N)C1=NC2=C(C=CC=C2F)C1 Chemical compound C[C@H](N)C1=NC2=C(C=CC=C2F)C1 HMVMQJIZRWNTLH-LURJTMIESA-N 0.000 description 1
- SPNIHYUAIFAIQA-QMMMGPOBSA-N C[C@H](N)C1=NC=C(C2=CC=C(F)C=C2)C1 Chemical compound C[C@H](N)C1=NC=C(C2=CC=C(F)C=C2)C1 SPNIHYUAIFAIQA-QMMMGPOBSA-N 0.000 description 1
- DLYBKAXJQHBLDR-ZETCQYMHSA-N C[C@H](N)C1=NC=C(C2=CC=C(F)C=C2F)C1 Chemical compound C[C@H](N)C1=NC=C(C2=CC=C(F)C=C2F)C1 DLYBKAXJQHBLDR-ZETCQYMHSA-N 0.000 description 1
- DLCPFIASQTUHFY-VIFPVBQESA-N C[C@H](N)C1=NC=C(C2=CC=CC=C2)C1 Chemical compound C[C@H](N)C1=NC=C(C2=CC=CC=C2)C1 DLCPFIASQTUHFY-VIFPVBQESA-N 0.000 description 1
- VRQFGUUGLMUJNK-QMMMGPOBSA-N C[C@H](N)C1=NC=C(C2=CC=CC=C2F)C1 Chemical compound C[C@H](N)C1=NC=C(C2=CC=CC=C2F)C1 VRQFGUUGLMUJNK-QMMMGPOBSA-N 0.000 description 1
- RISOWEAIPABMHX-JTQLQIEISA-N C[C@H](N)C1=NC=C(CC2=CC=CC=C2)C1 Chemical compound C[C@H](N)C1=NC=C(CC2=CC=CC=C2)C1 RISOWEAIPABMHX-JTQLQIEISA-N 0.000 description 1
- HXDMEDLLDIIZPJ-VIFPVBQESA-N C[C@H](NC(=O)OC(C)(C)C)C(=O)CC1=C(N)C(F)=CC=C1 Chemical compound C[C@H](NC(=O)OC(C)(C)C)C(=O)CC1=C(N)C(F)=CC=C1 HXDMEDLLDIIZPJ-VIFPVBQESA-N 0.000 description 1
- HKZWFUBKUCVAFF-HNNXBMFYSA-N C[C@H](NC(=O)OCC1=CC=CC=C1)C1=NC=C(C2=CC=CC=C2)C1 Chemical compound C[C@H](NC(=O)OCC1=CC=CC=C1)C1=NC=C(C2=CC=CC=C2)C1 HKZWFUBKUCVAFF-HNNXBMFYSA-N 0.000 description 1
- DQZAZDOLCRTPQB-MDOVXXIYSA-N C[C@H](NC(=O)[C@@H](CC(=O)CCC1=CC=C(F)C=C1)[C@@H](C)O)/C1=N/C2=C(F)C=CC=C2C1 Chemical compound C[C@H](NC(=O)[C@@H](CC(=O)CCC1=CC=C(F)C=C1)[C@@H](C)O)/C1=N/C2=C(F)C=CC=C2C1 DQZAZDOLCRTPQB-MDOVXXIYSA-N 0.000 description 1
- OWMDAVJBFGGWDU-NJSLBKSFSA-N C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCCC[C@@H]1C)C1=NC=C(C2=C(F)C=C(F)C=C2)C1 Chemical compound C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCCC[C@@H]1C)C1=NC=C(C2=C(F)C=C(F)C=C2)C1 OWMDAVJBFGGWDU-NJSLBKSFSA-N 0.000 description 1
- TVEYUNHJRFCCQV-OZWPHOJSSA-N C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C1=NC=C(C2=C(F)C=CC=C2)C1 Chemical compound C[C@H](NC(=O)[C@@H](N)CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)C1=NC=C(C2=C(F)C=CC=C2)C1 TVEYUNHJRFCCQV-OZWPHOJSSA-N 0.000 description 1
- NFOVBJIUFRBVQA-TVNVSJRUSA-N C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)N/C1=C/C2=C(C=CC=C2)O1)C1=NC=C(C2=CC=CC=C2F)C1 Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)N/C1=C/C2=C(C=CC=C2)O1)C1=NC=C(C2=CC=CC=C2F)C1 NFOVBJIUFRBVQA-TVNVSJRUSA-N 0.000 description 1
- JDHSAPHCLKDIRN-DUPMHHLHSA-N C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)N/C1=N/C2=C(C=CC=C2)O1)C1=NC=C(C2=CC=CC=C2F)C1 Chemical compound C[C@H](NC(=O)[C@H](CC(=O)N1CCC[C@@H]1C1=CC=CC=C1)N/C1=N/C2=C(C=CC=C2)O1)C1=NC=C(C2=CC=CC=C2F)C1 JDHSAPHCLKDIRN-DUPMHHLHSA-N 0.000 description 1
- VASTUTZBWBSRCN-GTVKUMRUSA-N C[C@H]([C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(N(C)Cc1ccccc1)=O)C(N1[C@@H](C)CCCC1)=O Chemical compound C[C@H]([C@@H](C(N[C@@H](C)C(N=C12)=NC1=CC=CC2F)=O)NC(N(C)Cc1ccccc1)=O)C(N1[C@@H](C)CCCC1)=O VASTUTZBWBSRCN-GTVKUMRUSA-N 0.000 description 1
- CVYCEXUDKJSZBD-STSQHVNTSA-N C[C@H]1CCCCN1C(=O)C[C@H](N/C1=N/C2=C(C=CC=C2)O1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](N/C1=N/C2=C(C=CC=C2)O1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 CVYCEXUDKJSZBD-STSQHVNTSA-N 0.000 description 1
- OSXVYOAYMPSSIE-WWMYMODYSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 OSXVYOAYMPSSIE-WWMYMODYSA-N 0.000 description 1
- YCVNMXVCSJDXET-STSQHVNTSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 YCVNMXVCSJDXET-STSQHVNTSA-N 0.000 description 1
- NISHVBKKMQOGPM-WWMYMODYSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(C1)CC(F)(F)C2)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 NISHVBKKMQOGPM-WWMYMODYSA-N 0.000 description 1
- RNSMRPFGHBVQHJ-FGSXEWAUSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(CCC2)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 RNSMRPFGHBVQHJ-FGSXEWAUSA-N 0.000 description 1
- RXCWEEMKXLDUKN-WWMYMODYSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(COC2)C1)C(=O)C[C@@H](C)C1=NC2=C(N1)C(F)=CC=C2 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)C1CC2(COC2)C1)C(=O)C[C@@H](C)C1=NC2=C(N1)C(F)=CC=C2 RXCWEEMKXLDUKN-WWMYMODYSA-N 0.000 description 1
- VTZGDGIQOQJXSJ-FGSXEWAUSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CC1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 VTZGDGIQOQJXSJ-FGSXEWAUSA-N 0.000 description 1
- UNFVDNJPONDCTP-LQWHRVPQSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)CCC(C)(C)C)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 UNFVDNJPONDCTP-LQWHRVPQSA-N 0.000 description 1
- RKFUWBNGOBMSCM-NMMYMHLASA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)N(C)CC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 RKFUWBNGOBMSCM-NMMYMHLASA-N 0.000 description 1
- UURKQAWWYLXKRS-MSYCTHLASA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 UURKQAWWYLXKRS-MSYCTHLASA-N 0.000 description 1
- VOHGBZRHPQVBCZ-HKHHCORWSA-N C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)C[C@H](NC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1)C(=O)C[C@@H](C)C1=NC2=C(C=CC=C2F)N1 VOHGBZRHPQVBCZ-HKHHCORWSA-N 0.000 description 1
- KSGSDSJFNQZLPC-XJCBTKLQSA-N C[C@H]1CCCCN1C(=O)N[C@H](N/C1=N/C2=C(C=CC=C2)O1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 Chemical compound C[C@H]1CCCCN1C(=O)N[C@H](N/C1=N/C2=C(C=CC=C2)O1)C(=O)C[C@@H](C)C1=NC=C(C2=CC=C(F)C=C2F)N1 KSGSDSJFNQZLPC-XJCBTKLQSA-N 0.000 description 1
- VPIMSZVJAZALOS-YPBQGGFRSA-N C[C@H]1CCCCN1C(=O)N[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 Chemical compound C[C@H]1CCCCN1C(=O)N[C@H](NC(=O)C1CC(C)(C)C1)C(=O)C[C@@H](C)C1=NC=C(C2=C(F)C=C(F)C=C2)N1 VPIMSZVJAZALOS-YPBQGGFRSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001611011 Caligus Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001414836 Cimex Species 0.000 description 1
- 241001327638 Cimex lectularius Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000490513 Ctenocephalides canis Species 0.000 description 1
- 241000258924 Ctenocephalides felis Species 0.000 description 1
- 241000256059 Culex pipiens Species 0.000 description 1
- 241000016327 Culicoides imicola Species 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 201000003808 Cystic echinococcosis Diseases 0.000 description 1
- 241000303991 Cystoisospora canis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241001128004 Demodex Species 0.000 description 1
- 241000577477 Dermacentor reticulatus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 241000577456 Dicrocoelium dendriticum Species 0.000 description 1
- 241001147669 Dictyocaulus viviparus Species 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000935792 Dipylidium caninum Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000244170 Echinococcus granulosus Species 0.000 description 1
- 241000223932 Eimeria tenella Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KYSUEPWILKTYPX-CZZAQMAHSA-N FC1=C(C=CC=C1)C1=CN=C(N1)[C@H](C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(=O)C1=NOC(=C1)C Chemical compound FC1=C(C=CC=C1)C1=CN=C(N1)[C@H](C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(=O)C1=NOC(=C1)C KYSUEPWILKTYPX-CZZAQMAHSA-N 0.000 description 1
- OAFWPVORMRCADZ-HOIFWPIMSA-N FC1=CC2=C(NC(=N2)[C@H](C)NC(=O)[C@H](CC(=O)N2[C@H](CCCC2)CC)NC(CCC(C)C)=O)C=C1F Chemical compound FC1=CC2=C(NC(=N2)[C@H](C)NC(=O)[C@H](CC(=O)N2[C@H](CCCC2)CC)NC(CCC(C)C)=O)C=C1F OAFWPVORMRCADZ-HOIFWPIMSA-N 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 241000882763 Fascioloides magna Species 0.000 description 1
- MFXAGCQVWGPEJH-UHFFFAOYSA-N Fellutamide B Natural products CCCCCCCCCC(O)CC(=O)NC(CC(N)=O)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C=O MFXAGCQVWGPEJH-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001660201 Gasterophilus intestinalis Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 241000315566 Habronema Species 0.000 description 1
- 241000257232 Haematobia irritans Species 0.000 description 1
- 241000243974 Haemonchus contortus Species 0.000 description 1
- 241000406097 Hammondia hammondi Species 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 241000948220 Histomonas meleagridis Species 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000543830 Hypoderma bovis Species 0.000 description 1
- 241001480843 Ixodes ricinus Species 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 241001467800 Knemidokoptes Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000222697 Leishmania infantum Species 0.000 description 1
- 241001247234 Lepeophtheirus salmonis Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000736227 Lucilia sericata Species 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000556230 Metastrongylus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000986229 Muellerius capillaris Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000257159 Musca domestica Species 0.000 description 1
- JMOXSQYGVIXBBZ-UHFFFAOYSA-N N,N-dimethyl-beta-alanine Chemical compound CN(C)CCC(O)=O JMOXSQYGVIXBBZ-UHFFFAOYSA-N 0.000 description 1
- PUFABYYLZJTXQD-PXNSSMCTSA-N N-[(2S)-1-(1H-benzimidazol-2-ylmethylamino)-4-[(2S)-2-methylpiperidin-1-yl]-1,4-dioxobutan-2-yl]-4,4-dimethylpentanamide Chemical compound N1C(=NC2=C1C=CC=C2)CNC(=O)[C@H](CC(=O)N1[C@H](CCCC1)C)NC(CCC(C)(C)C)=O PUFABYYLZJTXQD-PXNSSMCTSA-N 0.000 description 1
- KTUCEWAXZNUKAG-PTOFZMKOSA-N N-[(2S)-1-[1-(1H-benzimidazol-2-yl)ethylamino]-1,4-dioxo-4-[(2S)-2-phenylpyrrolidin-1-yl]butan-2-yl]-4-methylpentanamide Chemical compound N1C(=NC2=C1C=CC=C2)C(C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(CCC(C)C)=O KTUCEWAXZNUKAG-PTOFZMKOSA-N 0.000 description 1
- ZSZHFLQXTZEGAG-OPXMRZJTSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2S)-2-phenylpyrrolidin-1-yl]butan-2-yl]-4,4-dimethylpentanamide Chemical compound N1C(=NC2=C1C=CC=C2)[C@H](C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(CCC(C)(C)C)=O ZSZHFLQXTZEGAG-OPXMRZJTSA-N 0.000 description 1
- KTUCEWAXZNUKAG-OPXMRZJTSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-1,4-dioxo-4-[(2S)-2-phenylpyrrolidin-1-yl]butan-2-yl]-4-methylpentanamide Chemical compound N1C(=NC2=C1C=CC=C2)[C@H](C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(CCC(C)C)=O KTUCEWAXZNUKAG-OPXMRZJTSA-N 0.000 description 1
- BPZKJLNRYXSQTC-UWVAXJGDSA-N N-[(2S)-1-[[(1S)-1-(1H-benzimidazol-2-yl)ethyl]amino]-4-[(2R)-2-methylpyrrolidin-1-yl]-1,4-dioxobutan-2-yl]-4,4-dimethylpentanamide Chemical compound N1C(=NC2=C1C=CC=C2)[C@H](C)NC(=O)[C@H](CC(=O)N1[C@@H](CCC1)C)NC(CCC(C)(C)C)=O BPZKJLNRYXSQTC-UWVAXJGDSA-N 0.000 description 1
- YXVCTZKSFWUMJM-WWMYMODYSA-N N-[(2S)-1-[[(1S)-1-[5-(2,4-difluorophenyl)-1H-imidazol-2-yl]ethyl]amino]-4-[(2R)-2-methylpyrrolidin-1-yl]-1,4-dioxobutan-2-yl]-4,4-dimethylpentanamide Chemical compound FC1=C(C=CC(=C1)F)C1=CN=C(N1)[C@H](C)NC(=O)[C@H](CC(=O)N1[C@@H](CCC1)C)NC(CCC(C)(C)C)=O YXVCTZKSFWUMJM-WWMYMODYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 108010020856 N-terminal nucleophile hydrolase Proteins 0.000 description 1
- UFVDEOPJHQYWBU-JZBYGGRQSA-N N1C(=NC2=C1C=CC=C2)C(C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(=O)C1CC(C1)C Chemical compound N1C(=NC2=C1C=CC=C2)C(C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(=O)C1CC(C1)C UFVDEOPJHQYWBU-JZBYGGRQSA-N 0.000 description 1
- BYVNONMCPNXACM-OEOAZWSVSA-N N1C(=NC2=C1C=CC=C2)[C@H](C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(=O)C1=NOC(=C1)C Chemical compound N1C(=NC2=C1C=CC=C2)[C@H](C)NC(=O)[C@H](CC(N1[C@@H](CCC1)C1=CC=CC=C1)=O)NC(=O)C1=NOC(=C1)C BYVNONMCPNXACM-OEOAZWSVSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- QKVZRTFLBOCWNX-LJRYBOSXSA-N N[C@H](C(=O)N[C@@H](C)C1NC(C=N1)C1=C(C=CC=C1)F)CC(N1[C@H](CCC1)C1=CC=CC=C1)=O Chemical compound N[C@H](C(=O)N[C@@H](C)C1NC(C=N1)C1=C(C=CC=C1)F)CC(N1[C@H](CCC1)C1=CC=CC=C1)=O QKVZRTFLBOCWNX-LJRYBOSXSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 241001147662 Neospora caninum Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001492486 Nosema apis Species 0.000 description 1
- 241000562094 Notoedres cati Species 0.000 description 1
- DJXMDWNVJGVKSP-NQCNTLBGSA-N O=C(N[C@@H](CC(=O)N1CCCC1C1CC1)C(=O)CC1(C2=CC3=C(N2)C(F)=CC=C3)CC1)C1CC2(C1)CC(F)(F)C2 Chemical compound O=C(N[C@@H](CC(=O)N1CCCC1C1CC1)C(=O)CC1(C2=CC3=C(N2)C(F)=CC=C3)CC1)C1CC2(C1)CC(F)(F)C2 DJXMDWNVJGVKSP-NQCNTLBGSA-N 0.000 description 1
- 241000543819 Oestrus ovis Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000243794 Ostertagia ostertagi Species 0.000 description 1
- 241000790252 Otodectes cynotis Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241001480234 Paragonimus westermani Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000722350 Phlebotomus <genus> Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241001649230 Psoroptes ovis Species 0.000 description 1
- 241000718000 Pulex irritans Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241001481696 Rhipicephalus sanguineus Species 0.000 description 1
- 241000304160 Sarcophaga carnaria Species 0.000 description 1
- 241000509416 Sarcoptes Species 0.000 description 1
- 241000242679 Schistosoma bovis Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000244174 Strongyloides Species 0.000 description 1
- 241000122938 Strongylus vulgaris Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000255632 Tabanus atratus Species 0.000 description 1
- 241001672170 Taenia pisiformis Species 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- 241000244157 Taenia solium Species 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- NSFFHOGKXHRQEW-UHFFFAOYSA-N Thiostrepton B Natural products N1C(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)NC(C(C2=N3)O)C=CC2=C(C(C)O)C=C3C(=O)OC(C)C(C=2SC=C(N=2)C2N=3)NC(=O)C(N=4)=CSC=4C(C(C)(O)C(C)O)NC(=O)C(N=4)CSC=4C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=4)=CSC=4C21CCC=3C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-UHFFFAOYSA-N 0.000 description 1
- 241000244030 Toxocara canis Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241001414833 Triatoma Species 0.000 description 1
- 241000243777 Trichinella spiralis Species 0.000 description 1
- 241000031115 Trichobilharzia regenti Species 0.000 description 1
- 241000557621 Trichomonas gallinae Species 0.000 description 1
- 241000243797 Trichostrongylus Species 0.000 description 1
- 241000960389 Trichuris suis Species 0.000 description 1
- 241001058196 Tritrichomonas foetus Species 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 241000223089 Trypanosoma equiperdum Species 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 208000007456 balantidiasis Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000005621 boronate group Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 108010063626 fellutamide B Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000004615 furo[2,3-b]pyridinyl group Chemical group O1C(=CC=2C1=NC=CC2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HIRNDYDRQNZASU-UHFFFAOYSA-N n-benzyl-n-methylcarbamoyl chloride Chemical compound ClC(=O)N(C)CC1=CC=CC=C1 HIRNDYDRQNZASU-UHFFFAOYSA-N 0.000 description 1
- PUADMGQHCWUWEM-UHFFFAOYSA-N n-benzylcarbamoyl chloride Chemical compound ClC(=O)NCC1=CC=CC=C1 PUADMGQHCWUWEM-UHFFFAOYSA-N 0.000 description 1
- TYRGLVWXHJRKMT-QMMMGPOBSA-N n-benzyloxycarbonyl-l-serine-betalactone Chemical compound OC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1 TYRGLVWXHJRKMT-QMMMGPOBSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- BWOVQCBKUXJWNF-UHFFFAOYSA-N n-methyl-n-(2-methylpropyl)carbamoyl chloride Chemical compound CC(C)CN(C)C(Cl)=O BWOVQCBKUXJWNF-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000023837 negative regulation of proteolysis Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- CVXGFPPAIUELDV-UHFFFAOYSA-N phenacylazanium;chloride Chemical compound [Cl-].[NH3+]CC(=O)C1=CC=CC=C1 CVXGFPPAIUELDV-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- BIFDXOOJPDHKJH-UHFFFAOYSA-N piperidine-1-carbonyl chloride Chemical compound ClC(=O)N1CCCCC1 BIFDXOOJPDHKJH-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- FUQHLUSGMOSPRQ-UHFFFAOYSA-N spiro[3.3]heptane-2-carboxylic acid Chemical compound C1C(C(=O)O)CC11CCC1 FUQHLUSGMOSPRQ-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- UVFAEQZFLBGVRM-MSMWPWNWSA-N succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CCC(O)=O)CC(C)C)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C1=CC=C(O)C=C1 UVFAEQZFLBGVRM-MSMWPWNWSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical class FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- NSFFHOGKXHRQEW-AIHSUZKVSA-N thiostrepton Chemical compound C([C@]12C=3SC=C(N=3)C(=O)N[C@H](C(=O)NC(/C=3SC[C@@H](N=3)C(=O)N[C@H](C=3SC=C(N=3)C(=O)N[C@H](C=3SC=C(N=3)[C@H]1N=1)[C@@H](C)OC(=O)C3=CC(=C4C=C[C@H]([C@@H](C4=N3)O)N[C@H](C(N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N2)=O)[C@@H](C)CC)[C@H](C)O)[C@](C)(O)[C@@H](C)O)=C\C)[C@@H](C)O)CC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-AIHSUZKVSA-N 0.000 description 1
- 229930188070 thiostrepton Natural products 0.000 description 1
- 229940063214 thiostrepton Drugs 0.000 description 1
- NSFFHOGKXHRQEW-OFMUQYBVSA-N thiostrepton A Natural products CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]4NC(=O)c5csc(n5)[C@@H](NC(=O)[C@H]6CSC(=N6)C(=CC)NC(=O)[C@@H](NC(=O)c7csc(n7)[C@]8(CCC(=N[C@@H]8c9csc4n9)c%10nc(cs%10)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)[C@](C)(O)[C@@H](C)O)[C@H](C)O NSFFHOGKXHRQEW-OFMUQYBVSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940096911 trichinella spiralis Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 230000004906 unfolded protein response Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to peptidomimetic proteasome inhibitors.
- proteasomes are highly conserved self-compartmentalizing proteases found in three kingdoms of life.
- a proteasome is a large, ATP-dependent, multi-subunit, barrel-shaped N-terminal nucleophile hydrolase present in the cytosol and nucleus of eukaryotic cells and is responsible for the degradation of the majority of cellular proteins (Baumeister et al., “The Proteasome: Paradigm of a Self-Compartmentalizing Protease,” Cell 92(3):367-380 (1998); Goldberg A L., “Functions of the Proteasome:from Protein Degradation and Immune Surveillance to Cancer Therapy,” Biochem. Soc. Trans. 35(Pt 1):12-17 (2007)).
- Degradation product oligopeptides are reservoirs of antigenic peptides for MHC class I antigen presentation.
- the 20S core that is constitutively expressed in most cells is a stack of 4 rings of 14 ⁇ and ⁇ subunits organized in a ⁇ 1-7 ⁇ 1-7 ⁇ 1-7 ⁇ 1-7 fashion, where 2 copies of each caspase-like ⁇ 1, trypsin-like ⁇ 2, and chymotrypsin-like ⁇ 5 active subunits are located in the inner ⁇ rings (Baumeister, et al., “The Proteasome: Paradigm of a Self-Compartmentalizing Protease,” Cell 92:367-380 (1998)).
- the chymotrypsin-like ⁇ 5 active subunits of the 20S have been clinically validated as a target for the treatment of multiple myeloma and certain lymphomas.
- proteasome inhibitors that were approved by FDA: bortezomib, carfilzomib, and ixazomib: bortezomib and ixazomib are reversible peptide boronates and carfilzomib an irreversible peptide epoxyketone (Borissenko et al., “20S Proteasome and its Inhibitors: Crystallographic Knowledge for Drug Development,” Chem. Rev.
- Proteasome inhibition interrupts many cellular pathways, particularly, the NF-kB activation pathway, the induction of unfolded protein response, and ER stress, while strongly inducing apoptosis. For this reason, highly specific proteasome inhibitors have been approved for the treatment of hematological cancer. Proteasome inhibitors can also markedly limit the overall supply of peptides for MHC class I molecules and, thus, block antigen presentation (Rock et al., “Protein Degradation and the Generation of MHC Class I-Presented Peptides,” Adv. Immunol. 80:1-70 (2002)). As a result, proteasome inhibitors reduce immune response via multiple routes.
- Antibody-secreting plasma cells are highly sensitive to proteasome inhibition and BTZ, which inhibits both c-20S and i-20S, has been used in renal transplant recipients to prevent antibody-mediated graft rejection (Aull et al., Clin Transpl 495-498 (2009); Raghavan et al., “Bortezomib in Kidney Transplantation,” J. Transplant. 2010: 698594 (2010); Al-Homsi et al., “Effect of Novel Proteasome and Immunoproteasome Inhibitors on Dendritic Cell Maturation, Function, and Expression of I ⁇ b and Nf ⁇ b,” Transpl. Immunol.
- BTZ was also reported to be efficacious in patients with refractory systemic lupus erythematosus (Alexander et al., “The Proteasome Inhibitor Bortezomib Depletes Plasma Cells and Ameliorates Clinical Manifestations of Refractory Systemic Lupus Erythematosus,” Ann. Rheum. Dis. 74:1474-1478 (2015).
- Plasmodium falciparum P. falciparum
- P. falciparum the most deadly of the human malarias, accounts for nearly 0.5 million deaths a year, primarily in children.
- the most important current therapies are combinations of artemisinins (ART).
- ART resistant parasites Ariey et al., “A Molecular Marker of Artemisinin-Resistant Plasmodium Falciparum Malaria,” Nature 505(7481):50-55 (2014); Straimer et al., “K13-Propeller Mutations Confer Artemisinin Resistance in Plasmodium Falciparum Clinical Isolates,” Science 347(6220):428-431 (2015); Dogovski et al., “Targeting the Cell Stress Response of Plasmodium Falciparum to Overcome Artemisinin Resistance,” PLoS Biol.
- Upregulation of the ubiquitin proteasome system is important for survival of artemisinin-resistant parasites and emphasizes the importance of the UPS in parasite survival and its importance as a drug target moving forward (Dogovski et al., “Targeting the Cell Stress Response of Plasmodium Falciparum to Overcome Artemisinin Resistance,” PLoS Biol. 13(4):e1002132 (2015); Mok et al., “Drug Resistance. Population Transcriptomics of Human Malaria Parasites Reveals the Mechanism of Artemisinin Resistance,” Science 347(6220):431-435(2015)).
- UPS ubiquitin proteasome system
- Proteasome inhibitors are known to kill malaria parasites in vitro and are efficacious against multiple parasite stages; peptide epoxyketone inhibitors, a peptide vinyl sulfone inhibitor, and a cyclic peptide inhibitor, have potent anti-malarial activities (Dogovski et al., “Targeting the Cell Stress Response of Plasmodium Falciparum to Overcome Artemisinin Resistance,” PLoS Biol. 13(4):e1002132 (2015); Featherstone C. “Proteasome Inhibitors in Development for Malaria,” Mol. Med. Today 3(9):367 (1997); Gantt et al., “Proteasome Inhibitors Block Development of Plasmodium Spp,” Antimicrob.
- proteasome represents an important target for therapeutic intervention of various disorders.
- proteasome inhibitors there is an ongoing need for new and/or improved proteasome inhibitors.
- the present invention is directed to overcoming these and other deficiencies in the art.
- a first aspect of the present invention relates to a compound of Formula (I):
- R is H or C 1-6 alkyl
- R′ is H or C 1-6 alkyl
- R 2 is independently selected at each occurrence thereof from
- R 3 is independently selected at each occurrence thereof from the group consisting of H, C 1-12 alkyl, -Boc, —C(O)(CH 2 ) n R 5 , —(CH 2 ) n C(O)R 5 , —C(O)OR 5 , —C(O)(CH 2 ) n NR 6 R 7 , —S(O) 2 R 5 , monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 4 is H, halogen, NH 2 , NHCOOC 1-12 alkyl, or C 1-12 alkyl;
- R 5 is selected from the group consisting of C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 6 , R 7 are each independently selected from the group consisting of H, C 1-6 alkyl, and arylalkyl;
- R 6 and R 7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R 9 ;
- R 8 is selected independently at each occurrence thereof from the group consisting of halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl, wherein C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R 9 ;
- R 9 is selected from the group consisting of H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, and aryl, wherein C 1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R 10 is H or arylalkyl
- W is CHR 2 , NR 2 , or
- X is selected from the group consisting of —C(O)—NH—, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH 2 ) m —;
- Z is optional and, if present, is aryl or bicyclic heteroaryl
- k 1 or 2;
- n 0, 1, or 2;
- n 0, 1, 2, 3, or 4, with the proviso that R 2 is not —CH 2 C(O)NH 2 , —CH 2 C(O)NHCH 2 C(CH 3 ) 3 , or —(CH 2 ) 2 C(O)NH 2 , or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof.
- a second aspect of the present invention relates to a method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject.
- This method includes administering to the subject in need thereof a compound according to any aspect of the present invention.
- a third aspect of the present invention relates to a method of inhibiting proteasome activity.
- This method includes contacting a proteasome with a compound according to any aspect of the present invention under conditions effective to inhibit proteasome activity.
- a first aspect of the present invention relates to a compound of Formula (I):
- R is H or C 1-6 alkyl
- R′ is H or C 1-6 alkyl
- R 1 is H or C 1-6 alkyl
- R and R 1 are taken together with the carbon to which they are attached to form a C 3-8 cycloalkyl ring;
- R 2 is independently selected at each occurrence thereof from
- R 3 is independently selected at each occurrence thereof from the group consisting of H, C 1-12 alkyl, -Boc, —C(O)(CH 2 ) n R 5 , —(CH 2 ) n C(O)R 5 , —C(O)OR 5 , —C(O)(CH 2 ) n NR 6 R 7 , —S(O) 2 R 5 , monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 4 is H, halogen, NH 2 , NHCOOC 1-12 alkyl, or C 1-12 alkyl;
- R 5 is selected from the group consisting of C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 6 , R 7 are each independently selected from the group consisting of H, C 1-6 alkyl, and arylalkyl;
- R 6 and R 7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R 9 ;
- R 8 is selected independently at each occurrence thereof from the group consisting of halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl, wherein C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R 9 ;
- R 9 is selected from the group consisting of H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, and aryl, wherein C 1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R 10 is H or arylalkyl
- W is CHR 2 , NR 2 , or
- X is selected from the group consisting of —C(O)—NH—, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH 2 ) m —;
- Z is optional and, if present, is aryl or bicyclic heteroaryl
- k 1 or 2;
- n 0, 1, or 2;
- n 0, 1, 2, 3, or 4, with the proviso that R 2 is not —CH 2 C(O)NH 2 , —CH 2 C(O)NHCH 2 C(CH 3 ) 3 , or —(CH 2 ) 2 C(O)NH 2 , or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof.
- alkyl means an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 12 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, and 3-pentyl.
- cycloalkyl means a non-aromatic mono- or multicyclic ring system of about 3 to about 12 carbon atoms, preferably of about 3 to about 8 carbon atoms.
- exemplary monocyclic cycloalkyls include cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[1.1.1]pentyl, and the like.
- cycloalkylalkyl means a cycloalkyl-alkyl-group in which the cycloalkyl and alkyl are as defined herein.
- exemplary cycloalkylalkyl groups include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopropylethyl, cyclobutylethyl, and cyclopentylethyl.
- the alkyl radical and the cycloalkyl radical may be optionally substituted as defined herein.
- aryl means an aromatic monocyclic or multicyclic ring system of 6 to about 14 carbon atoms, preferably of 6 to about 10 carbon atoms.
- Representative aryl groups include phenyl and naphthyl.
- arylalkyl means an alkyl substituted with one or more aryl groups, wherein the alkyl and aryl groups are as herein described.
- arylmethyl or arylethyl group in which a single or a double carbon spacer unit is attached to an aryl group, where the carbon spacer and the aryl group can be optionally substituted as described herein.
- Representative arylalkyl groups include
- heteroaryl means an aromatic monocyclic or multicyclic ring system of about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is/are element(s) other than carbon, for example, nitrogen, oxygen, or sulfur.
- element(s) other than carbon for example, nitrogen, oxygen, or sulfur.
- heteroaryl only one of the rings needs to be aromatic for the ring system to be defined as “Heteroaryl”.
- Preferred heteroaryls contain about 5 to 6 ring atoms.
- aza, oxa, thia, or thio before heteroaryl means that at least a nitrogen, oxygen, or sulfur atom, respectively, is present as a ring atom.
- a nitrogen atom of a heteroaryl is optionally oxidized to the corresponding N-oxide.
- Representative heteroaryls include pyridyl, 2-oxo-pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, furanyl, pyrrolyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indolinyl, 2-oxoindolinyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, indazolyl, benzimidazolyl, benzooxazolyl, benzothiazo
- heterocyclyl refers to a stable 3- to 18-membered ring (radical) which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
- the heterocycle may be a monocyclic, or a polycyclic ring system, which may include fused, bridged, or spiro ring systems; and the nitrogen, carbon, or sulfur atoms in the heterocycle may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the ring may be partially or fully saturated.
- heterocycles include, without limitation, azepinyl, azocanyl, pyranyl dioxanyl, dithianyl, 1,3-dioxolanyl, tetrahydrofuryl, dihydropyrrolidinyl, decahydroisoquinolyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, oxazolidinyl, oxiranyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydropyranyl, thiamorpholinyl
- non-aromatic heterocycle means a non-aromatic monocyclic or multicyclic system containing 3 to 10 atoms, preferably 4 to about 7 carbon atoms, in which one or more of the atoms in the ring system is/are element(s) other than carbon, for example, nitrogen, oxygen, or sulfur.
- Non-aromatic heterocycle groups include pyrrolidinyl, 2-oxopyrrolidinyl, piperidinyl, 2-oxopiperidinyl, azepanyl, 2-oxoazepanyl, 2-oxooxazolidinyl, morpholino, 3-oxomorpholino, thiomorpholino, 1,1-dioxothiomorpholino, piperazinyl, tetrohydro-2H-oxazinyl, and the like.
- polycyclic or “multi-cyclic” used herein indicates a molecular structure having two or more rings, including, but not limited to, fused, bridged, or spiro rings.
- a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable.
- the protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or “deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere.
- alkoxy means groups of from 1 to 12 carbon atoms of a straight, branched, or cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like. Lower-alkoxy refers to groups containing one to four carbons.
- alkoxy also includes methylenedioxy and ethylenedioxy in which each oxygen atom is bonded to the atom, chain, or ring from which the methylenedioxy or ethylenedioxy group is pendant so as to form a ring.
- phenyl substituted by alkoxy may be, for example,
- a compound with a hydroxy group drawn next to a nitrogen on a heterocycle can exist as the “keto” form.
- 3-(2-hydroxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)propanoic acid can exist as 3-(2-oxo-2,3-dihydro-[1,2,4]triazolo[1,5-a]pyridin-6-yl)propanoic acid.
- halogen means fluoro, chloro, bromo, or iodo.
- substituted or “substitution” of an atom means that one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded.
- “Unsubstituted” atoms bear all of the hydrogen atoms dictated by their valency. When a substituent is keto (i.e., ⁇ O), then two hydrogens on the atom are replaced. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds; by “stable compound” or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
- a group may have a substituent at each substitutable atom of the group (including more than one substituent on a single atom), provided that the designated atom's normal valency is not exceeded and the identity of each substituent is independent of the others.
- Up to three H atoms in each residue are replaced with alkyl, halogen, haloalkyl, hydroxy, loweralkoxy, carboxy, carboalkoxy (also referred to as alkoxycarbonyl), carboxamido (also referred to as alkylaminocarbonyl), cyano, carbonyl, nitro, amino, alkylamino, dialkylamino, mercapto, alkylthio, sulfoxide, sulfone, acylamino, amidino, phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, or heteroaryloxy.
- method of treating means amelioration or relief from the symptoms and/or effects associated with the disorders described herein.
- treatment means amelioration or relief from the symptoms and/or effects associated with the disorders described herein.
- reference to “treatment” of a patient is intended to include prophylaxis.
- pharmaceutically acceptable salts means the relatively non-toxic, inorganic, and organic acid addition salts, and base addition salts, of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds. In particular, acid addition salts can be prepared by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
- Exemplary acid addition salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, sulphamates, malonates, salicylates, propionates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methane-sulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinateslaurylsulphon
- Base addition salts can also be prepared by separately reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt thus formed.
- Base addition salts include pharmaceutically acceptable metal and amine salts. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminum salts. The sodium and potassium salts are preferred.
- Suitable inorganic base addition salts are prepared from metal bases which include, for example, sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, and zinc hydroxide.
- Suitable amine base addition salts are prepared from amines which have sufficient basicity to form a stable salt, and preferably include those amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use, such as ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylarnine, dibenzylamine, ephenamine
- prodrugs as used herein means those prodrugs of the compounds useful according to the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
- prodrug means compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. Functional groups which may be rapidly transformed, by metabolic cleavage, in vivo form a class of groups reactive with the carboxyl group of the compounds of this invention.
- alkanoyl such as acetyl, propionyl, butyryl, and the like
- unsubstituted and substituted aroyl such as benzoyl and substituted benzoyl
- alkoxycarbonyl such as ethoxycarbonyl
- trialkylsilyl such as trimethyl- and triethysilyl
- monoesters formed with dicarboxylic acids such as succinyl
- the compounds bearing such groups act as pro-drugs.
- the compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group.
- prodrugs A thorough discussion of prodrugs is provided in the following: Design of Prodrugs, H. Bundgaard, ed., Elsevier (1985); Methods in Enzymology, K. Widder et al, Ed., Academic Press, 42, p. 309-396 (1985); A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard, ed., Chapter 5; “Design and Applications of Prodrugs” p.
- prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohol and amine functional groups in the compounds of the invention.
- solvate refers to a compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (I′), Formula (I′A), Formula (PB), Formula (I′C), Formula (I′D), Formula (I′E), Formula (I′F), Formula (I′G), Formula (I′C′), Formula (I′D′), Formula (I′E′), Formula (I′F′), Formula (I′G′), and Formula (II) in the solid state, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
- a suitable solvent for therapeutic administration is physiologically tolerable at the dosage administered. Examples of suitable solvents for therapeutic administration are ethanol and water. When water is the solvent, the solvate is referred to as a hydrate.
- solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions.
- terapéuticaally effective amounts is meant to describe an amount of compound of the present invention effective to produce the desired therapeutic effect. Such amounts generally vary according to a number of factors well within the purview of ordinarily skilled artisans given the description provided herein to determine and account for. These include, without limitation: the particular subject, as well as its age, weight, height, general physical condition, and medical history; the particular compound used, as well as the carrier in which it is formulated and the route of administration selected for it; and, the nature and severity of the condition being treated.
- composition means a composition comprising a compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (I′), Formula (I′A), Formula (I′B), Formula (I′C), Formula (I′D), Formula (I′E), Formula (I′F), Formula (I′G), Formula (I′C′), Formula (I′D′), Formula (I′E′), Formula (I′F′), Formula (I′G′), and Formula (II) and at least one component comprising pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifingal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms.
- suspending agents examples include ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances.
- Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like.
- Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monosterate and gelatin.
- suitable carriers, diluents, solvents, or vehicles include water, ethanol, polyols, suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
- excipients include lactose, milk sugar, sodium citrate, calcium carbonate, and dicalcium phosphate.
- disintegrating agents include starch, alginic acids, and certain complex silicates.
- lubricants include magnesium stearate, sodium lauryl sulphate, talc, as well as high molecular weight polyethylene glycols.
- pharmaceutically acceptable means it is, within the scope of sound medical judgement, suitable for use in contact with the cells of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable dosage forms means dosage forms of the compound of the invention, and includes, for example, tablets, dragees, powders, elixirs, syrups, liquid preparations, including suspensions, sprays, inhalants tablets, lozenges, emulsions, solutions, granules, capsules, and suppositories, as well as liquid preparations for injections, including liposome preparations. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., latest edition.
- Compounds described herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms.
- Each chiral center may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. This technology is meant to include all such possible isomers, as well as mixtures thereof, including racemic and optically pure forms.
- Optically active (R)- and (S)-, ( ⁇ )- and (+)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
- the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
- the basic nitrogen can be quaternized with any agents known to those of ordinary skill in the art including, for example, lower alkyl halides, such as methyl, ethyl, propyl and butyl chloride, bromides and iodides; dialkyl sulfates including dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides including benzyl and phenethyl bromides. Water or oil-soluble or dispersible products may be obtained by such quaternization.
- lower alkyl halides such as methyl, ethyl, propyl and butyl chloride, bromides and iodides
- dialkyl sulfates including dimethyl, diethyl, dibutyl and diamyl sulfates
- reaction of the carboxylic acid derivative ( 1 ) with amine ( 2 ) leads to formation of the final product ( 3 ).
- the reaction can be carried out in a variety of solvents, for example in methylene chloride (CH 2 Cl 2 ), tetrahydrofuran (THF), dimethylformamide (DMF), or other such solvents or in the mixture of such solvents.
- CH 2 Cl 2 methylene chloride
- THF tetrahydrofuran
- DMF dimethylformamide
- Reaction of the carboxylic acid derivative ( 4 ) with amine ( 2 ) leads to formation of the compound ( 5 ).
- the reaction can be carried out in a variety of solvents, for example in methylene chloride (CH 2 Cl 2 ), tetrahydrofuran (THF), dimethylformamide (DMF), or other such solvents or in the mixture of such solvents.
- CH 2 Cl 2 methylene chloride
- THF tetrahydrofuran
- DMF dimethylformamide
- the non-participating carboxylic acids or amines on the reacting set of amino acids or peptide fragments can be protected by a suitable protecting group (PG) which can be selectively removed at a later time if desired.
- PG protecting group
- useful protective groups for the amino group are benzyloxycarbonyl (Cbz), t-butyloxycarbonyl (t-BOC), 2,2,2-trichloroethoxycarbonyl (Troc), t-amyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-(trichlorosilyl)ethoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc), phthaloyl, acetyl (Ac), formyl, trifluoroacetyl, and the like.
- amine ( 6 ) is reacted with R 3 -LG ( 7 ) (wherein LG is a suitable leaving group) to form final product ( 8 ).
- the non-participating carboxylic acids or amines on the reacting set of amino acids or peptide fragments can be protected by a suitable protecting group which can be selectively removed at a later time if desired.
- a suitable protecting group which can be selectively removed at a later time if desired.
- useful protective groups for the amino group are benzyloxycarbonyl (Cbz), t-butyloxycarbonyl (t-BOC), 2,2,2-trichloroethoxycarbonyl (Troc), t-amyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-(trichlorosilyl)ethoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc), phthaloyl, acetyl (Ac), formyl, trifluoroacetyl, and the like.
- amine ( 6 a ) is reacted with R 3 -LG ( 7 ) (wherein LG is a suitable leaving group) to form final product ( 8 a ).
- the non-participating carboxylic acids or amines on the reacting set of amino acids or peptide fragments can be protected by a suitable protecting group which can be selectively removed at a later time if desired.
- a suitable protecting group which can be selectively removed at a later time if desired.
- useful protective groups for the amino group are benzyloxycarbonyl (Cbz), t-butyloxycarbonyl (t-BOC), 2,2,2-trichloroethoxycarbonyl (Troc), t-amyloxycarbonyl, 4-methoxybenzyloxycarbonyi, 2-(trichlorosilyl)ethoxycarbonyl, 9-fluorenyhnethoxycarbonyl (Frnoc), phthaloyl, acetyl (Ac), formyl, trifluoroacetyl, and the like.
- amine ( 6 b ) is reacted with R 3 -LG ( 7 ) (wherein is a suitable leaving group) to form final product ( 8 b ).
- compound has the Formula (IA):
- compound has the Formula (IB):
- compound has the Formula (IC):
- One embodiment relates to the compound of Formulae (I) where R 1 is H or Me.
- a further embodiment relates to the compound of Formulae (I) where R 2 is selected from the group consisting of
- R 3 is selected from the group consisting of H, Boc,
- Another embodiment relates to the compound of Formulae (I) where R 4 is H, Me, F, NH 2 , or NHBoc.
- Yet another embodiment relates to the compound of Formulae (I) where Y is —CH 2 —.
- a further embodiment relates to the compound of Formulae (I) where Z is
- Another embodiment relates to the compound of Formulae (I) where the compound has a structure selected from the group consisting of:
- compound has the Formula (I′):
- R is H or C 1-6 alkyl
- R 1 is H or C 1-6 alkyl
- R and R 1 are taken together with the carbon to which they are attached to form a C 3-8 cycloalkyl ring;
- R 2 is independently selected at each occurrence thereof from the group consisting of C 1-6 alkyl, and —(CH 2 ) n C(O)NR 6 R 7 , wherein C 1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR 10 ;
- R 3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH 2 ) n R 5 , —(CH 2 ) n C(O)R 5 , —C(O)OR 5 , —C(O)(CH 2 ) n NR 6 R 7 , —S(O) 2 R 5 , monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C 1-6 alkyl;
- R 4 is H, C 1-12 alkyl, or halogen
- R 5 is selected from the group consisting of C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 6 , R 7 are each independently selected from the group consisting of H, C 1-6 alkyl, and arylalkyl;
- R 6 and R 7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R 9 ;
- R 8 is selected independently at each occurrence thereof from the group consisting of halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl, wherein C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R 9 ;
- R 9 is selected from the group consisting of H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, and aryl, wherein C 1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R 10 is H or arylalkyl
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle
- Y is optional and, if present, is —(CH 2 ) m —;
- Z is optional and, if present, is aryl
- n 0, 1, or 2;
- n 0, 1, 2, 3, or 4;
- compound has the Formula (I′A):
- A is NH, N, O, or S.
- compound has the Formula (PB):
- A is NH, N, O, or S
- B is NH, N, O, or S.
- compound has the Formula (I′C):
- compound has the Formula (I′D):
- compound has the Formula (I′E):
- compound has the Formula (I′F):
- compound has the Formula (I′G):
- compound has the Formula (I′C′):
- compound has the Formula (I′D′):
- compound has the Formula (I′E′):
- compound has the Formula (I′F′):
- compound has the Formula (I′G′):
- One embodiment relates to the compound of Formulae (I′) where R 1 is H or Me.
- Another embodiment relates to the compound of Formulae (I′) where R 4 is H, Me, or F.
- Yet another embodiment relates to the compound of Formulae (I′) where Y is —CH 2 —.
- Another embodiment relates to the compound of Formulae (I′) where n Z is
- a further embodiment relates to the compound of Formulae (I′) where the compound has a structure selected from the group consisting of:
- compound has the Formula:
- compound has the Formula (II):
- R is H or C 1-6 alkyl
- R 1 is H or C 1-6 alkyl
- R and R 1 are taken together with the carbon to which they are attached to form a C 3-8 cycloalkyl ring;
- R 2 is independently selected at each occurrence thereof from the group consisting of C 1-6 alkyl, and —(CH 2 ) n C(O)NR 6 R 7 , wherein C 1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR 10 ;
- R 3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH 2 ) n R 5 , —(CH 2 ) n C(O)R 5 , —C(O)OR 5 , —C(O)(CH 2 ) n NR 6 R 7 , —S(O) 2 R 5 , monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C 1-6 alkyl;
- R 4 is H, C 1-12 alkyl, or halogen
- R 5 is selected from the group consisting of C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 6 , R 7 are each independently selected from the group consisting of H, C 1-6 alkyl, and arylalkyl;
- R 6 and R 7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R 9 ;
- R 8 is selected independently at each occurrence thereof from the group consisting of halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl, wherein C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R 9 ;
- R 9 is selected from the group consisting of H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, and aryl, wherein C 1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R 10 is H or arylalkyl
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle
- Y is optional and, if present, is —(CH 2 ) m —;
- Z is optional and, if present, is aryl
- W is N or CH
- n 0, 1, or 2;
- n 0, 1, 2, 3, or 4;
- Another aspect of the present invention relates to a method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject.
- This method includes administering to the subject in need thereof a compound of Formula (I):
- R is H or C 1-6 alkyl
- R′ is H or C 1-6 alkyl
- R 1 is H or C 1-6 alkyl
- R and R 1 are taken together with the carbon to which they are attached to form a C 3-8 cycloalkyl ring;
- R 2 is independently selected at each occurrence thereof from
- R 3 is independently selected at each occurrence thereof from the group consisting of H, C 1-12 alkyl, -Boc, —C(O)(CH 2 ) n R 5 , —(CH 2 ) n C(O)R 5 , —C(O)OR 5 , —C(O)(CH 2 ) n NR 6 R 7 , —S(O) 2 R 5 , monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 6 , R 7 are each independently selected from the group consisting of H, C 1-6 alkyl, and arylalkyl;
- R 8 is selected independently at each occurrence thereof from the group consisting of halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl, wherein C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R 9 ;
- R 9 is selected from the group consisting of H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, and aryl, wherein C 1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R 10 is H or arylalkyl
- W is CHR 2 , NR 2 , or
- X is selected from the group consisting of —C(O)—NH—, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH 2 ) m —;
- Z is optional and, if present, is aryl or bicyclic heteroaryl
- k 1 or 2;
- n 0, 1, or 2;
- n 0, 1, 2, 3, or 4
- One embodiment of the present invention relates to a method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject.
- This method includes administering to the subject in need thereof a compound of Formula (I′):
- R is H or C 1-6 alkyl
- R 1 is H or C 1-6 alkyl
- R and R 1 are taken together with the carbon to which they are attached to form a C 3-8 cycloalkyl ring;
- R 2 is independently selected at each occurrence thereof from the group consisting of C 1-6 alkyl, and —(CH 2 ) n C(O)NR 6 R 7 , wherein C 1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR 10 ;
- R 3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH 2 ) n R 5 , —(CH 2 ) n C(O)R 5 , —C(O)OR 5 , —C(O)(CH 2 )—NR 6 R 7 , —S(O) 2 R 5 , monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C 1-6 alkyl;
- R 4 is H, C 1-12 alkyl, or halogen
- R 5 is selected from the group consisting of C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 6 , R 7 are each independently selected from the group consisting of H, C 1-6 alkyl, and arylalkyl;
- R 6 and R 7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R 9 ;
- R 8 is selected independently at each occurrence thereof from the group consisting of halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl, wherein C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R 9 ;
- R 9 is selected from the group consisting of H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, and aryl, wherein C 1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R 10 is H or arylalkyl
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle
- Y is optional and, if present, is —(CH 2 ) m —;
- Z is optional and, if present, is aryl
- n 0, 1, or 2;
- n 0, 1, 2, 3, or 4;
- Another aspect of the present invention relates to a method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject.
- This method includes administering to the subject in need thereof a compound of Formula:
- Another aspect of the present invention relates to a method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject.
- This method includes administering to the subject in need thereof a compound of Formula (II):
- R is H or C 1-6 alkyl
- R 1 is H or C 1-6 alkyl
- R and R 1 are taken together with the carbon to which they are attached to form a C 3-8 cycloalkyl ring;
- R 2 is independently selected at each occurrence thereof from the group consisting of C 1-6 alkyl, and —(CH 2 ) n C(O)NR 6 R 7 , wherein C 1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR 10 ;
- R 3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH 2 ) n R 5 , —(CH 2 ) n C(O)R 5 , —C(O)OR 5 , —C(O)(CH 2 ) n NR 6 R 7 , —S(O) 2 R 5 , monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C 1-6 alkyl;
- R 4 is H, C 1-12 alkyl, or halogen
- R 5 is selected from the group consisting of C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 6 , R 7 are each independently selected from the group consisting of H, C 1-6 alkyl, and arylalkyl;
- R 6 and R 7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R 9 ;
- R 8 is selected independently at each occurrence thereof from the group consisting of halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl, wherein C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R 9 ;
- R 9 is selected from the group consisting of H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, and aryl, wherein C 1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R 10 is H or arylalkyl;
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle
- Y is optional and, if present, is —(CH 2 ) m —;
- Z is optional and, if present, is aryl
- W is N or CH
- n 0, 1, or 2;
- n 0, 1, 2, 3, or 4;
- bacterial infection is treated.
- the bacterial infection is
- parasite infection is treated.
- the parasite infection is selected from, but not limited to, the group consisting of malaria, leishmaniasis, river blindness, Chagas disease, sleeping disease, cryptosporidiosis, amebiasis, cyclosporiasis, giardiasis, and toxoplasmosis.
- parasite infection is veterinary parasite infection.
- the veterinary parasite infection is caused by protozoan parasites, helminth parasites, arachnids, insects, or custaceans.
- Exemplary protozoan parasites include, but are not limited to, Babesia divergens, Balantidium coli, Eimeria tenella, Giardia lamblia ( Giardia duodenalis ), Hammondia hammondi, Histomonas meleagridis, Isospora canis, Leishmania donovani, Leishmania infantum, Neospora caninum, Toxoplasma gondii, Trichomonas gallinae, Tritrichomonas foetus, Trypanosoma brucei, and Trypanosoma equiperdum.
- Exemplary helminth parasites include, but are not limited to, Ancylostoma duodenale, Ascaris suum, Dicrocoelium dendriticum, Dictyocaulus viviparus, Dipylidium caninum, Echinococcus granulosus, Fasciola hepatica, Fascioloides magna, Habronema species, Haemonchus contortus, Metastrongylus, Muellerius capillaris, Ostertagia ostertagi, Paragonimus westermani, Schistosoma bovis, Strongyloides species, Strongylus vulgaris, Syngamus trachea (Gapeworm), Taenia pisiformis, Taenia saginata, Taenia solium, Toxocara canis, Trichinella spiralis, Trichobilharzia regenti, Trichostrongylus species, and Trichuris suis.
- Exemplary arachnids, insects, and custaceans include, but are not limited to, Caligus species, Cimex colombarius, Cimex lectularius, Culex pipiens, Culicoides imicola, Demodex bovis, Dermacentor reticulatus, Gasterophilus intestinalis, Haematobia irritans, Hypoderma bovis, Ixodes ricinus, Knemidocoptes mutans, Lepeophtheirus salmonis, Lucilia sericata, Musca domestica, Nosema apis, Notoedres cati, Oestrus ovis, Otodectes cynotis, Phlebotomus species, Psoroptes ovis, Pulex irritans, Rhipicephalus sanguineus, Sarcoptes equi, Sarcophaga carnaria, Tabanus atratus, Triatoma species, Ctenocephalides canis, and Ctenocephalides felis.
- an autoimmune disorder is treated.
- the autoimmune disorder is selected from the group consisting of arthritis, colitis, multiple sclerosis, lupus, Sjogren Syndrome, Systemic Lupus Erythematosus and lupus nephritis, glomerulonephritis, Rheumatoid Arthritis, Inflammatory bowel disease (IBD), ulcerative colitis, Crohn's diseases, Psoriasis, and asthma.
- immunosuppression is provided for transplanted organs or tissues.
- the immunosuppression is used to prevent transplant rejection and graft-verse-host disease.
- an inflammatory disorder is treated.
- the inflammatory disorder is Crohn's disease.
- cancer refers to a cellular disorder characterized by uncontrolled or disregulated cell proliferation, decreased cellular differentiation, inappropriate ability to invade surrounding tissue, and/or ability to establish new growth at ectopic sites.
- cancer includes, but is not limited to, solid tumors and bloodborne tumors.
- cancer encompasses diseases of skin, tissues, organs, bone, cartilage, blood, and vessels.
- cancer further encompasses primary and metastatic cancers.
- Non-limiting examples of solid tumors that can be treated with the disclosed proteasome inhibitors include pancreatic cancer; bladder cancer; colorectal cancer; breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent and androgen-independent prostate cancer; renal cancer, including, e.g., metastatic renal cell carcinoma; hepatocellular cancer; lung cancer, including, e.g., non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and adenocarcinoma of the lung; ovarian cancer, including, e.g., progressive epithelial or primary peritoneal cancer; cervical cancer; gastric cancer; esophageal cancer; head and neck cancer, including, e.g., squamous cell carcinoma of the head and neck; melanoma; neuroendocrine cancer, including metastatic neuroendocrine tumors; brain tumors, including, e.g., glioma, anaplastic oligodendroglioma, adult
- cancer is treated.
- the cancer is selected from the group consisting of neoplastic disorders, hematologic malignances, lymphocytic malignancies, mantel cell lymphoma, leukemia, Waldenstrom Macroglobulinemia, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, metastatic breast cancer, prostate cancer, androgen-dependent and androgen-independent prostate cancer, renal cancer, metastatic renal cell carcinoma, hepatocellular cancer, lung cancer, non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and adenocarcinoma of the lung, ovarian cancer, progressive epithelial or primary peritoneal cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, squamous cell carcinoma of the head and neck, melanoma, neuroendocrine cancer, metastatic neuroendocrine tumors, brain tumors, glioma, anaplastic oligodendroglioma, adult
- a neurodegenerative disease or disorder is treated.
- the neurodegenerative disease or disorder is Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS).
- Another aspect of the present invention relates to a method of inhibiting proteasome activity.
- This method includes contacting a proteasome with a compound of Formula (I):
- R is H or C 1-6 alkyl
- R′ is H or C 1-6 alkyl
- R 1 is H or C 1-6 alkyl
- R and R 1 are taken together with the carbon to which they are attached to form a C 3-8 cycloalkyl ring;
- R 2 is independently selected at each occurrence thereof from
- R 3 is independently selected at each occurrence thereof from the group consisting of H, C 1-12 alkyl, -Boc, —C(O)(CH 2 ) n R 5 , —(CH 2 ) n C(O)R 5 , —C(O)OR 5 , —C(O)(CH 2 ) n NR 6 R 7 , —S(O) 2 R 5 , monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 4 is H, halogen, NH 2 , NHCOOC 1-12 alkyl, or C 1-12 alkyl;
- R 5 is selected from the group consisting of C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 6 , R 7 are each independently selected from the group consisting of H, C 1-6 alkyl, and arylalkyl;
- R 6 and R 7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R 9 ;
- R 8 is selected independently at each occurrence thereof from the group consisting of halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl, wherein C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R 9 ;
- R 9 is selected from the group consisting of H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, and aryl, wherein C 1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R 10 is H or arylalkyl
- W is CHR 2 , NR 2 , or
- X is selected from the group consisting of —C(O)—NH—, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH 2 ) m —;
- Z is optional and, if present, is aryl or bicyclic heteroaryl
- k 1 or 2;
- n 0, 1, or 2;
- n 0, 1, 2, 3, or 4
- R 2 is not —CH 2 C(O)NH 2 , —CH 2 C(O)NHCH 2 C(CH 3 ) 3 , or —(CH 2 ) 2 C(O)NH 2 , or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof under conditions effective to inhibit proteasome activity.
- One embodiment of the present invention relates to a method of inhibiting proteasome activity. This method includes contacting a proteasome with a compound of Formula (I′):
- R is H or C 1-6 alkyl
- R 1 is H or C 1-6 alkyl
- R and R 1 are taken together with the carbon to which they are attached to form a C 3-8 cycloalkyl ring;
- R 2 is independently selected at each occurrence thereof from the group consisting of C 1-6 alkyl, and —(CH 2 ) n C(O)NR 6 R 7 , wherein C 1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR 10 ;
- R 3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH 2 ) n R 5 , —(CH 2 )—C(O)R 5 , —C(O)OR 5 , —C(O)(CH 2 )—NR 6 R 7 , —S(O) 2 R 5 , monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C 1-6 alkyl;
- R 4 is H, C 1-12 alkyl, or halogen
- R 5 is selected from the group consisting of C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 6 , R 7 are each independently selected from the group consisting of H, C 1-6 alkyl, and arylalkyl;
- R 6 and R 7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R 9 ;
- R 8 is selected independently at each occurrence thereof from the group consisting of halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl, wherein C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R 9 ;
- R 9 is selected from the group consisting of H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, and aryl, wherein C 1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R 10 is H or arylalkyl
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle
- Y is optional and, if present, is —(CH 2 ) m —;
- Z is optional and, if present, is aryl
- n 0, 1, or 2;
- n 0, 1, 2, 3, or 4;
- Another aspect of the present invention relates to a method of inhibiting proteasome activity.
- This method includes contacting a proteasome with a compound of Formula (II):
- Another aspect of the present invention relates to a method of inhibiting proteasome activity.
- This method includes contacting a proteasome with a compound of Formula (II):
- R is H or C 1-6 alkyl
- R 1 is H or C 1-6 alkyl
- R and R 1 are taken together with the carbon to which they are attached to form a C 3-8 cycloalkyl ring;
- R 2 is independently selected at each occurrence thereof from the group consisting of C 1-6 alkyl, and —(CH 2 ) n C(O)NR 6 R 7 , wherein C 1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR 10 ;
- R 3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH 2 ) n R 5 , —(CH 2 )—C(O)R 5 , —C(O)OR 5 , —C(O)(CH 2 )—NR 6 R 7 , —S(O) 2 R 5 , monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C 1-6 alkyl;
- R 4 is H, C 1-12 alkyl, or halogen
- R 5 is selected from the group consisting of C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C 1-12 alkyl, monocyclic or bicyclic C 3-10 cycloalkyl, C 3-12 cycloalkylalkyl, C 1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R 8 ;
- R 6 , R 7 are each independently selected from the group consisting of H, C 1-6 alkyl, and arylalkyl;
- R 6 and R 7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R 9 ;
- R 8 is selected independently at each occurrence thereof from the group consisting of halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl, wherein C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R 9 ;
- R 9 is selected from the group consisting of H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, and aryl, wherein C 1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R 10 is H or arylalkyl
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle
- Y is optional and, if present, is —(CH 2 ) m —;
- Z is optional and, if present, is aryl
- W is N or CH
- n 0, 1, or 2;
- n 0, 1, 2, 3, or 4;
- another aspect of the present invention is a pharmaceutical composition containing a therapeutically effective amount of the compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (I′), Formula (I′A), Formula (PB), Formula (I′C), Formula (I′D), Formula (I′E), Formula (I′F), Formula (I′G), Formula (I′C′), Formula (I′D′), Formula (I′E′), Formula (I′F′), Formula (I′G′), and Formula (II), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
- the carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- agents suitable for treating a subject can be administered using any method standard in the art.
- the agents in their appropriate delivery form, can be administered orally, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, or intranasally.
- the compositions of the present invention may be administered alone or with suitable pharmaceutical carriers, and can be in solid or liquid form, such as tablets, capsules, powders, solutions, suspensions, or emulsions.
- the agents of the present invention may be orally administered, for example, with an inert diluent, or with an assimilable edible carrier, or it may be enclosed in hard or soft shell capsules, or it may be compressed into tablets, or they may be incorporated directly with the food of the diet.
- Agents of the present invention may also be administered in a time release manner incorporated within such devices as time-release capsules or nanotubes. Such devices afford flexibility relative to time and dosage.
- the agents of the present invention may be incorporated with excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, and the like.
- Such compositions and preparations should contain at least 0.1% of the agent, although lower concentrations may be effective and indeed optimal.
- the percentage of the agent in these compositions may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit.
- the amount of an agent of the present invention in such therapeutically useful compositions is such that a suitable dosage will be obtained
- oral dosage forms of the agents of the present invention are also contemplated.
- the agents may be chemically modified so that oral delivery of the derivative is efficacious.
- the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine.
- the increase in overall stability of the component or components and increase in circulation time in the body are also contemplated.
- moieties include: polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline (Abuchowski and Davis, “Soluble Polymer-Enzyme Adducts,” In: Enzymes as Drugs, Hocenberg and Roberts, eds., Wiley-Interscience, New York, N.Y., pp. 367-383 (1981), which are hereby incorporated by reference in their entirety).
- Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane.
- Preferred for pharmaceutical usage, as indicated above, are polyethylene glycol moieties.
- the tablets, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, sucrulose, or saccharin.
- a binder such as gum tragacanth, acacia, corn starch, or gelatin
- excipients such as dicalcium phosphate
- a disintegrating agent such as corn starch, potato starch, alginic acid
- a lubricant such as magnesium stearate
- a sweetening agent such as sucrose, lactose, sucrulose, or saccharin.
- a liquid carrier such as a fatty oil.
- tablets may be coated with shellac, sugar, or both.
- a syrup may contain, in addition to active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye, and flavoring such as cherry or orange flavor.
- the agents of the present invention may also be administered parenterally.
- Solutions or suspensions of the agent can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils.
- Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil.
- water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
- agents of the present invention When it is desirable to deliver the agents of the present invention systemically, they may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Intraperitoneal or intrathecal administration of the agents of the present invention can also be achieved using infusion pump devices such as those described by Medtronic, Northridge, Calif. Such devices allow continuous infusion of desired compounds avoiding multiple injections and multiple manipulations.
- the agents may also be formulated as a depot preparation.
- Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- the agents of the present invention may also be administered directly to the airways in the form of an aerosol.
- the agent of the present invention in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
- suitable propellants for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
- the agent of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.
- Effective doses of the compositions of the present invention, for the treatment of cancer or pathogen infection vary depending upon many different factors, including type and stage of cancer or the type of pathogen infection, means of administration, target site, physiological state of the patient, other medications or therapies administered, and physical state of the patient relative to other medical complications. Treatment dosages need to be titrated to optimize safety and efficacy.
- the percentage of active ingredient in the compositions of the present invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time.
- the dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient.
- the doses are generally from about 0.01 to about 100 mg/kg body weight, preferably about 0.01 to about 10 mg/kg body weight per day by inhalation, from about 0.01 to about 100 mg/kg body weight, preferably 0.1 to 70 mg/kg body weight, more especially 0.1 to 10 mg/kg body weight per day by oral administration, and from about 0.01 to about 50 mg/kg body weight, preferably 0.01 to 10 mg/kg body weight per day by intravenous administration.
- the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health, and other characteristics which can influence the efficacy of the medicinal product.
- the products according to the present invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. It goes without saying that, for other patients, it will be necessary to prescribe not more than one or two doses per day.
- Carboxylic acid (1.0 eq.), O-(7-azabenzotriazol-1-yl)-N,N,N,N′-tetramethyluronium hexafluorophosphate (HATU) (1.2 eq.), and 1-hydroxy-7-azabenzotriazole (HOAt) (0.6M in DMF) (1.0 eq.) were dissolved in DMF under argon atmosphere. The solution was cooled to 0° C. and amine was added. After stirring for 5 minutes at 0° C., Hünig's base (2-3 eq.) was added. The reaction mixture was stirred at 0° C. for 1 hour. After completion of the reaction (1 hour, monitored by LCMS), water (10 mL) was added to the reaction mixture and the mixture was stirred for 30 minutes. Product was isolated by either ethyl acetate extraction or by filtering the precipitate.
- HATU O-(7-azabenzotriazol-1-yl)-N,N,N,
- the substance was dissolved in methanol. Palladium on carbon (10%) was added carefully. Air in the flask was exchanged with hydrogen. The mixture was stirred at room temperature for 3-4 hours under hydrogen atmosphere using a hydrogen balloon. After completion of reaction, the mixture was filtered through Celite. Filtrate was evaporated and dried under vacuum to give the product.
- the primary amine (generally TFA salt) was dissolved in dichloromethane. The solution was cooled to 0° C. and triethylamine (2.0-3.0 eq.) was added. Sulfonyl chloride (1.5 eq.) was added to the solution in one portion and the reaction mixture was warmed to room temperature (over 15 minutes). After completion of reaction (2-3 hours), dichloromethane was evaporated and crude product was isolated by ethyl acetate extraction.
- TFA salt triethylamine
- the title compound was synthesized by following the general protocol for HATU mediated coupling of (S)-2-(tert-butoxycarbonylamino)propanoic acid and 3-fluorobenzene-1,2-diamine on a 2.0 mmol scale.
- the product 600 mg, quant. ESI-MS (m/z): 298.22 (M+H + )) was isolated and used directly in the next step.
- Example 106 Preparation of N-((S)-1-(((S)-1-(5-(2,4-Difluorophenyl)-1H-imidazol-2-yl)ethyl)amino)-4-((S)-2-methylpiperidin-1-yl)-1,4-dioxobutan-2-yl)-4-methylpentanamide (CEN-88)
- Example 111 Preparation of N-((S)-1-(((S)-1-(5-(2,4-Difluorophenyl)-1H-imidazol-2-yl)ethyl)amino)-4-((S)-2-methylpiperidin-1-yl)-1,4-dioxobutan-2-yl)-1-methyl-1H-imidazole-4-carboxamide (CEN-93)
- Example 129 Preparation of N-((S)-1-(((S)-1-(5-(2,4-Difluorophenyl)-1H-imidazol-2-yl)ethyl)amino)-1,4-dioxo-4-((R)-2-(trifluoromethyl)piperidin-1-yl)butan-2-yl)-4-methylpentanamide (CEN-111)
- Example 138 Preparation of N-((S)-1,4-Dioxo-1-(((S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl)amino)-4-((R)-2-phenylpyrrolidin-1-yl)butan-2-yl)-5-methylisoxazole-3-carboxamide (CEN-120)
- reaction buffer 20 mM HEPES, 0.5 mM EDTA, pH7.5, 0.1% BSA
- enzyme final concentration was 0.2 nM for c-20S, and 0.4 nM for i-20S
- substrate 25 ⁇ M for suc-LLVY-AMC for ⁇ 5c and 15 ⁇ M for Ac-ANW-AMC
- reaction buffer 20 mM HEPES, 0.5 mM EDTA, pH7.5, 0.1% BSA
- enzyme final concentration was 0.2 nM for c-20S, and 0.4 nM for i-20S
- substrate 25 ⁇ M for suc-LLVY-AMC for ⁇ 5c and 15 ⁇ M for Ac-ANW-AMC
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I′):where the substituents R, R1, R3, R4, R, W, X, Y, Z, k, and m are as defined herein andwhere the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.
Description
- This application claims the priority benefit of U.S. Provisional Patent Application Ser. No. 62/571,146, filed Oct. 11, 2017, which is hereby incorporated by reference in its entirety.
- The present invention relates to peptidomimetic proteasome inhibitors.
- Proteasomes are highly conserved self-compartmentalizing proteases found in three kingdoms of life. A proteasome is a large, ATP-dependent, multi-subunit, barrel-shaped N-terminal nucleophile hydrolase present in the cytosol and nucleus of eukaryotic cells and is responsible for the degradation of the majority of cellular proteins (Baumeister et al., “The Proteasome: Paradigm of a Self-Compartmentalizing Protease,” Cell 92(3):367-380 (1998); Goldberg A L., “Functions of the Proteasome:from Protein Degradation and Immune Surveillance to Cancer Therapy,” Biochem. Soc. Trans. 35(Pt 1):12-17 (2007)). Through regulated degradation, a proteasome regulates protein homeostasis, the cell cycle, signal transduction, protein trafficking, immune responses, etc, which are important cellular functions. Degradation product oligopeptides are reservoirs of antigenic peptides for MHC class I antigen presentation.
- The 20S core that is constitutively expressed in most cells (c-20S) is a stack of 4 rings of 14 α and β subunits organized in a α1-7β1-7β1-7α1-7 fashion, where 2 copies of each caspase-like β1, trypsin-like β2, and chymotrypsin-like β5 active subunits are located in the inner β rings (Baumeister, et al., “The Proteasome: Paradigm of a Self-Compartmentalizing Protease,” Cell 92:367-380 (1998)). The chymotrypsin-like β5 active subunits of the 20S have been clinically validated as a target for the treatment of multiple myeloma and certain lymphomas. Presently, there are three proteasome inhibitors that were approved by FDA: bortezomib, carfilzomib, and ixazomib: bortezomib and ixazomib are reversible peptide boronates and carfilzomib an irreversible peptide epoxyketone (Borissenko et al., “20S Proteasome and its Inhibitors: Crystallographic Knowledge for Drug Development,” Chem. Rev. 107:687-717 (2007); Parlati et al., Haematol-Hematol. J. 94:148-149 (2009); Huber et al., “Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development,” Angew. Chem. Int. Ed. Engl. 51(35):8708-8720 (2012)).
- Proteasome inhibition interrupts many cellular pathways, particularly, the NF-kB activation pathway, the induction of unfolded protein response, and ER stress, while strongly inducing apoptosis. For this reason, highly specific proteasome inhibitors have been approved for the treatment of hematological cancer. Proteasome inhibitors can also markedly limit the overall supply of peptides for MHC class I molecules and, thus, block antigen presentation (Rock et al., “Protein Degradation and the Generation of MHC Class I-Presented Peptides,” Adv. Immunol. 80:1-70 (2002)). As a result, proteasome inhibitors reduce immune response via multiple routes. Antibody-secreting plasma cells are highly sensitive to proteasome inhibition and BTZ, which inhibits both c-20S and i-20S, has been used in renal transplant recipients to prevent antibody-mediated graft rejection (Aull et al., Clin Transpl 495-498 (2009); Raghavan et al., “Bortezomib in Kidney Transplantation,” J. Transplant. 2010: 698594 (2010); Al-Homsi et al., “Effect of Novel Proteasome and Immunoproteasome Inhibitors on Dendritic Cell Maturation, Function, and Expression of Iκb and Nfκb,” Transpl. Immunol. 29:1-6 (2013); Pai et al., “Treatment of Chronic Graft-Versus-Host Disease with Bortezomib,” Blood 124:1677-1688 (2014)). BTZ was also reported to be efficacious in patients with refractory systemic lupus erythematosus (Alexander et al., “The Proteasome Inhibitor Bortezomib Depletes Plasma Cells and Ameliorates Clinical Manifestations of Refractory Systemic Lupus Erythematosus,” Ann. Rheum. Dis. 74:1474-1478 (2015).
- Plasmodium falciparum (P. falciparum), the most deadly of the human malarias, accounts for nearly 0.5 million deaths a year, primarily in children. The most important current therapies are combinations of artemisinins (ART). The emergence of ART resistant parasites (Ariey et al., “A Molecular Marker of Artemisinin-Resistant Plasmodium Falciparum Malaria,” Nature 505(7481):50-55 (2014); Straimer et al., “K13-Propeller Mutations Confer Artemisinin Resistance in Plasmodium Falciparum Clinical Isolates,” Science 347(6220):428-431 (2015); Dogovski et al., “Targeting the Cell Stress Response of Plasmodium Falciparum to Overcome Artemisinin Resistance,” PLoS Biol. 13(4):e1002132 (2015); Mbengue et al., “A Molecular Mechanism of Artemisinin Resistance in Plasmodium Falciparum Malaria,” Nature 520(7549):683-687 (2015)) highlights the need for new antimalarials with novel targets (Wells T N et al., “Malaria Medicines: a Glass Half Full?” Nat. Rev. Drug Discov. 14(6):424-442 (2015)). Upregulation of the ubiquitin proteasome system (UPS) is important for survival of artemisinin-resistant parasites and emphasizes the importance of the UPS in parasite survival and its importance as a drug target moving forward (Dogovski et al., “Targeting the Cell Stress Response of Plasmodium Falciparum to Overcome Artemisinin Resistance,” PLoS Biol. 13(4):e1002132 (2015); Mok et al., “Drug Resistance. Population Transcriptomics of Human Malaria Parasites Reveals the Mechanism of Artemisinin Resistance,” Science 347(6220):431-435(2015)).
- Proteasome inhibitors are known to kill malaria parasites in vitro and are efficacious against multiple parasite stages; peptide epoxyketone inhibitors, a peptide vinyl sulfone inhibitor, and a cyclic peptide inhibitor, have potent anti-malarial activities (Dogovski et al., “Targeting the Cell Stress Response of Plasmodium Falciparum to Overcome Artemisinin Resistance,” PLoS Biol. 13(4):e1002132 (2015); Featherstone C. “Proteasome Inhibitors in Development for Malaria,” Mol. Med. Today 3(9):367 (1997); Gantt et al., “Proteasome Inhibitors Block Development of Plasmodium Spp,” Antimicrob. Agents Chemother. 42(10):2731-2738 (1948); Aminake et al., “The Proteasome of Malaria Parasites: A Multi-Stage Drug Target for Chemotherapeutic Intervention?” Int. J. Parasitol. Drugs Drug Resist. 2:1-10 (2012); Li et al., “Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor with Parasite-Specific Toxicity,” Chem. Biol. 19(12):1535-1545 (2012); Tschan et al., “Broad-Spectrum Antimalarial Activity of Peptido Sulfonyl Fluorides, a New Class of Proteasome Inhibitors,” Antimicrob. Agents Chemother. 57(8):3576-8354 (2013); Li et al., “Assessing Subunit Dependency of the Plasmodium Proteasome Using Small Molecule Inhibitors and Active Site Probes,” ACS Chem. Biol. 9(8):1869-1876 (2014); Li et al., “Structure- and Function-Based Design of Plasmodium-Selective Proteasome Inhibitors,” Nature 530(7589):233-236 (2016)). Bortezomib (BTZ) and MLN-273 were effective against plasmodium in blood and liver stages (Lindenthal et al., “The Proteasome Inhibitor MLN-273 Blocks Exoerythrocytic and Erythrocytic Development of Plasmodium Parasites,” Parasitology 131(Pt 1):37-44 (2005); Reynolds et al., “Antimalarial Activity of the Anticancer and Proteasome Inhibitor Bortezomib and its Analog ZL3B,” BMC. Clin. Pharmacol. 7:13 (2007)); MG-132 against blood stage and gametocytes (Lindenthal et al., “The Proteasome Inhibitor MLN-273 Blocks Exoerythrocytic and Erythrocytic Development of Plasmodium Parasites,” Parasitology 131(Pt 1):37-44 (2005); Prudhomme et al., “Marine Actinomycetes: a New Source of Compounds Against the Human Malaria Parasite,” PLoS One 3(6):e2335 (2008)); epoxomicin against blood and liver stages and gametocytes (Aminake et al., “Thiostrepton and Derivatives Exhibit Antimalarial And Gametocytocidal Activity by Dually Targeting Parasite Proteasome and Apicoplast,” Antimicrob. Agents Chemother. 55(4):1338-1348 (2011); Czesny et al., “The Proteasome Inhibitor Epoxomicin Has Potent Plasmodium Falciparum Gametocytocidal Activity,” Antimicrob. Agents Chemother. 53(10):4080-4085 (2009); Kreidenweiss et al., “Comprehensive Study of Proteasome Inhibitors Against Plasmodium Falciparum Laboratory Strains and Field Isolates From Gabon,” Malar. J. 7:187 (2008); Li et al., “Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor With Parasite-Specific Toxicity,” Chem. Biol. 19(12):1535-1545 (2012)). These inhibitors are in general not species selective. They are cytotoxic to host cells and unsuitable for treating malaria. There is an urgent need to develop Plasmodium spp. proteasome (Pf20S) selective inhibitors that target parasite proteasomes over human host proteasomes.
- Species selective proteasome inhibitors have been reported (Hu et al., “Structure of the Mycobacterium Tuberculosis Proteasome and Mechanism of Inhibition by a Peptidyl Boronate,” Mol. Microbiol. 59:1417-1428 (2006); Li et al., “Structural Basis for the Assembly and Gate Closure Mechanisms of the Mycobacterium Tuberculosis 20S Proteasome,” Embo. J. 29:2037-2047 (2010); Lin et al., “N,C-Capped Dipeptides With Selectivity for Mycobacterial Proteasome Over Human Proteasomes: Role of S3 and S1 Binding Pockets,” J. Am. Chem. Soc. 135:9968-9971 (2013); Lin et al., “Mycobacterium Tuberculosis prcBA Genes Encode a Gated Proteasome With Broad Oligopeptide Specificity,” Mol. Microbiol. 59:1405-1416 (2006); Lin et al., “Fellutamide B is a Potent Inhibitor of the Mycobacterium Tuberculosis Proteasome,” Arch. Biochem. Biophys. 501:214-220 (2010); Lin et al., “Inhibitors Selective for Mycobacterial Versus Human Proteasomes,” Nature 461(7264):621-626 (2009); Lin et al., “Distinct Specificities of Mycobacterium Tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates,” J. Biol. Chem. 283:34423-31 (2008)).
- As shown by the above references, the proteasome represents an important target for therapeutic intervention of various disorders. Thus, there is an ongoing need for new and/or improved proteasome inhibitors.
- The present invention is directed to overcoming these and other deficiencies in the art.
- A first aspect of the present invention relates to a compound of Formula (I):
- wherein
- R is H or C1-6 alkyl;
- R′ is H or C1-6 alkyl;
-
- R1 is H or C1-6 alkyl;
- or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
- R2 is independently selected at each occurrence thereof from
- or —(CH2)nC(O)NR6R7;
- R3 is independently selected at each occurrence thereof from the group consisting of H, C1-12 alkyl, -Boc, —C(O)(CH2)nR5, —(CH2)nC(O)R5, —C(O)OR5, —C(O)(CH2)nNR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R4 is H, halogen, NH2, NHCOOC1-12 alkyl, or C1-12 alkyl;
- R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
- or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
- R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
- R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R10 is H or arylalkyl;
- W is CHR2, NR2, or
- X is selected from the group consisting of —C(O)—NH—, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH2)m—;
- Z is optional and, if present, is aryl or bicyclic heteroaryl;
- is the point of attachment to NHR3 moiety;
- is the point of attachment to C(O) moiety;
- k is 1 or 2;
- m is 0, 1, or 2; and
- n is 0, 1, 2, 3, or 4, with the proviso that R2 is not —CH2C(O)NH2, —CH2C(O)NHCH2C(CH3)3, or —(CH2)2C(O)NH2, or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof.
- A second aspect of the present invention relates to a method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject. This method includes administering to the subject in need thereof a compound according to any aspect of the present invention.
- A third aspect of the present invention relates to a method of inhibiting proteasome activity. This method includes contacting a proteasome with a compound according to any aspect of the present invention under conditions effective to inhibit proteasome activity.
- A first aspect of the present invention relates to a compound of Formula (I):
- wherein
- R is H or C1-6 alkyl;
- R′ is H or C1-6 alkyl;
- R1 is H or C1-6 alkyl;
- or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
- R2 is independently selected at each occurrence thereof from
- or —(CH2)nC(O)NR6R7;
- R3 is independently selected at each occurrence thereof from the group consisting of H, C1-12 alkyl, -Boc, —C(O)(CH2)nR5, —(CH2)nC(O)R5, —C(O)OR5, —C(O)(CH2)nNR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R4 is H, halogen, NH2, NHCOOC1-12 alkyl, or C1-12 alkyl;
- R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
- or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
- R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
- R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R10 is H or arylalkyl;
- W is CHR2, NR2, or
- X is selected from the group consisting of —C(O)—NH—, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH2)m—;
- Z is optional and, if present, is aryl or bicyclic heteroaryl;
- is the point of attachment to NHR3 moiety;
- is the point of attachment to C(O) moiety;
- k is 1 or 2;
- m is 0, 1, or 2; and
- n is 0, 1, 2, 3, or 4, with the proviso that R2 is not —CH2C(O)NH2, —CH2C(O)NHCH2C(CH3)3, or —(CH2)2C(O)NH2, or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof.
- As used above, and throughout the description herein, the following terms, unless otherwise indicated, shall be understood to have the following meanings. If not defined otherwise herein, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this technology belongs. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.
- The term “alkyl” means an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 12 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, and 3-pentyl.
- The term “cycloalkyl” means a non-aromatic mono- or multicyclic ring system of about 3 to about 12 carbon atoms, preferably of about 3 to about 8 carbon atoms. Exemplary monocyclic cycloalkyls include cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[1.1.1]pentyl, and the like.
- The term “cycloalkylalkyl” means a cycloalkyl-alkyl-group in which the cycloalkyl and alkyl are as defined herein. Exemplary cycloalkylalkyl groups include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopropylethyl, cyclobutylethyl, and cyclopentylethyl. The alkyl radical and the cycloalkyl radical may be optionally substituted as defined herein.
- The term “aryl” means an aromatic monocyclic or multicyclic ring system of 6 to about 14 carbon atoms, preferably of 6 to about 10 carbon atoms. Representative aryl groups include phenyl and naphthyl.
- The term “arylalkyl” means an alkyl substituted with one or more aryl groups, wherein the alkyl and aryl groups are as herein described. One particular example is an arylmethyl or arylethyl group, in which a single or a double carbon spacer unit is attached to an aryl group, where the carbon spacer and the aryl group can be optionally substituted as described herein. Representative arylalkyl groups include
- The term “heteroaryl” means an aromatic monocyclic or multicyclic ring system of about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is/are element(s) other than carbon, for example, nitrogen, oxygen, or sulfur. In the case of multicyclic ring system, only one of the rings needs to be aromatic for the ring system to be defined as “Heteroaryl”. Preferred heteroaryls contain about 5 to 6 ring atoms. The prefix aza, oxa, thia, or thio before heteroaryl means that at least a nitrogen, oxygen, or sulfur atom, respectively, is present as a ring atom. A nitrogen atom of a heteroaryl is optionally oxidized to the corresponding N-oxide. Representative heteroaryls include pyridyl, 2-oxo-pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, furanyl, pyrrolyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indolinyl, 2-oxoindolinyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, indazolyl, benzimidazolyl, benzooxazolyl, benzothiazolyl, benzoisoxazolyl, benzoisothiazolyl, benzotriazolyl, benzo[1,3]dioxolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, pthalazinyl, quinoxalinyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 4H-chromenyl, indolizinyl, quinolizinyl, 6aH-thieno[2,3-d]imidazolyl, 1H-pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, thieno[2,3-b]furanyl, thieno[2,3 -b]pyridinyl, thieno[3,2-b]pyridinyl, furo[2,3 -b]pyridinyl, furo[3,2-b]pyridinyl, thieno[3,2-d]pyrimidinyl, furo[3,2-d]pyrimidinyl, thieno[2,3-b]pyrazinyl, imidazo[1,2-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl, 2-oxo-2,3-dihydrobenzo[d]oxazolyl, 3,3-dimethyl-2-oxoindolinyl, 2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, benzo[c][1,2,5]oxadiazolyl, benzo[c][1,2,5]thiadiazolyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, [1,2,4]triazolo[4,3-a]pyrazinyl, 3-oxo-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl, and the like.
- As used herein, “heterocyclyl” refers to a stable 3- to 18-membered ring (radical) which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. For purposes of this application, the heterocycle may be a monocyclic, or a polycyclic ring system, which may include fused, bridged, or spiro ring systems; and the nitrogen, carbon, or sulfur atoms in the heterocycle may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the ring may be partially or fully saturated. Examples of such heterocycles include, without limitation, azepinyl, azocanyl, pyranyl dioxanyl, dithianyl, 1,3-dioxolanyl, tetrahydrofuryl, dihydropyrrolidinyl, decahydroisoquinolyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, oxazolidinyl, oxiranyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl sulfoxide, and thiamorpholinyl sulfone. Further heterocycles and heteroaryls are described in Katritzky et al., eds., Comprehensive Heterocyclic Chemistry: The Structure, Reactions, Synthesis and Use of Heterocyclic Compounds, Vol. 1-8, Pergamon Press, N.Y. (1984), which is hereby incorporated by reference in its entirety.
- The term “non-aromatic heterocycle” means a non-aromatic monocyclic or multicyclic system containing 3 to 10 atoms, preferably 4 to about 7 carbon atoms, in which one or more of the atoms in the ring system is/are element(s) other than carbon, for example, nitrogen, oxygen, or sulfur. Representative non-aromatic heterocycle groups include pyrrolidinyl, 2-oxopyrrolidinyl, piperidinyl, 2-oxopiperidinyl, azepanyl, 2-oxoazepanyl, 2-oxooxazolidinyl, morpholino, 3-oxomorpholino, thiomorpholino, 1,1-dioxothiomorpholino, piperazinyl, tetrohydro-2H-oxazinyl, and the like.
- The term “monocyclic” used herein indicates a molecular structure having one ring.
- The term “polycyclic” or “multi-cyclic” used herein indicates a molecular structure having two or more rings, including, but not limited to, fused, bridged, or spiro rings.
- Terminology related to “protecting”, “deprotecting,” and “protected” functionalities occurs throughout this application. Such terminology is well understood by persons of skill in the art and is used in the context of processes which involve sequential treatment with a series of reagents. In that context, a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable. The protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or “deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere. Thus, when a sequence of reagents is specified, as it is in the processes described herein, the person of ordinary skill can readily envision those groups that would be suitable as “protecting groups.” Suitable groups for that purpose are discussed in standard textbooks in the field of chemistry, such as Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York (1991), which is hereby incorporated by reference in its entirety.
- The term “alkoxy” means groups of from 1 to 12 carbon atoms of a straight, branched, or cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like. Lower-alkoxy refers to groups containing one to four carbons. For the purposes of the present patent application, alkoxy also includes methylenedioxy and ethylenedioxy in which each oxygen atom is bonded to the atom, chain, or ring from which the methylenedioxy or ethylenedioxy group is pendant so as to form a ring. Thus, for example, phenyl substituted by alkoxy may be, for example,
- A compound with a hydroxy group drawn next to a nitrogen on a heterocycle can exist as the “keto” form. For example, 3-(2-hydroxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)propanoic acid can exist as 3-(2-oxo-2,3-dihydro-[1,2,4]triazolo[1,5-a]pyridin-6-yl)propanoic acid.
- The term “halogen” means fluoro, chloro, bromo, or iodo.
- The term “substituted” or “substitution” of an atom means that one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded.
- “Unsubstituted” atoms bear all of the hydrogen atoms dictated by their valency. When a substituent is keto (i.e., ═O), then two hydrogens on the atom are replaced. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds; by “stable compound” or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
- The term “optionally substituted” is used to indicate that a group may have a substituent at each substitutable atom of the group (including more than one substituent on a single atom), provided that the designated atom's normal valency is not exceeded and the identity of each substituent is independent of the others. Up to three H atoms in each residue are replaced with alkyl, halogen, haloalkyl, hydroxy, loweralkoxy, carboxy, carboalkoxy (also referred to as alkoxycarbonyl), carboxamido (also referred to as alkylaminocarbonyl), cyano, carbonyl, nitro, amino, alkylamino, dialkylamino, mercapto, alkylthio, sulfoxide, sulfone, acylamino, amidino, phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, or heteroaryloxy.
- The term “method of treating” means amelioration or relief from the symptoms and/or effects associated with the disorders described herein. As used herein, reference to “treatment” of a patient is intended to include prophylaxis.
- The term “compounds of the invention”, and equivalent expressions, are meant to embrace compounds of general Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (I′), Formula (I′A), Formula (I′B), Formula (I′C), Formula (I′D), Formula (I′E), Formula (I′F), Formula (I′G), Formula (I′C′), Formula (I′D′), Formula (I′E′), Formula (I′F′), Formula (I′G′), and Formula (II) as hereinbefore described, which expression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.
- The term “pharmaceutically acceptable salts” means the relatively non-toxic, inorganic, and organic acid addition salts, and base addition salts, of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds. In particular, acid addition salts can be prepared by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Exemplary acid addition salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, sulphamates, malonates, salicylates, propionates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methane-sulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinateslaurylsulphonate salts, and the like (see, for example, Berge et al., “Pharmaceutical Salts,” J. Pharm. Sci., 66:1-9 (1977) and Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, which are hereby incorporated by reference in their entirety). Base addition salts can also be prepared by separately reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt thus formed. Base addition salts include pharmaceutically acceptable metal and amine salts. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminum salts. The sodium and potassium salts are preferred. Suitable inorganic base addition salts are prepared from metal bases which include, for example, sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, and zinc hydroxide. Suitable amine base addition salts are prepared from amines which have sufficient basicity to form a stable salt, and preferably include those amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use, such as ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylarnine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e.g., lysine and arginine, dicyclohexylamine, and the like.
- The term “pharmaceutically acceptable prodrugs” as used herein means those prodrugs of the compounds useful according to the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term “prodrug” means compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. Functional groups which may be rapidly transformed, by metabolic cleavage, in vivo form a class of groups reactive with the carboxyl group of the compounds of this invention. They include, but are not limited to, such groups as alkanoyl (such as acetyl, propionyl, butyryl, and the like), unsubstituted and substituted aroyl (such as benzoyl and substituted benzoyl), alkoxycarbonyl (such as ethoxycarbonyl), trialkylsilyl (such as trimethyl- and triethysilyl), monoesters formed with dicarboxylic acids (such as succinyl), and the like. Because of the ease with which the metabolically cleavable groups of the compounds useful according to this invention are cleaved in vivo, the compounds bearing such groups act as pro-drugs. The compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group. A thorough discussion of prodrugs is provided in the following: Design of Prodrugs, H. Bundgaard, ed., Elsevier (1985); Methods in Enzymology, K. Widder et al, Ed., Academic Press, 42, p. 309-396 (1985); A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard, ed., Chapter 5; “Design and Applications of Prodrugs” p. 113-191 (1991); Advanced Drug Delivery Reviews, H. Bundgard, 8, p. 1-38 (1992); J. Pharm. Sci., 77:285 (1988); Nakeya et al, Chem. Pharm. Bull., 32:692 (1984); Higuchi et al., “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and Bioreversible Carriers in Drug Design, Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press (1987), which are incorporated herein by reference in their entirety. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohol and amine functional groups in the compounds of the invention.
- The term “solvate” refers to a compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (I′), Formula (I′A), Formula (PB), Formula (I′C), Formula (I′D), Formula (I′E), Formula (I′F), Formula (I′G), Formula (I′C′), Formula (I′D′), Formula (I′E′), Formula (I′F′), Formula (I′G′), and Formula (II) in the solid state, wherein molecules of a suitable solvent are incorporated in the crystal lattice. A suitable solvent for therapeutic administration is physiologically tolerable at the dosage administered. Examples of suitable solvents for therapeutic administration are ethanol and water. When water is the solvent, the solvate is referred to as a hydrate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions.
- The term “therapeutically effective amounts” is meant to describe an amount of compound of the present invention effective to produce the desired therapeutic effect. Such amounts generally vary according to a number of factors well within the purview of ordinarily skilled artisans given the description provided herein to determine and account for. These include, without limitation: the particular subject, as well as its age, weight, height, general physical condition, and medical history; the particular compound used, as well as the carrier in which it is formulated and the route of administration selected for it; and, the nature and severity of the condition being treated.
- The term “pharmaceutical composition” means a composition comprising a compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (I′), Formula (I′A), Formula (I′B), Formula (I′C), Formula (I′D), Formula (I′E), Formula (I′F), Formula (I′G), Formula (I′C′), Formula (I′D′), Formula (I′E′), Formula (I′F′), Formula (I′G′), and Formula (II) and at least one component comprising pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifingal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms. Examples of suspending agents include ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monosterate and gelatin. Examples of suitable carriers, diluents, solvents, or vehicles include water, ethanol, polyols, suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Examples of excipients include lactose, milk sugar, sodium citrate, calcium carbonate, and dicalcium phosphate. Examples of disintegrating agents include starch, alginic acids, and certain complex silicates. Examples of lubricants include magnesium stearate, sodium lauryl sulphate, talc, as well as high molecular weight polyethylene glycols.
- The term “pharmaceutically acceptable” means it is, within the scope of sound medical judgement, suitable for use in contact with the cells of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- The term “pharmaceutically acceptable dosage forms” means dosage forms of the compound of the invention, and includes, for example, tablets, dragees, powders, elixirs, syrups, liquid preparations, including suspensions, sprays, inhalants tablets, lozenges, emulsions, solutions, granules, capsules, and suppositories, as well as liquid preparations for injections, including liposome preparations. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., latest edition.
- Compounds described herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. Each chiral center may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. This technology is meant to include all such possible isomers, as well as mixtures thereof, including racemic and optically pure forms. Optically active (R)- and (S)-, (−)- and (+)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
- This technology also envisions the “quaternization” of any basic nitrogen-containing groups of the compounds disclosed herein. The basic nitrogen can be quaternized with any agents known to those of ordinary skill in the art including, for example, lower alkyl halides, such as methyl, ethyl, propyl and butyl chloride, bromides and iodides; dialkyl sulfates including dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides including benzyl and phenethyl bromides. Water or oil-soluble or dispersible products may be obtained by such quaternization.
- In the characterization of some of the substituents, it is recited that certain substituents may combine to form rings. Unless stated otherwise, it is intended that such rings may exhibit various degrees of unsaturation (from fully saturated to fully unsaturated), may include heteroatoms and may be substituted with lower alkyl or alkoxy.
- Compounds of the present invention can be produced according to the general schemes outlined below (Scheme 1, Scheme 1 a, Scheme 2, and Scheme 2 a).
- Reaction of the carboxylic acid derivative (1) with amine (2) leads to formation of the final product (3). The reaction can be carried out in a variety of solvents, for example in methylene chloride (CH2Cl2), tetrahydrofuran (THF), dimethylformamide (DMF), or other such solvents or in the mixture of such solvents.
- Compounds of Formula (I) wherein W is CHR2, k is 1, Xis bicyclic heteroaryl, and Y and Z are absent can be prepared according to Scheme 1 a. Reaction of the carboxylic acid derivative (1 a) with amine (2 a) leads to formation of the final product (3 a). The reaction can be carried out in a variety of solvents, for example in methylene chloride (CH2Cl2), tetrahydrofuran (THF), dimethylformamide (DMF), or other such solvents or in the mixture of such solvents.
- Reaction of the carboxylic acid derivative (4) with amine (2) leads to formation of the compound (5). The reaction can be carried out in a variety of solvents, for example in methylene chloride (CH2Cl2), tetrahydrofuran (THF), dimethylformamide (DMF), or other such solvents or in the mixture of such solvents. During the reaction process, the non-participating carboxylic acids or amines on the reacting set of amino acids or peptide fragments can be protected by a suitable protecting group (PG) which can be selectively removed at a later time if desired. A detailed description of these groups and their selection and chemistry is contained in “The Peptides, Vol. 3”, Gross and Meinenhofer, Eds., Academic Press, New York, 1981, which is hereby incorporated by reference in its entirety. Thus, useful protective groups for the amino group are benzyloxycarbonyl (Cbz), t-butyloxycarbonyl (t-BOC), 2,2,2-trichloroethoxycarbonyl (Troc), t-amyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-(trichlorosilyl)ethoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc), phthaloyl, acetyl (Ac), formyl, trifluoroacetyl, and the like. Following the deprotection, amine (6) is reacted with R3-LG (7) (wherein LG is a suitable leaving group) to form final product (8).
- Compounds of Formula (I) wherein W is CHR2, k is 1, X is bicyclic heteroaryl, and Y and Z are absent can be prepared according to Scheme 2 a. Reaction of the carboxylic acid derivative (4 a) with amine (2 a) leads to formation of the compound (5 a). The reaction can be carried out in a variety of solvents, for example in methylene chloride (CH2Cl2), tetrahydrofuran (THF), dimethylformamide (DMF), or other such solvents or in the mixture of such solvents. During the reaction process, the non-participating carboxylic acids or amines on the reacting set of amino acids or peptide fragments can be protected by a suitable protecting group which can be selectively removed at a later time if desired. A detailed description of these groups and their selection and chemistry is contained in “The Peptides, Vol. 3”, Gross and Meinenhofer, Eds., Academic Press, New York, 1981, which is hereby incorporated by reference in its entirety. Thus, useful protective groups for the amino group are benzyloxycarbonyl (Cbz), t-butyloxycarbonyl (t-BOC), 2,2,2-trichloroethoxycarbonyl (Troc), t-amyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-(trichlorosilyl)ethoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc), phthaloyl, acetyl (Ac), formyl, trifluoroacetyl, and the like. Following the deprotection, amine (6 a) is reacted with R3-LG (7) (wherein LG is a suitable leaving group) to form final product (8 a).
- Compounds of the present invention can also be prepared according to the general schemes outlined below (Scheme 3 and Scheme 4).
- Compounds of Formula (I) wherein W is CHR2, k is 1, X is monocyclic heteroaryl, Y is —(CH2)m—, and Z is aryl can be prepared according to Scheme 3. Reaction of the carboxylic acid derivative (1 a) with amine (2 b) leads to formation of the final product (3 b). The reaction can be carried out in a variety of solvents, for example in methylene chloride (CH2Cl2), tetrahydrofuran (THF), dimethylformamide (DMF), or other such solvents or in the mixture of such solvents.
- Compounds of Formula (I) wherein W is CHR2, k is 1, X is monocyclic heteroaryl, Y is —(CH2)m—, and Z is aryl can also be prepared according to Scheme 4. Reaction of the carboxylic acid derivative (4 a) with amine (2 c) leads to formation of the compound (5 b). The reaction can be carried out in a variety of solvents, for example in methylene chloride (CH2Cl2), tetrahydrofuran (THF), dimethylformamide (DMF), or other such solvents or in the mixture of such solvents. During the reaction process, the non-participating carboxylic acids or amines on the reacting set of amino acids or peptide fragments can be protected by a suitable protecting group which can be selectively removed at a later time if desired. A detailed description of these groups and their selection and chemistry is contained in “The Peptides, Vol. 3”, Gross and. Meinenhofer, Eds., Academic Press, New York, 1981, which is hereby incorporated by reference in its entirety. Thus, useful protective groups for the amino group are benzyloxycarbonyl (Cbz), t-butyloxycarbonyl (t-BOC), 2,2,2-trichloroethoxycarbonyl (Troc), t-amyloxycarbonyl, 4-methoxybenzyloxycarbonyi, 2-(trichlorosilyl)ethoxycarbonyl, 9-fluorenyhnethoxycarbonyl (Frnoc), phthaloyl, acetyl (Ac), formyl, trifluoroacetyl, and the like. Following the deprotection, amine (6 b) is reacted with R3-LG (7) (wherein is a suitable leaving group) to form final product (8 b).
- In one embodiment, compound has the Formula (IA):
- In another embodiment, compound has the Formula (IB):
- In another embodiment, compound has the Formula (IC):
- One embodiment relates to the compound of Formulae (I) where R1 is H or Me.
- Another embodiment relates to the compound of Formulae (I) where R and R1 are taken together with the carbon to which they are attached to form
- group, and wherein
- is the point of attachment to NH; and
- is the point of attachment to X.
- Another embodiment relates to the compound of Formulae (I) where R and R1 are taken together with the carbon to which they are attached to form
- group, and wherein
- is the point of attachment to NH; and
- is the point of attachment to X.
- A further embodiment relates to the compound of Formulae (I) where R2 is selected from the group consisting of
- wherein
- is the point of attachment to the corresponding carbon atom of the structure of Formula (I).
- Yet another embodiment relates to the compound of Formulae (I) where R3 is selected from the group consisting of H, Boc,
- wherein
- is the point of attachment to the corresponding carbon atom of the structure of Formula (I).
- Another embodiment relates to the compound of Formulae (I) where R4 is H, Me, F, NH2, or NHBoc.
- Yet another embodiment relates to the compound of Formulae (I) where X is selected from the group consisting of
- wherein
- is the point of attachment to C(R1)(R2) moiety;
- is the point of attachment to Y, Z, or R4.
- Yet another embodiment relates to the compound of Formulae (I) where Y is —CH2—.
- A further embodiment relates to the compound of Formulae (I) where Z is
- and
wherein - is the point of attachment to Y or X;
- is the point of attachment to R4.
- Another embodiment relates to the compound of Formulae (I) where the compound has a structure selected from the group consisting of:
- In one embodiment, compound has the Formula (I′):
- wherein
- R is H or C1-6 alkyl;
- R1 is H or C1-6 alkyl;
- or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
- R2 is independently selected at each occurrence thereof from the group consisting of C1-6 alkyl, and —(CH2)nC(O)NR6R7, wherein C1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR10;
- R3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH2)nR5, —(CH2)nC(O)R5, —C(O)OR5, —C(O)(CH2)nNR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C1-6 alkyl;
- R4 is H, C1-12 alkyl, or halogen;
- R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
- or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
- R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
- R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R10 is H or arylalkyl;
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH2)m—;
- Z is optional and, if present, is aryl;
- m is 0, 1, or 2; and
- n is 0, 1, 2, 3, or 4;
- or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof.
- In another embodiment, compound has the Formula (I′A):
- wherein
- A is NH, N, O, or S.
- In another embodiment, compound has the Formula (PB):
- wherein
-
- A is NH, N, O, or S; and
- B is NH, N, O, or S.
- In yet another embodiment, compound has the Formula (I′C):
- In yet another embodiment, compound has the Formula (I′D):
- In another embodiment, compound has the Formula (I′E):
- In yet another embodiment, compound has the Formula (I′F):
- In a further embodiment, compound has the Formula (I′G):
- In another embodiment, compound has the Formula (I′C′):
- In yet another embodiment, compound has the Formula (I′D′):
- In a further embodiment, compound has the Formula (I′E′):
- In another embodiment, compound has the Formula (I′F′):
- In yet another embodiment, compound has the Formula (I′G′):
- One embodiment relates to the compound of Formulae (I′) where R1 is H or Me.
- Another embodiment relates to the compound of Formulae (I′) where R and R1 are taken together with the carbon to which they are attached to form
- group, and wherein
- is the point of attachment to NH; and
- is the point of attachment to X.
- Another embodiment relates to the compound of Formulae (I′) where R2 is selected from the group consisting of
- wherein
- is the point of attachment to the corresponding carbon atom of the structure of Formula (I).
- Yet another embodiment relates to the compound of Formulae (I′) where R3 is selected from the group consisting of H, Boc,
- wherein
- is the point of attachment to the corresponding carbon atom of the structure of Formula (I).
- Another embodiment relates to the compound of Formulae (I′) where R4 is H, Me, or F.
- Yet another embodiment relates to the compound of Formulae (I′) where X is selected from the group consisting of
- wherein
- is the point of attachment to C(R1)(R2) moiety;
- is the point of attachment to Y, Z, or R4.
- Yet another embodiment relates to the compound of Formulae (I′) where Y is —CH2—.
- Another embodiment relates to the compound of Formulae (I′) where n Z is
- and
wherein - is the point of attachment to Y or X;
- is the point of attachment to R4.
- A further embodiment relates to the compound of Formulae (I′) where the compound has a structure selected from the group consisting of:
- In another embodiment, compound has the Formula:
- or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof
- In yet another embodiment, compound has the Formula (II):
- wherein
- R is H or C1-6 alkyl;
- R1 is H or C1-6 alkyl;
- or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
- R2 is independently selected at each occurrence thereof from the group consisting of C1-6 alkyl, and —(CH2)nC(O)NR6R7, wherein C1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR10;
- R3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH2)nR5, —(CH2)nC(O)R5, —C(O)OR5, —C(O)(CH2)nNR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C1-6 alkyl;
- R4 is H, C1-12 alkyl, or halogen;
- R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
- or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
- R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
- R9is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R10 is H or arylalkyl;
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH2)m—;
- Z is optional and, if present, is aryl;
- W is N or CH;
- m is 0, 1, or 2; and
- n is 0, 1, 2, 3, or 4;
- or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof.
- Another aspect of the present invention relates to a method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject. This method includes administering to the subject in need thereof a compound of Formula (I):
- wherein
- R is H or C1-6 alkyl;
- R′ is H or C1-6 alkyl;
- R1 is H or C1-6 alkyl;
- or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
- R2 is independently selected at each occurrence thereof from
- or —(CH2)nC(O)NR6R7;
- R3 is independently selected at each occurrence thereof from the group consisting of H, C1-12 alkyl, -Boc, —C(O)(CH2)nR5, —(CH2)nC(O)R5, —C(O)OR5, —C(O)(CH2)nNR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R4 is H, halogen, NH2, NHCOOC1-12 alkyl, or C1-12 alkyl;
- R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
- or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
- R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
- R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R10 is H or arylalkyl;
- W is CHR2, NR2, or
- X is selected from the group consisting of —C(O)—NH—, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH2)m—;
- Z is optional and, if present, is aryl or bicyclic heteroaryl;
- is the point of attachment to NHR3 moiety;
- is the point of attachment to C(O) moiety;
- k is 1 or 2;
- m is 0, 1, or 2; and
- n is 0, 1, 2, 3, or 4,
-
- with the proviso that R2 is not —CH2C(O)NH2, —CH2C(O)NHCH2C(CH3)3, or —(CH2)2C(O)NH2,
or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof.
- with the proviso that R2 is not —CH2C(O)NH2, —CH2C(O)NHCH2C(CH3)3, or —(CH2)2C(O)NH2,
- One embodiment of the present invention relates to a method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject. This method includes administering to the subject in need thereof a compound of Formula (I′):
- wherein
- R is H or C1-6 alkyl;
- R1 is H or C1-6 alkyl;
- or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
- R2 is independently selected at each occurrence thereof from the group consisting of C1-6 alkyl, and —(CH2)nC(O)NR6R7, wherein C1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR10;
- R3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH2)nR5, —(CH2)nC(O)R5, —C(O)OR5, —C(O)(CH2)—NR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C1-6 alkyl;
- R4 is H, C1-12 alkyl, or halogen;
- R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
- or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
- R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
- R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R10 is H or arylalkyl;
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH2)m—;
- Z is optional and, if present, is aryl;
- m is 0, 1, or 2; and
- n is 0, 1, 2, 3, or 4;
- or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof.
- Another aspect of the present invention relates to a method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject. This method includes administering to the subject in need thereof a compound of Formula:
- Another aspect of the present invention relates to a method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject. This method includes administering to the subject in need thereof a compound of Formula (II):
- wherein
- R is H or C1-6 alkyl;
- R1 is H or C1-6 alkyl;
- or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
- R2 is independently selected at each occurrence thereof from the group consisting of C1-6 alkyl, and —(CH2)nC(O)NR6R7, wherein C1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR10;
- R3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH2)nR5, —(CH2)nC(O)R5, —C(O)OR5, —C(O)(CH2)nNR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C1-6 alkyl;
- R4 is H, C1-12 alkyl, or halogen;
- R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
- or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
- R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
- R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen; R10 is H or arylalkyl;
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH2)m—;
- Z is optional and, if present, is aryl;
- W is N or CH;
- m is 0, 1, or 2; and
- n is 0, 1, 2, 3, or 4;
- or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof.
- In one embodiment, bacterial infection is treated. The bacterial infection is
- Mycobacterium tuberculosis.
- In another embodiment, parasite infection is treated. The parasite infection is selected from, but not limited to, the group consisting of malaria, leishmaniasis, river blindness, Chagas disease, sleeping disease, cryptosporidiosis, amebiasis, cyclosporiasis, giardiasis, and toxoplasmosis.
- In yet another embodiment, parasite infection is veterinary parasite infection. The veterinary parasite infection is caused by protozoan parasites, helminth parasites, arachnids, insects, or custaceans. Exemplary protozoan parasites include, but are not limited to, Babesia divergens, Balantidium coli, Eimeria tenella, Giardia lamblia (Giardia duodenalis), Hammondia hammondi, Histomonas meleagridis, Isospora canis, Leishmania donovani, Leishmania infantum, Neospora caninum, Toxoplasma gondii, Trichomonas gallinae, Tritrichomonas foetus, Trypanosoma brucei, and Trypanosoma equiperdum. Exemplary helminth parasites include, but are not limited to, Ancylostoma duodenale, Ascaris suum, Dicrocoelium dendriticum, Dictyocaulus viviparus, Dipylidium caninum, Echinococcus granulosus, Fasciola hepatica, Fascioloides magna, Habronema species, Haemonchus contortus, Metastrongylus, Muellerius capillaris, Ostertagia ostertagi, Paragonimus westermani, Schistosoma bovis, Strongyloides species, Strongylus vulgaris, Syngamus trachea (Gapeworm), Taenia pisiformis, Taenia saginata, Taenia solium, Toxocara canis, Trichinella spiralis, Trichobilharzia regenti, Trichostrongylus species, and Trichuris suis. Exemplary arachnids, insects, and custaceans include, but are not limited to, Caligus species, Cimex colombarius, Cimex lectularius, Culex pipiens, Culicoides imicola, Demodex bovis, Dermacentor reticulatus, Gasterophilus intestinalis, Haematobia irritans, Hypoderma bovis, Ixodes ricinus, Knemidocoptes mutans, Lepeophtheirus salmonis, Lucilia sericata, Musca domestica, Nosema apis, Notoedres cati, Oestrus ovis, Otodectes cynotis, Phlebotomus species, Psoroptes ovis, Pulex irritans, Rhipicephalus sanguineus, Sarcoptes equi, Sarcophaga carnaria, Tabanus atratus, Triatoma species, Ctenocephalides canis, and Ctenocephalides felis.
- In another embodiment, an autoimmune disorder is treated. The autoimmune disorder is selected from the group consisting of arthritis, colitis, multiple sclerosis, lupus, Sjogren Syndrome, Systemic Lupus Erythematosus and lupus nephritis, glomerulonephritis, Rheumatoid Arthritis, Inflammatory bowel disease (IBD), ulcerative colitis, Crohn's diseases, Psoriasis, and asthma.
- In yet another embodiment, immunosuppression is provided for transplanted organs or tissues. The immunosuppression is used to prevent transplant rejection and graft-verse-host disease.
- In a further embodiment, an inflammatory disorder is treated. The inflammatory disorder is Crohn's disease.
- The compounds and pharmaceutical compositions of the present invention are particularly useful for the treatment of cancer. As used herein, the term “cancer” refers to a cellular disorder characterized by uncontrolled or disregulated cell proliferation, decreased cellular differentiation, inappropriate ability to invade surrounding tissue, and/or ability to establish new growth at ectopic sites. The term “cancer” includes, but is not limited to, solid tumors and bloodborne tumors. The term “cancer” encompasses diseases of skin, tissues, organs, bone, cartilage, blood, and vessels. The term “cancer” further encompasses primary and metastatic cancers.
- Non-limiting examples of solid tumors that can be treated with the disclosed proteasome inhibitors include pancreatic cancer; bladder cancer; colorectal cancer; breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent and androgen-independent prostate cancer; renal cancer, including, e.g., metastatic renal cell carcinoma; hepatocellular cancer; lung cancer, including, e.g., non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and adenocarcinoma of the lung; ovarian cancer, including, e.g., progressive epithelial or primary peritoneal cancer; cervical cancer; gastric cancer; esophageal cancer; head and neck cancer, including, e.g., squamous cell carcinoma of the head and neck; melanoma; neuroendocrine cancer, including metastatic neuroendocrine tumors; brain tumors, including, e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma; bone cancer; and soft tissue sarcoma.
- In one embodiment, cancer is treated. The cancer is selected from the group consisting of neoplastic disorders, hematologic malignances, lymphocytic malignancies, mantel cell lymphoma, leukemia, Waldenstrom Macroglobulinemia, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, metastatic breast cancer, prostate cancer, androgen-dependent and androgen-independent prostate cancer, renal cancer, metastatic renal cell carcinoma, hepatocellular cancer, lung cancer, non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and adenocarcinoma of the lung, ovarian cancer, progressive epithelial or primary peritoneal cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, squamous cell carcinoma of the head and neck, melanoma, neuroendocrine cancer, metastatic neuroendocrine tumors, brain tumors, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma, bone cancer, and soft tissue sarcoma.
- In another embodiment, a neurodegenerative disease or disorder is treated. The neurodegenerative disease or disorder is Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS).
- Another aspect of the present invention relates to a method of inhibiting proteasome activity. This method includes contacting a proteasome with a compound of Formula (I):
- wherein
- R is H or C1-6 alkyl;
- R′ is H or C1-6 alkyl;
- R1 is H or C1-6 alkyl;
- or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
- R2 is independently selected at each occurrence thereof from
- or —(CH2)nC(O)NR6R7;
- R3 is independently selected at each occurrence thereof from the group consisting of H, C1-12 alkyl, -Boc, —C(O)(CH2)nR5, —(CH2)nC(O)R5, —C(O)OR5, —C(O)(CH2)nNR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R4 is H, halogen, NH2, NHCOOC1-12 alkyl, or C1-12 alkyl;
- R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
- or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
- R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
- R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R10 is H or arylalkyl;
- W is CHR2, NR2, or
- X is selected from the group consisting of —C(O)—NH—, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH2)m—;
- Z is optional and, if present, is aryl or bicyclic heteroaryl;
- is the point of attachment to NHR3 moiety;
- is the point of attachment to C(O) moiety;
- k is 1 or 2;
- m is 0, 1, or 2; and
- n is 0, 1, 2, 3, or 4,
- with the proviso that R2 is not —CH2C(O)NH2, —CH2C(O)NHCH2C(CH3)3, or —(CH2)2C(O)NH2,
or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof under conditions effective to inhibit proteasome activity. - One embodiment of the present invention relates to a method of inhibiting proteasome activity. This method includes contacting a proteasome with a compound of Formula (I′):
- wherein
- R is H or C1-6 alkyl;
- R1 is H or C1-6 alkyl;
- or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
- R2 is independently selected at each occurrence thereof from the group consisting of C1-6 alkyl, and —(CH2)nC(O)NR6R7, wherein C1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR10;
- R3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH2)nR5, —(CH2)—C(O)R5, —C(O)OR5, —C(O)(CH2)—NR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C1-6 alkyl;
- R4 is H, C1-12 alkyl, or halogen;
- R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
- or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
- R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
- R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R10 is H or arylalkyl;
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH2)m—;
- Z is optional and, if present, is aryl;
- m is 0, 1, or 2; and
- n is 0, 1, 2, 3, or 4;
- or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof under conditions effective to inhibit proteasome activity.
- Another aspect of the present invention relates to a method of inhibiting proteasome activity. This method includes contacting a proteasome with a compound of Formula (II):
- or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof under conditions effective to inhibit proteasome activity.
- Another aspect of the present invention relates to a method of inhibiting proteasome activity. This method includes contacting a proteasome with a compound of Formula (II):
- wherein
- R is H or C1-6 alkyl;
- R1 is H or C1-6 alkyl;
- or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
- R2 is independently selected at each occurrence thereof from the group consisting of C1-6 alkyl, and —(CH2)nC(O)NR6R7, wherein C1-6 alkyl can be optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from OH or C(O)OR10;
- R3 is independently selected at each occurrence thereof from the group consisting of H, -Boc, —C(O)(CH2)nR5, —(CH2)—C(O)R5, —C(O)OR5, —C(O)(CH2)—NR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with C1-6 alkyl;
- R4 is H, C1-12 alkyl, or halogen;
- R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
- R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
- or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
- R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
- R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
- R10 is H or arylalkyl;
- X is monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, or monocyclic and bicyclic non-aromatic heterocycle;
- Y is optional and, if present, is —(CH2)m—;
- Z is optional and, if present, is aryl;
- W is N or CH;
- m is 0, 1, or 2; and
- n is 0, 1, 2, 3, or 4;
- or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof under conditions effective to inhibit proteasome activity.
- While it may be possible for compounds of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (I′), Formula (I′A), Formula (PB), Formula (I′C), Formula (I′D), Formula (I′E), Formula (I′F), Formula (I′G), Formula (I′C′), Formula (I′D′), Formula (I′E′), Formula (I′F′), Formula (I′G′), and Formula (II), to be administered as raw chemicals, it will often be preferable to present them as a part of a pharmaceutical composition. Accordingly, another aspect of the present invention is a pharmaceutical composition containing a therapeutically effective amount of the compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (I′), Formula (I′A), Formula (PB), Formula (I′C), Formula (I′D), Formula (I′E), Formula (I′F), Formula (I′G), Formula (I′C′), Formula (I′D′), Formula (I′E′), Formula (I′F′), Formula (I′G′), and Formula (II), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier. The carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- In practicing the method of the present invention, agents suitable for treating a subject can be administered using any method standard in the art. The agents, in their appropriate delivery form, can be administered orally, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, or intranasally. The compositions of the present invention may be administered alone or with suitable pharmaceutical carriers, and can be in solid or liquid form, such as tablets, capsules, powders, solutions, suspensions, or emulsions.
- The agents of the present invention may be orally administered, for example, with an inert diluent, or with an assimilable edible carrier, or it may be enclosed in hard or soft shell capsules, or it may be compressed into tablets, or they may be incorporated directly with the food of the diet. Agents of the present invention may also be administered in a time release manner incorporated within such devices as time-release capsules or nanotubes. Such devices afford flexibility relative to time and dosage. For oral therapeutic administration, the agents of the present invention may be incorporated with excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, and the like. Such compositions and preparations should contain at least 0.1% of the agent, although lower concentrations may be effective and indeed optimal. The percentage of the agent in these compositions may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit. The amount of an agent of the present invention in such therapeutically useful compositions is such that a suitable dosage will be obtained.
- Also specifically contemplated are oral dosage forms of the agents of the present invention. The agents may be chemically modified so that oral delivery of the derivative is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the component or components and increase in circulation time in the body. Examples of such moieties include: polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline (Abuchowski and Davis, “Soluble Polymer-Enzyme Adducts,” In: Enzymes as Drugs, Hocenberg and Roberts, eds., Wiley-Interscience, New York, N.Y., pp. 367-383 (1981), which are hereby incorporated by reference in their entirety). Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. Preferred for pharmaceutical usage, as indicated above, are polyethylene glycol moieties.
- The tablets, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, sucrulose, or saccharin. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
- Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar, or both. A syrup may contain, in addition to active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye, and flavoring such as cherry or orange flavor.
- The agents of the present invention may also be administered parenterally. Solutions or suspensions of the agent can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
- When it is desirable to deliver the agents of the present invention systemically, they may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Intraperitoneal or intrathecal administration of the agents of the present invention can also be achieved using infusion pump devices such as those described by Medtronic, Northridge, Calif. Such devices allow continuous infusion of desired compounds avoiding multiple injections and multiple manipulations.
- In addition to the formulations described previously, the agents may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- The agents of the present invention may also be administered directly to the airways in the form of an aerosol. For use as aerosols, the agent of the present invention in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. The agent of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.
- Effective doses of the compositions of the present invention, for the treatment of cancer or pathogen infection vary depending upon many different factors, including type and stage of cancer or the type of pathogen infection, means of administration, target site, physiological state of the patient, other medications or therapies administered, and physical state of the patient relative to other medical complications. Treatment dosages need to be titrated to optimize safety and efficacy.
- The percentage of active ingredient in the compositions of the present invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.01 to about 100 mg/kg body weight, preferably about 0.01 to about 10 mg/kg body weight per day by inhalation, from about 0.01 to about 100 mg/kg body weight, preferably 0.1 to 70 mg/kg body weight, more especially 0.1 to 10 mg/kg body weight per day by oral administration, and from about 0.01 to about 50 mg/kg body weight, preferably 0.01 to 10 mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health, and other characteristics which can influence the efficacy of the medicinal product.
- The products according to the present invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. It goes without saying that, for other patients, it will be necessary to prescribe not more than one or two doses per day.
- Example 1—General Procedure for HATU—Mediated Coupling Reaction
- Carboxylic acid (1.0 eq.), O-(7-azabenzotriazol-1-yl)-N,N,N,N′-tetramethyluronium hexafluorophosphate (HATU) (1.2 eq.), and 1-hydroxy-7-azabenzotriazole (HOAt) (0.6M in DMF) (1.0 eq.) were dissolved in DMF under argon atmosphere. The solution was cooled to 0° C. and amine was added. After stirring for 5 minutes at 0° C., Hünig's base (2-3 eq.) was added. The reaction mixture was stirred at 0° C. for 1 hour. After completion of the reaction (1 hour, monitored by LCMS), water (10 mL) was added to the reaction mixture and the mixture was stirred for 30 minutes. Product was isolated by either ethyl acetate extraction or by filtering the precipitate.
- The substance was dissolved in methanol. Palladium on carbon (10%) was added carefully. Air in the flask was exchanged with hydrogen. The mixture was stirred at room temperature for 3-4 hours under hydrogen atmosphere using a hydrogen balloon. After completion of reaction, the mixture was filtered through Celite. Filtrate was evaporated and dried under vacuum to give the product.
- The primary amine (generally TFA salt) was dissolved in dichloromethane. The solution was cooled to 0° C. and triethylamine (2.0-3.0 eq.) was added. Sulfonyl chloride (1.5 eq.) was added to the solution in one portion and the reaction mixture was warmed to room temperature (over 15 minutes). After completion of reaction (2-3 hours), dichloromethane was evaporated and crude product was isolated by ethyl acetate extraction.
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of (S)-2-(tert-butoxycarbonylamino)propanoic acid and 3-fluorobenzene-1,2-diamine on a 2.0 mmol scale. The product (600 mg, quant. ESI-MS (m/z): 298.22 (M+H+)) was isolated and used directly in the next step.
-
- To a solution of tert-butyl (S)-(1-((2-amino-3-fluorophenyl)amino)-1-oxopropan-2-yl)carbamate (600 mg) in EtOH (4 ml) was added HCl (7 ml), and the reaction mixture was heated to reflux for 4 hours. Solvent was removed by evaporation to give a gum (400 mg) assumed diHCl salt. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 2.13; ESI-MS (m/z): 180.10 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of (S)-4-(benzyloxy)-3-(tert-butoxycarbonylamino)-4-oxobutanoic acid and (S)-2-ethylpiperidine hydrochloride on a 0.7 mmol scale, and isolated as a white solid in quant. yield. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 4.58; ESI-MS (m/z): 419.24 (M+H+).
-
- The title compound was synthesized by following the O-Debenzylation protocol of 1-3 on a 0.7 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 3.64; ESI-MS (m/z): 329.20 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of 1-4 and 1-2 on a 0.3 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 3.97; ESI-MS (m/z): 490.22 (M+H+).
-
- The title compound was synthesized by following the general protocol for Boc-Deprotection protocol of 1-5 on a 0.1 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 3.97; ESI-MS (m/z): 390.22 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and 2-cyclopropylacetic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.41; ESI-MS (m/z): 472.26 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and 4-methylpentanoic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.97; ESI-MS (m/z): 488.29 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and 3-(dimethylamino)propanoic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.21; ESI-MS (m/z): 489.29 (M+H+).
-
- To a solution of CEN-1 (4 mg) in DCM (0.5mL) was added isobutyl carbonochloridate (1.403 mg) and triethylamine (3.58 μl), the reaction solution was stirred at room temperature for 15 min, and evaporated. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.17; ESI-MS (m/z): 490.2 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and 5-methylisoxazole-3-carboxylic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.67; ESI-MS (m/z): 499.23 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and 3,3,3-trifluoropropanoic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.57; ESI-MS (m/z): 500.22 (M+H+).
-
- To a solution of CEN-1 (4 mg) in DMF (0.5 mL) was added 5-chloro-3-isopropyl-1,2,4-oxadiazole (2 mg), and the reaction mixture was stirred at 80° C. for 1 hour. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.91; ESI-MS (m/z): 500.27 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and 3,3-dimethylcyclobutane-1-carboxylic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.49; ESI-MS (m/z): 500.29 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and 2-isopropylcyclopropane-1-carboxylic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.15; ESI-MS (m/z): 500.29 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and thiazole-5-carboxylic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.91; ESI-MS (m/z): 501.2 (M+H+).
-
- To a solution of CEN-1 (5 mg) in DCM (0.5 mL) was added piperidine-1-carbonyl chloride (2 mg) and triethylamine (5 μl), the reaction solution was stirred at room temperature for 60 min, and evaporated. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.82; ESI-MS (m/z): 501.29 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and 4,4-dimethylpentanoic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.26; ESI-MS (m/z): 502.31 (M+H+).
-
- To a solution of CEN-1 (5 mg) in DCM (0.5 mL) was added morpholine-4-carbonyl chloride (2 mg) and triethylamine (5 μl), the reaction solution was stirred at r.t. for 60 min, and evaporated. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.13; ESI-MS (m/z): 503.26 (M+H+).
-
- To a solution of CEN-1 (5 mg) in DCM (0.5 mL) was added isobutyl(methyl)carbamic chloride (2 mg) and triethylamine (3 μl), the reaction solution was stirred at room temperature for 20 min, and evaporated. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.07; ESI-MS (m/z): 503.30 (M+H+).
-
- To a solution of CEN-1 (3 mg) in NMP (0.5 mL) was added 2-chlorobenzo[d]oxazole (2 mg), the reaction solution was stirred at 150° C. for 10 min. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.00; ESI-MS (m/z): 507.24 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and spiro[3.3]heptane-2-carboxylic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.51; ESI-MS (m/z): 512.29 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and 2-methylthiazole-5-carboxylic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.03; ESI-MS (m/z): 515.21 (M+H+).
-
- To a solution of CEN-1 (4 mg) in NMP (0.5 mL) was added 2-chloro-6-methylbenzo[d]oxazole (2 mg), the reaction solution was stirred at 150° C. for 10 min. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.35; ESI-MS (m/z): 521.25 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and 3-phenylpropanoic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.98; ESI-MS (m/z): 522.27 (M+H+).
-
- To a solution of CEN-1 (5 mg) in DCM (0.5 mL) was added benzylcarbamic chloride (2 mg) and triethylamine (3 μl), the reaction solution was stirred at room temperature for 10 min, and evaporated. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.66; ESI-MS (m/z): 523.27 (M+H+).
-
- To a solution of CEN-1 (4 mg) in NMP (0.5 mL) was added 2-chlorobenzo[d]thiazole (2 mg), the reaction solution was stirred at 150° C. for 10 min. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.34; ESI-MS (m/z): 523.22 (M+H+).
-
- To a solution of CEN-1 (5 mg) in DCM (0.5 mL) was added benzyl carbonochloridate (2 mg) and triethylamine (5 μl), the reaction solution was stirred at room temperature for 10 min, and evaporated. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.42; ESI-MS (m/z): 524.25 (M+H+).
-
- The title compound was synthesized by following the general procedure for N-Sulfonamide formation of CEN-1 with 3-methylbutane-1-sulfonyl chloride on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.21; ESI-MS (m/z): 524.26 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-1 and (1S,2S)-2-phenylcyclopropane-1-carboxylic acid on a 0.01 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.36; ESI-MS (m/z): 534.27 (M+H+).
-
- To a solution of CEN-1 (5 mg) in DCM (0.5 mL) was added benzyl(methyl)carbamic chloride (3 mg) and triethylamine (5 μl), the reaction solution was stirred at r.t. for 15 min, and evaporated. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.19; ESI-MS (m/z): 537.29 (M+H+).
-
- To a solution of CEN-1 (2 mg) in NMP (0.25 mL) was added 5-chloro-3-(4-fluorobenzyl)-1,2,4-oxadiazole (1 mg), the reaction solution was stirred at 150° C. for 10 min. The title product was purified by Prep-HPLC. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.46; ESI-MS (m/z): 566.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.59; ESI-MS (m/z): 470.30 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.93; ESI-MS (m/z): 484.32 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.75; ESI-MS (m/z): 501.2 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.19; ESI-MS (m/z): 442.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.15; ESI-MS (m/z): 456.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.16; ESI-MS (m/z): 456.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.29; ESI-MS (m/z): 456.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.81; ESI-MS (m/z): 467.23 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.83; ESI-MS (m/z): 467.23 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.54; ESI-MS (m/z): 470.30 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.67; ESI-MS (m/z): 474.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.18; ESI-MS (m/z): 486.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.00; ESI-MS (m/z): 486.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.01; ESI-MS (m/z): 488.29 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.18; ESI-MS (m/z): 498.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.72; ESI-MS (m/z): 500.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.69; ESI-MS (m/z): 500 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.75; ESI-MS (m/z): 506.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.48; ESI-MS (m/z): 502.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 9 min): tR (min): 5.57; ESI-MS (m/z): 504.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.36; ESI-MS (m/z): 504.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.77; ESI-MS (m/z): 504.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-5. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.12; ESI-MS (m/z): 510.24 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.80; ESI-MS (m/z): 512.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.37; ESI-MS (m/z): 515.23 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.28; ESI-MS (m/z): 515.23 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.09; ESI-MS (m/z): 518.30 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.10; ESI-MS (m/z): 520.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-15. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.88; ESI-MS (m/z): 523.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 7.07; ESI-MS (m/z): 534.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.67; ESI-MS (m/z): 540.25 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.94; ESI-MS (m/z): 540 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.76; ESI-MSf(m/z): 540.25 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 7.16; ESI-MS (m/z): 546.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 7.32; ESI-MS (m/z): 546.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.13; ESI-MS (m/z): 548.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 7.40; ESI-MS (m/z): 558.2 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.81; ESI-MS (m/z): 558 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 7.07; ESI-MS (m/z): 545 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 7.24; ESI-MS (m/z): 561 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-2. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 7.26; ESI-MS (m/z): 565 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→95% MeCN, 0.1% TFA, 5 min): tR (min): 3.19; ESI-MS (m/z): 516.40 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→95% MeCN, 0.1% TFA, 5 min): tR (min): 3.17; ESI-MS (m/z): 530.45 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→95% MeCN, 0.1% TFA, 5 min): tR (min): 2.66; ESI-MS (m/z): 435.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→95% MeCN, 0.1% TFA, 5 min): tR (min): 2.65; ESI-MS (m/z): 431.34 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→95% MeCN, 0.1% TFA, 5 min): tR (min): 3.12; ESI-MS (m/z): 526.45 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of ((benzyloxy)carbonyl)-L-alanine and 2-amino-1-phenylethan-1-one hydrochloride on a 1.3 mmol scale, and isolated as a white solid in quant. yield. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 3.53; ESI-MS (m/z): 363.13 (M+Na+).
-
- To a solution of 2-1 (450 mg, 1.32 mmol) in AcOH (4 mL) was added ammonium acetate (2.04 g, 26.4 mmol), and the reaction mixture was heated to reflux for 2 hours. After the reaction was completed, the mixture was poured into H2O (15 mL) and extracted with DCM (10 mL×3). The combined organic layers were washed with saturated brine (50 mL×2), dried over Na2SO4, and concentrated under vacuum to give title product (400 mg) as a gum. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 2.55; ESI-MS (m/z): 322.14 (M+H+).
-
- The title compound was synthesized by following the O-Debenzylation protocol of 2-2 on a 1.0 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 2.12; ESI-MS (m/z): 188.10 (M+H+).
-
- The title compound was synthesized by the similar method described for 2-3. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 2.29; ESI-MS (m/z): 206.1 (M+H+).
-
- The title compound was synthesized by the similar method described for 2-3. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 2.20; ESI-MS (m/z): 206.1 (M+H+).
-
- The title compound was synthesized by the similar method described for 2-3. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 2.35; ESI-MS (m/z): 224.1 (M+H+).
-
- The title compound was synthesized by the similar method described for 2-3. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 1.81; ESI-MS (m/z): 202.1 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of 2-4 and (S)-4-(benzyloxy)-2-(tert-butoxycarbonylamino)-4-oxobutanoic acid on a 0.7 mmol scale, and isolated as a white solid (160mg). LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 2.90; ESI-MS (m/z): 511.21 (M+H+).
-
- The title compound was synthesized by following the O-Debenzylation protocol of 2-8 on a 1.0 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 2.51; ESI-MS (m/z): 421.10 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of 2-9 and (R)-2-phenylpyrrolidine on a 0.1 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 2.83; ESI-MS (m/z): 550.1 (M+H+).
-
- The title compound was synthesized by following the general protocol for Boc-Deprotection protocol of 2-10 on a 0.05 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.25; ESI-MS (m/z): 450.22 (M+H+).
-
- The title compound was synthesized by following the general protocol for HATU mediated coupling of CEN-74 and 5-methylisoxazole-3-carboxylic acid on a 0.1 mmol scale. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.72; ESI-MS (m/z): 559.20 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-74. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 3.81; ESI-MS (m/z): 420.21 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.30; ESI-MS (m/z): 490.25 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 6.5 min): tR (min): 2.77; ESI-MS (m/z): 492.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.51; ESI-MS (m/z): 492.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.24; ESI-MS (m/z):
- 501 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.20; ESI-MS (m/z): 502.25 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.48; ESI-MS (m/z): 502 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.41; ESI-MS (m/z): 504.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.59; ESI-MS (m/z): 504.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.54; ESI-MS (m/z): 504.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.88; ESI-MS (m/z): 512.20 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.52; ESI-MS (m/z): 516.27 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.67; ESI-MS (m/z): 518.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.75; ESI-MS (m/z): 518.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.77; ESI-MS (m/z): 518.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.83; ESI-MS (m/z): 518.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.04; ESI-MS (m/z): 520.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.30; ESI-MS (m/z): 528.24 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.47; ESI-MS (m/z): 529.22 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-8. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.81; ESI-MS (m/z): 530.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.01; ESI-MS (m/z): 530.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.02; ESI-MS (m/z): 530.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.81; ESI-MS (m/z): 531.19 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.96; ESI-MS (m/z): 532.30 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.16; ESI-MS (m/z): 532.30 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.73; ESI-MS (m/z): 533.3 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.47; ESI-MS (m/z): 538.25 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-8. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.70; ESI-MS (m/z): 538.25 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.83; ESI-MS (m/z): 540 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.98; ESI-MS (m/z): 545.20 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.92; ESI-MS (m/z): 546.28 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 6.41; ESI-MS (m/z): 546.31 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.78; ESI-MS (m/z): 552.23 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-16. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.80; ESI-MS (m/z): 537.23 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.54; ESI-MS (m/z): 560.20 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.17; ESI-MS (m/z): 572.25(M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.75; ESI-MS (m/z): 574.22 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.81; ESI-MS (m/z): 574.22 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-24. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.80; ESI-MS (m/z): 554.25 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 5→95% MeCN, 0.1% TFA, 8 min): tR (min): 3.56; ESI-MS (m/z): 577.3 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.39; ESI-MS (m/z): 493.34 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.37; ESI-MS (m/z): 493.24 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.36; ESI-MS (m/z): 511.23 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.43; ESI-MS (m/z): 511.23 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 5→95% MeCN, 0.1% TFA, 8 min): tR (min): 3.47; ESI-MS (m/z): 541.5 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.61; ESI-MS (m/z): 528.29 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 4.94; ESI-MS (m/z): 524.31 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.84; ESI-MS (m/z): 555.26 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-75. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.27; ESI-MS (m/z): 480.29 (M+H+).
-
- The title compound was synthesized by the similar method described for CEN-16. LC-MS (linear gradient 10→98% MeCN, 0.1% TFA, 12 min): tR (min): 5.73; ESI-MS (m/z): 567.24 (M+H+).
- Synthesized compounds are shown in Table 1.
-
TABLE 1 Molecular Formula Weight Structure IUPAC Name 492.6 5-methyl-N-[(1S)-3-(2-methyl-1- piperidyl)-3-oxo-1-[[(1S)-1-(5- phenyl-1H-imidazol-2- yl)ethyl]carbamoyl]propyl] isoxazole-3-carboxamide 492.6 5-methyl-N-((S)-4-((S)-2- methylpiperidin-1-yl)-1,4-dioxo- 1-(((S)-1-(5-phenyl-1H- imidazol-2- yl)ethyl)amino)butan-2- yl)isoxazole-3-carboxamide 510.6 N-((S)-1-(((S)-1-(5-(2- fluorophenyl)-1H-imidazol-2- yl)ethyl)amino)-4-((S)-2- methylpiperidin-1-yl)-1,4- dioxobutan-2-yl)-5- methylisoxazole-3-carboxamide 510.6 N-((S)-1-(((S)-1-(5-(4- fluorophenyl)-1H-imidazol-2-yl) ethyl)amino)-4-((S)-2- methylpiperidin-1-yl)-1,4- dioxobutan-2-yl)-5- methylisoxazole-3-carboxamide 533.6 N-((2S)-1-(((S)-1-((2,4- difluorobenzyl)amino)-1- oxopropan-2-yl)(methyl)amino)- 4-(2-methylpiperidin-1-yl)-1,4- dioxobutan-2-yl)-5- methylisoxazole-3-carboxamide 621.8 tert-butyl (3-(((S)-2-((S)-4-((S)-2- methylpiperidin-1-yl)-4-oxo-2-(3- phenylpropanamido)butanamido) propanamido)methyl)phenyl)- carbamate 521.7 (S)-N-((S)-1-((3- aminobenzyl)amino)-1- oxopropan-2-yl)-4-((S)-2- methylpiperidin-1-yl)-4-oxo-2- (3- phenylpropanamido)butanamide 466.5 N-((2S)-1-((1-(1H-benzo [d]imidazol-2- yl)ethyl)amino)-4-((S)-2- methylpiperidin-1-yl)-1,4- dioxobutan-2-yl)-5- methylisoxazole-3-carboxamide 558.6 N-[(1S)-1-[[(1S)-1-[5-(2- fluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-oxo-3- [(2S)-2-phenylpyrrolidin-1- yl]propyl]-5-methyl-isoxazole-3- carboxamide 566.6 (2S)-2-(1,3-benzoxazol-2- ylamino)-N-[(1S)-1-[4-(2- fluorophenyl)-1H-imidazol-2- yl]ethyl]-4-oxo-4-[(2R)-2- phenylpyrrolidin-1- yl]butanamide 449.5 (2S)-2-amino-N-[(1S)-1-[5-(2- fluorophenyl)-2,5-dihydro- 1H-imidazol-2- yl]ethyl]-4-oxo-4- [(2R)-2-phenylpyrrolidin-1- yl]butanamide 528.6 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-5-methyl-isoxazole-3- carboxamide 514.6 N-[(1S)-1-[1-(1H-benzimidazol- 2-yl)ethylcarbamoyl]-3-oxo-3- [(2S)-2-phenylpyrrolidin-1- yl]propyl]-5-methyl-isoxazole-3- carboxamide 506.6 N-[(1S)-1-[[(1S)-1-(5-benzyl- 1H-imidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-5-methyl-isoxazole-3- carboxamide 554.64 N-[(1S)-1-[[(1S)-1-(5-benzyl- 1H-imidazol-2- yl)ethyl]carbamoyl]-3-oxo- 3-[(2S)-2-phenylpyrrolidin-1- yl]propyl]-5-methyl-isoxazole-3- carboxamide 523.67 (2S)-N-[(1S)-1-(5-benzyl-1H- imidazol-2-yl)ethyl]-4-[(2S)-2- methyl-1-piperidyl]-4-oxo-2- [(2-tetrahydropyran-4- ylacetyl)amino]butanamide 479.61 (2S)-N-[(1S)-1-(5-benzyl-1H- imidazol-2-yl)ethyl]-2-[(2- cyclopropylacetyl)amino]-4- [(2S)-2-methyl-1-piperidyl]-4- oxo-butanamide 527.66 (2S)-N-[(1S)-1-(5-benzyl-1H- imidazol-2-yl)ethyl]-2-[(2- cyclopropylacetyl)amino]-4-oxo- 4-[(2S)-2-phenylpyrrolidin-1- yl]butanamide 501.57 (2S)-2-[(2- cyclopropylacetyl)amino]-N- [(1S)-1-[5-(2,4-difluorophenyl)- 1H-imidazol-2-yl]ethyl]-4-[(2S)- 2-methyl-1-piperidyl]-4-oxo- butanamide 545.62 (2S)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-4-[(2S)-2-methyl-1- piperidyl]-4-oxo-2-[(2- tetrahydropyran-4- ylacetyl)amino]butanamide 573.65 (2S)-2-(benzylsulfonylamino)- N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-4-[(2S)-2-methyl-1- piperidyl]-4-oxo-butanamide 539.64 (2S)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-2- (isobutylsulfonylamino)-4-[(2S)- 2-methyl-1-piperidyl]-4-oxo- butanamide 559.63 (2S)-2-(benzenesulfonamido)-N- [(1S)-1-[5-(2,4-difluorophenyl)- 1H-imidazol-2-yl]ethyl]-4-[(2S)- 2-methyl-1-piperidyl]-4-oxo- butanamide 573.65 (2S)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-4-[(2S)-2-methyl-1- piperidyl]-4-oxo-2- (ptolylsulfonylamino) butanamide 511.59 (2S)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-2- (ethylsulfonylamino)-4-[(2S)-2- methyl-1-piperidyl]-4-oxo- butanamide 537.6 (2S)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-4-[(2S)-2- methyl-1-piperidyl]-4-oxo-2- (phenacylamino)butanamide 501.57 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]cyclobutanecarboxamide 517.61 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanamide 466.53 N-[(1S)-1-[[(1S)-1-(1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3- oxo-propyl]-5-methyl- isoxazole-3-carboxamide 455.59 N-[(1S)-1-[[(1S)-1-(1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanamide 503.64 N-[(1S)-1-[[(1S)-1-(1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo-3- [(2S)-2-phenylpyrrolidin-1- yl]propyl]-4-methyl- pentanamide 503.64 N-((S)-1-(((R)-1-(1H- benzo[d]imidazol-2- yl)ethyl)amino)-1,4-dioxo-4- ((R)-2-phenylpyrrolidin-1- yl)butan-2-yl)-4- methylpentanamide 503.58 (2S)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-2-[(3-methyl-2-oxo- butyl)amino]-4-[(2S)-2-methyl- 1-piperidyl]-4-oxo-butanamide 514.58 N-[(1S)-1-[[(1S)-1-(1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo-3- [(2S)-2-phenylpyrrolidin-1- yl]propyl]-5-methyl-isoxazole-3- carboxamide 503.64 N-[(1S)-1-[1-(1H-benzimidazol- 2-yl)ethylcarbamoyl]-3-oxo-3- [(2S)-2-phenylpyrrolidin-1- yl]propyl]-4-methyl- pentanamide 539.69 (2S)-N-[1-(1H-benzimidazol-2- yl)ethyl]-2- (isopentylsulfonylamino)-4-oxo- 4-[(2S)-2-phenylpyrrolidin-1- yl]butanamide 501.62 N-[(1S)-1-[1-(1H-benzimidazol- 2-yl)ethylcarbamoyl]-3-oxo-3- [(2S)-2-phenylpyrrolidin-1- yl]propyl]-3-methyl- cyclobutanecarboxamide 517.66 N-[(1S)-1-[[(1S)-1-(1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo-3- [(2S)-2-phenylpyrrolidin-1- yl]propyl]-4,4-dimethyl- pentanamide 553.66 (2S)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-2- (isopentylsulfonylamino)-4- [(2S)-2-methyl-1-piperidyl]-4- oxo-butanamide 531.64 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-4,4-dimethyl- pentanamide 489.56 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-oxo-3- pyrrolidin-1-yl-propyl]-4- methyl-pentanamide 503.58 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-oxo-3- pyrrolidin-1-yl-propyl]-4,4- dimethyl-pentanamide 500.5 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-oxo-3- pyrrolidin-1-yl-propyl]-5- methyl-isoxazole-3-carboxamide 517.61 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-[(2R)-2- methylpyrrolidin-1-yl]-3-oxo- propyl]-4,4-dimethyl- pentanamide 455.59 N-[(1S)-1-[[(1S)-1-(1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2R)-2- methylpyrrolidin-1-yl]-3-oxo- propyl]-4,4-dimethyl- pentanamide 539.70 (2S)-N-[(1S)-1-(1H- benzimidazol-2-yl)ethyl]-2- (isopentylsulfonylamino)-4-oxo- 4-[(2R)-2-phenylpyrrolidin-1- yl]butanamide 539.70 (2S)-N-[(1R)-1-(1H- benzimidazol-2- yl)ethyl]-2- (isopentylsulfonylamino)-4-oxo- 4-[(2R)-2-phenylpyrrolidin-1- yl]butanamide 474.55 N-[(1S)-2-[(2,4- difluorophenyl)methylamino]- 1-methyl-2-oxo-ethyl]-2- (isopentylamino)-6-pyrrolidin- 1-yl-pyrimidine-4-carboxamide 511.57 tert-butyl 2-(((S)-1-((2,4- difluorobenzyl)amino)-1- oxopropan-2-yl)carbamoyl)-2- (2-((S)-2-methylpiperidin-1-yl)- 2-oxoethyl)hydrazine-1- carboxylate 523.63 (2S)-N-[(2,4- difluorophenyl)methyl]-2-[[(4,4- dimethylpentanoylamino)-[2- [(2S)-2-methyl-1-piperidyl]-2- oxoethyl]carbamoyl]amino] propanamide 532.63 3-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-1-(4,4- dimethylpentanoylamino)-1-[2- [(2S)-2-methyl-1-piperidyl]-2- oxo-ethyl]urea 469.62 N-[(1S)-1-[[(1R)-1-(1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-4,4-dimethyl- pentanamide 455.59 N-[(1S)-1-(1H-benzimidazol-2- ylmethylcarbamoyl)-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-4,4-dimethyl- pentanamide 455.59 N-[(1S)-1-[[(1R)-1-(1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanamide 441.57 N-[(1S)-1-(1H-benzimidazol-2- ylmethylcarbamoyl)-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanamide 491.57 (2S)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-N',N'-diethyl-2-(4- methylpentanoylamino) butanediamide 503.58 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-oxo-3-(1- piperidyl)propyl]-4-methyl- pentanamide 517.61 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-[(2R)-2- methyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanamide 491.57 (2S)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-N′-isopropyl-N′- methyl-2-(4- methylpentanoylamino) butanediamide 515.6 (2S)-2-(3- cyclopropylpropanoylamino)-N- [(1S)-1-[5-(2,4-difluorophenyl)- 1H-imidazol-2-yl]ethyl]-4-[(2S)- 2-methyl-1-piperidyl]-4-oxo- butanamide 551.65 (2S)-2-(2- cyclopropylethylsulfonylamino)- N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-4-[(2S)-2-methyl-1- piperidyl]-4-oxo-butanamide 519.58 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-[(3S)-3- methylmorpholin-4-yl]-3-oxo- propyl]-4-methyl-pentanamide 571.58 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-oxo-3- [(2R)-2-(trifluoromethyl)-1- piperidyl]propyl]-4-methyl- pentanamide 531.64 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-[(2S)-2- ethyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanamide 517.61 N-[(1S)-3-(azepan-1-yl)-1- [[(1S)-1-[5-(2,4-difluorophenyl)- 1H-imidazol-2- yl]ethyl]carbamoyl]-3-oxo- propyl]-4-methyl-pentanamide 469.62 N-[(1S)-1-[[(1S)-1- (1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- ethyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanamide 483.65 N-[(1S)-1-[[(1S)-1- (1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- ethyl-1-piperidyl]-3-oxo- propyl]-4,4-dimethyl- pentanamide 545.66 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-(2- isopropyl-1-piperidyl)-3-oxo- propyl]-4-methyl- pentanamide 505.6 N-[(1S)-1-[[(1S)-1-(4,6-difluoro- 1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- ethyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanamide 501.64 N-[(1S)-3-[(2S)-2-ethyl-1- piperidyl]-1-[[(1S)-1-(4-fluoro- 1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo- propyl]-4,4-dimethyl- pentanamide 487.61 N-[(1S)-3-[(2S)-2-ethyl-1- piperidyl]-1-[[(1S)-1-(4-fluoro- 1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo- propyl]-4-methyl-pentanamide 473.58 N-[(1S)-1-[[(1S)-1-(4-fluoro-1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanamide 487.61 N-[(1S)-1-[[(1S)-1-(4-fluoro-1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-4,4-dimethyl- pentanamide 523.66 (2S)-4-[(2S)-2-ethyl-1- piperidyl]-N-[(1S)-1-(4-fluoro- 1H-benzimidazol-2-yl)ethyl]-2- (isopentylsulfonylamino)-4-oxo- butanamide 505.6 N-[(1S)-1-[[(1S)-1-(5,6-difluoro- 1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- ethyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanamide 498.55 N-[(1S)-3-[(2S)-2-ethyl-1- piperidyl]-1-[[(1S)-1-(4-fluoro- 1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo- propyl]-5-methyl-isoxazole-3- carboxamide 522.61 (2S)-2-(benzylcarbamoylamino)- 4-[(2S)-2-ethyl-1-piperidyl]-N- [(1S)-1-(4-fluoro-1H- benzimidazol-2-yl)ethyl]-4-oxo- butanamide 521.63 (2S)-4-[(2S)-2-ethyl-1- piperidyl]-N-[(1S)-1-(4-fluoro- 1H-benzimidazol-2-yl)ethyl]-4- oxo-2-(3- phenylpropanoylamino) butanamide 571.7 N-[(1S)-1-[[(1R,2R)-2-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]cyclopentyl]carbamoyl]-3- [(2S)-2-ethyl-1-piperidyl]-3-oxo- propyl]-4-methyl-pentanami 517.62 (2S)-N-[(1S)-2-(1H-indol-7- ylmethylamino)-1-methyl-2-oxo- ethyl]-4-oxo-2-(3- phenylpropanoylamino)-4- pyrrolidin-1-yl-butanamide 471.57 (2S)-2-[(2- cyclopropylacetyl)amino]-4- [(2S)-2-ethyl-1-piperidyl]-N- [(1S)-1-(4-fluoro-1H- benzimidazol-2-yl)ethyl]-4-oxo- butanamide 499.5 (2S)-4-[(2S)-2-ethyl-1- piperidyl]-N-[(1S)-1-(4-fluoro- 1H-benzimidazol-2-yl)ethyl]-4- oxo-2-(3,3,3- trifluoropropanoylamino) butanamide 506.57 (2S)-2-(1,3-benzoxazol-2- ylamino)-4-[(2S)-2-ethyl-1- piperidyl]-N-[(1S)-1-(4-fluoro- 1H-benzimidazol-2-yl)ethyl]-4- oxo-butanamide 488.6 (2S)-2-[3- (dimethylamino)propanoylamino]- 4-[(2S)-2-ethyl-1-piperidyl]-N- [(1S)-1-(4-fluoro-1H- benzimidazol-2-yl)ethyl]-4-oxo- butanamide 520.6 (2S)-4-[(2S)-2-ethyl-1- piperidyl]-N-[(1S)-1-(4-fluoro- 1H-benzimidazol-2-yl)ethyl]-2- [(5-methyl-1,3-benzoxazol-2- yl)amino]-4-oxo-butanamide 520.6 (2S)-4-[(2S)-2-ethyl-1- piperidyl]-N-[(1S)-1-(4-fluoro- 1H-benzimidazol-2-yl)ethyl]-2- [(6-methyl-1,3-benzoxazol-2- yl)amino]-4-oxo-butanamide 533.65 (1S,2S)-N-((S)-4-((S)-2- ethylpiperidin-1-yl)-1-(((S)-1-(4- fluoro-1H-benzo[d]imidazol-2- yl)ethyl)amino)-1,4-dioxobutan- 2-yl)-2-phenylcyclopropane-1- carboxamide 499.62 N-[(1S)-3-[(2S)-2-ethyl-1- piperidyl]-1-[[(1S)-1-(4- fluoro-1H-benzimidazol-2- yl)ethyl]carbamoyl]-3- oxo-propyl]-2-isopropyl- cyclopropanecarboxamide 485.59 N-[(1S)-1-[[(1S)-1-(4-fluoro-1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-2-isopropyl- cyclopropanecarboxamide 519.62 (1S,2S)-N-((S)-1-(((S)-1-(4- fluoro-1H-benzo[d]imidazol-2- yl)ethyl)amino)-4-((S)-2- methylpiperidin-1-yl)-1,4- dioxobutan-2-yl)-2- phenylcyclopropane-1- carboxamide 518.61 (2S)-N-[(1S)-2-(1H-indazol-7- ylmethylamino)-1-methyl- 2-oxo-ethyl]-4-oxo-2-(3- phenylpropanoylamino)-4- pyrrolidin-1-yl-butanamide 499.58 (2S)-4-[(2S)-2-ethyl-1- piperidyl]-N-[(1S)-1-(4-fluoro- 1H-benzimidazol-2-yl)ethyl]-2- [(3-isopropyl-1,2,4-oxadiazol-5- yl)amino]-4-oxo-butanamide 565.61 (2S)-4-[(2S)-2-ethyl-1- piperidyl]-N-[(1S)-1-(4-fluoro- 1H-benzimidazol-2- yl)ethyl]-2-[[3-[(4- fluorophenyl)methyl]- 1,2,4-oxadiazol-5-yl]amino]-4- oxo-butanamide 533.64 (1S,2R)-N-[(1S)-3-[(2S)-2-ethyl- 1-piperidyl]-1-[[(1S)-1-(4- fluoro-1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo- propyl]-2-phenyl- cyclopropanecarboxamide 519.61 (1S,2R)-N-[(1S)-1-[[(1S)-1-(4- fluoro-1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3- oxo-propyl]-2-phenyl- cyclopropanecarboxamide 522.64 (2S)-2-(1,3-benzothiazol-2- ylamino)-4-[(2S)-2-ethyl-1- piperidyl]-N-[(1S)-1-(4-fluoro- 1H-benzimidazol-2-yl)ethyl]-4- oxo-butanamide 536.64 (2S)-2-[[benzyl(methyl) carbamoyl]amino]- 4-[(2S)-2-ethyl-1-piperidyl]- N-[(1S)-1-(4-fluoro-1H- benzimidazol-2-yl)ethyl]-4- oxo-butanamide 502.58 N-[(1S)-3-[(2S)-2-ethyl-1- piperidyl]-1-[[(1S)-1-(4-fluoro- 1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo- propyl]morpholine-4- carboxamide 500.61 N-[(1S)-3-[(2S)-2-ethyl-1- piperidyl]-1-[[(1S)-1-(4-fluoro- 1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo- propyl]piperidine-1-carboxamide 502.62 (2S)-4-[(2S)-2-ethyl-1- piperidyl]-N-[(1S)-1-(4-fluoro- 1H-benzimidazol-2-yl)ethyl]-2- [[isobutyl(methyl)carbamoyl] amino]-4-oxo-butanamide 511.63 N-[(1S)-3-[(2S)-2-ethyl-1- piperidyl]-1-[[(1S)-1-(4- fluoro-1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo- propyl]spiro[3.3]heptane-2- carboxamide 497.6 N-[(1S)-1-[[(1S)-1-(4-fluoro- 1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]spiro[3.3]heptane-2- carboxamide 522.61 (2S)-2-[[benzyl(methyl) carbamoyl]amino]- N-[(1S)-1-(4-fluoro-1H- benzimidazol-2-yl)ethyl]-4- [(2S)-2-methyl-1-piperidyl]-4- oxo-butanamide 523.6 benzyl N-[(1S)-3-[(2S)-2-ethyl- 1-piperidyl]-1-[[(1S)-1-(4- fluoro-1H-benzimidazol-2- yl)ethyl]carbamoyl]-3- oxo-propyl]carbamate 509.57 benzyl N-[(1S)-1-[[(1S)-1-(4- fluoro-1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]carbamate 489.58 isobutyl N-[(1S)-3-[(2S)-2-ethyl- 1-piperidyl]-1-[[(1S)-1-(4- fluoro-1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo- propyl]carbamate 499.62 N-[(1S)-3-[(2S)-2-ethyl-1- piperidyl]-1-[[(1S)-1-(4-fluoro- 1H-benzimidazol-2- yl)ethyl]carbamoyl]-3-oxo- propyl]-3,3-dimethyl- cyclobutanecarboxamide 485.59 N-[(1S)-1-[[(1S)-1-(4-fluoro-1H- benzimidazol-2- yl)ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-3,3-dimethyl- cyclobutanecarboxamide 529.62 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]-3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-3,3-dimethyl- cyclobutanecarboxamide 529.62 N-[(1S)-1-[[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]carbamoyl]- 3-[(2S)-2- methyl-1-piperidyl]-3-oxo- propyl]-2-isopropyl- cyclopropanecarboxamide 536.57 (2S)-2-(1,3-benzoxazol-2- ylamino)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-4-[(2S)-2-methyl-1- piperidyl]-4-oxo-butanamide 529.58 (2S)-N-[(1S)-1-[5-(2,4- difluorophenyl)-1H-imidazol-2- yl]ethyl]-2-[(3-isopropyl-1,2,4- oxadiazol-5-yl)amino]-4-[(2S)- 2-methyl-1-piperidyl]-4-oxo- butanamide - Experiments to determine IC50 values against β5i and β5c for compounds were carried out in 96-well plates. In brief, 1 μL of compound in a 3× series dilution in DMSO at concentration ranging from 100 μM-0.0017 μM were spotted to the bottom of a black 96-well plate with solid bottom. 100 μL of reaction buffer (20 mM HEPES, 0.5 mM EDTA, pH7.5, 0.1% BSA) containing enzyme (final concentration was 0.2 nM for c-20S, and 0.4 nM for i-20S) and substrate (25 μM for suc-LLVY-AMC for β5c and 15 μM for Ac-ANW-AMC) were dispensed into each well, and the plate was then spun at 1000× rpm for 1 minute and then shaked on a shaker for 1 minute. Time course of the hydrolysis of each well was followed by recording the fluorescence of product AMC (Ex 360 nm and Em 460 nm) on a SpectraMax M5 plate reader for 1.5-2 hours. Initial reaction velocity of each well was fit to a dose-dependent inhibition equation using PRISM to determine the IC50. IC50s were determined only for β5i and β5c (Table 2). SDS was used as activator for both enzymes at concentration 0.02%.
-
TABLE 2 IC50 values Hu c-20S Mtb20SO IC50 G IC50 Formula ID (μM) (μM) Selectivity CF-503094 12 11 0.471 0.726 25 15 CF-503102 14 10 0.717 0.44 20 23 CF-503103 >15 >15 0.16 0.306 >90 >49 CF-503105 >18 19 0.259 0.256 >69 74 Not Registered 19 10 1.9 Not Registered 50.2 24.7 2 Not Registered 0.69 0.005 138 Not Registered 71.6 19.6 0.549 0.331 130 59 CF-503108 100 0.07 13.3 0.013 0.004 0.013 7692 17 1023 CF-503242 16.8 20.6 0.753 0.677 22 30 CF-503240 94 8.5 11 CF-503111 7.2 5.48 0.041 0.034 175 161 CF-503127 7 0.084 0.1 70 CF-503133 5.59 7.08 0.266 0.231 21 30 CF-503134 7.4 7.6 0.09 0.057 82 133 CF-503135 9.12 13.5 0.45 0.386 20 35 CF-503136 10.4 0.925 11 CF-503137 12.6 10.6 0.078 0.064 161 165 CF-503138 11.8 10.5 0.169 0.085 70 123 CF-503139 12.8 10.26 0.089 0.148 144 69 CF-503140 6.13 0.379 16 CF-503141 4.9 0.368 13 CF-503142 8.13 0.65 12 CF-503143 6.47 0.494 13 CF-503144 28.2 1.904 15 CF-503145 15.2 10 1.5 CF-503146 2.41 0.163 15 CF-503147 6.36 9.66 10.7 15.1 . . 8.73 0.049 0.053 0.037 0.032 . . 0.045 130 182 289 471 . . 194 CF-503148 17.45 0.906 19 CF-503149 18.95 23.5 0.136 0.118 139 199 CF-503150 16.77 13.7 53.1 9.3 10.6 50 0.047 0.045 0.05 0.069 0.059 0.042 357 304 1062 134 179 1190 CF-503185 proposed enantiomer of CF-503150 8.96 50 0.636 0.42 14 119 CF-503151 9.9 11.4 0.9 CF-503152 10.97 9.7 0.184 0.127 60 76 CF-503153 29.4 19.78 0.029 0.053 1013 373 CF-503154 13.9 11.8 0.116 0.202 119 58 CF-503155 8.4 0.125 67 CF-503156 16.6 0.088 188 CF-503157 7.5 9.66 1.066 0.691 7 14 CF-503158 5.3 8.5 0.027 0.022 196 386 CF-503159 10.4 3.47 3 CF-503160 10.3 0.796 13 CF-503161 16.7 3.34 5 CF-503162 6.3 5.7 0.173 0.128 36 44 CF-503163 16.49 3.5 5 CF-503183 10.14 9.7 10 0.224 0.242 0.124 45 40 80 CF-503184 10.7 2.6 4 CF-503175 4.59 5.46 4.6 5.6 1 1 CF-503201 8.5 >8 8.4 >8 1 1 CF-503202 8.5 9.12 8.32 8.8 1 1 CF-503189 7.61 10.24 7.38 8.04 1 1.3 CF-503190 17.32 2.66 7 CF-503191 10.35 0.456 23 CF-503192 15.56 4.9 3 CF-503193 17.6 0.647 27 CF-503197 7.28 1.11 7 CF-503198 7.25 1.57 5 CF-503199 10.47 1 10 CF-503200 14.87 0.919 16 CF-503204 11.65 0.098 119 CF-503206 6.16 0.506 12 CF-503210 15.18 0.407 37 CF-503212 4.87 0.346 14 CF-503213 4.49 4.43 0.033 0.029 136 153 CF-503214 10.18 0.667 15 CF-503216 14.8 14.47 0.296 0.333 50 43 CF-503217 6.85 8.99 0.127 0.835 54 11 CF-503218 2.78 3.18 0.136 0.168 20 19 CF-503219 4.06 4.5 0.793 0.84 5 5 CF-503222 11.24 12.33 11.7 0.015 0.029 0.041 749 425 285 CF-503223 10.62 10.18 0.028 0.033 379 308 CF-503225 16.16 16.86 0.097 0.118 197 143 CF-503227 4.83 6.49 0.079 0.081 61 80 CF-503230 17.8 8.6 0.4 0.52 44 17 CF-503229 5 6 1 CF-503274 7.09 0.069 103 CF-503304 9.36 9.4 0.359 0.327 26 29 CF-503291 2.64 3.39 0.007 0.006 377 565 CF-503292 4.95 9.23 8.19 8.6 0.657 4.6 0.522 0.561 7.5 2 16 15 CF-503293 4.06 11.58 19.08 36.7 0.095 2.21 0.047 0.035 43 5 406 1049 CF-503318 16.9 0.112 150 CF-503319 4.2 0.32 13 CF-503321 4.5 5.2 0.271 0.374 17 14 CF-503356 6.4 6.4 1 CF-503357 1.9 0.26 7 CF-503360 1.12 1.43 1.42 1.44 0.125 0.19 0.353 0.361 9 7 4 4 8.14 0.051 160 CF-503373 37.7 2.3 1.72 0.011 0.023 0.021 3427 100 82 CF-503381 2.47 2.7 0.041 0.036 60 75 12.34 0.166 74 CF-503390 5.5 2.72 0.121 0.088 45 31 CF-503417 3.6 2.99 1.35 1.77 3 2 CF-503419 1.36 1.2 0.257 0.319 5 4 CF-503363 8 0.0507 158 CF-503382 12 0.166 72 CF-503445 1.19 1.18 1 CF-503451 3.33 3.7 0.176 0.184 19 20 CF-503453 4.45 4.69 1 CF-503454 3 0.765 4 CF-503457 5.03 2.36 2 CF-503458 13.44 1.24 0.007 0.011 1920 112 CF-503459 27.4 2.1 0.013 0.02 2107 105 CF-503460 17.2 0.272 63 CF-503461 5.8 8.2 0.068 0.075 85 109 CF-503462 14.8 0.12 123 CF-503463 2.5 1.14 2 CF-503464 4.41 1.26 0.01 0.019 441 66 CF-503465 7.62 1.92 0.025 0.032 305 60 CF-503474 5.65 0.014 404 CF-503475 4.77 0.034 140 CF-503476 7.26 2.49 3 CF-503477 2.29 2.05 1 - The results of the 20S proteasome inhibitor assays are presented in Table 3.
-
TABLE 3 IC50 of Compounds Against Human Constitutive (Hu C-20S) β5 Active Subunit ID Formula Hu-C20S β5 (μM) CEN-1 14.2 CEN-2 16.9 CEN-3 10.6 CEN-4 6 .4 CEN-5 2 .5 CEN-6 7.1 CEN-7 4.2 CEN-8 3.6 CEN-9 4.4 CEN-10 37.7 CEN-11 19.2 CEN-12 3.0 CEN-13 11.2 CEN-14 4.5 CEN-15 5.0 CEN-16 4.5 CEN-17 13.4 CEN-18 9.5 CEN-19 1.1 CEN-20 2.6 CEN-21 9.4 CEN-22 1.2 CEN-23 5.8 CEN-24 17.8 CEN-25 8.1 CEN-26 3.3 CEN-27 1.4 CEN-28 14.8 CEN-29 6.9 CEN-30 4.5 CEN-31 17.6 CEN-32 23.5 CEN-33 16.5 CEN-34 15.6 CEN-35 19.6 CEN-36 17.5 CEN-37 17.3 CEN-38 16.2 CEN-39 7.6 CEN-40 2.7 CEN-41 4.8 CEN-42 27.4 CEN-43 13.8 CEN-44 0.9 CEN-45 4.1 CEN-46 8.4 CEN-47 29.4 CEN-48 50.0 CEN-49 50.0 CEN-50 14.8 CEN-51 15.0 CEN-52 7.5 CEN-53 9.7 CEN-54 16.6 CEN-55 12.3 CEN-56 17.2 CEN-57 28.0 CEN-58 13.9 CEN-59 10.0 CEN-60 10.7 CEN-61 8.8 CEN-62 2.4 CEN-63 6.8 CEN-64 2.4 CEN-65 >100.0 CEN-66 >100.0 CEN-67 >100.0 CEN-68 >100.0 CEN-69 >100.0 CEN-70 >100.0 CEN-71 >100.0 CEN-72 >100.0 CEN-73 >100.0 CEN-74 94.0 CEN-75 >100.0 CEN-76 14.2 CEN-77 10.4 CEN-78 14.9 CEN-79 7.3 CEN-80 16.7 CEN-81 10.5 CEN-82 2.4 CEN-83 10.3 CEN-84 7.3 CEN-85 9.9 CEN-86 28.2 CEN-87 11.7 CEN-88 15.1 CEN-89 5.7 CEN-90 10.2 CEN-91 10.5 CEN-92 15.2 CEN-93 10.9 CEN-94 5.5 CEN-95 2.3 CEN-96 5.7 CEN-97 4.8 CEN-98 7.1 CEN-99 8.5 CEN-100 4.4 CEN-101 7.6 CEN-102 10.2 CEN-103 15.2 CEN-104 4.9 CEN-105 3.9 CEN-106 12.8 CEN-107 2.8 CEN-108 6.2 CEN-109 7.3 CEN-110 8.1 CEN-111 4.9 CEN-112 6.1 CEN-113 6.5 CEN-114 9.7 CEN-115 >100.0 CEN-116 9.5 CEN-117 11.0 CEN-118 15.8 CEN-119 18.0 CEN-120 >100.0 CEN-121 10.6 CEN-122 13.5 CEN-123 7.4 CEN-124 10.4 CEN-125 20.6 - Although preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions, and the like can be made without departing from the spirit of the invention and these are therefore considered to be within the scope of the invention as defined in the claims which follow.
Claims (21)
1.-48. (canceled)
49. A method of treating bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy, in a subject or for achieving immunosuppression in transplanted organs or tissues in a subject, said method comprising:
administering to the subject in need thereof a compound of Formula (I):
wherein
R is H or C1-6 alkyl;
R′ is H or C1-6 alkyl;
R1 is H or C1-6 alkyl;
or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
R2 is independently selected at each occurrence thereof from
or —(CH2)nC(O)NR6R7;
R3 is independently selected at each occurrence thereof from the group consisting of H, C1-12 alkyl, -Boc, —C(O)(CH2)nR5, —(CH2)nC(O)R5, —C(O)OR5, —C(O)(CH2)nNR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
R4 is H, halogen, NH2, NHCOOC1-12 alkyl, or C1-12 alkyl;
R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
R10 is H or arylalkyl;
W is CHR2, NR2, or
X is selected from the group consisting of —C(O)—NH—, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle;
Y is optional and, if present, is —(CH2)m—;
Z is optional and, if present, is aryl or bicyclic heteroaryl;
is the point of attachment to NHR3 moiety;
is the point of attachment to C(O) moiety;
k is 1 or 2;
m is 0, 1, or 2; and
n is 0, 1, 2, 3, or 4,
with the proviso that R2 is not —CH2C(O)NH2, —CH2C(O)NHCH2C(CH3)3, or —(CH2)2C(O)NH2,
or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof.
56. The method of claim 49 , wherein a bacterial infection is treated, said bacterial infection being Mycobacterium tuberculosis.
57. The method of claim 49 , wherein a parasite infection is treated, said parasite infection being malaria, leishmaniasis, river blindness, Chagas disease, or sleeping disease.
58. The method of claim 49 , wherein a parasite infection is treated, said parasite infection being cryptosporidiosis, amebiasis, cyclosporiasis, giardiasis, or toxoplasmosis.
59. The method of claim 49 , wherein a parasite infection is treated, said parasite infection being veterinary parasite infection.
60. The method of claim 59 , wherein a veterinary parasite infection is caused by protozoan parasites, helminth parasites, arachnids, insects, or custaceans.
61. The method of claim 49 , wherein an autoimmune disorder is treated, said autoimmune disorder being selected from the group consisting of arthritis, colitis, multiple sclerosis, lupus, Sjogren Syndrome, Systemic Lupus Erythematosus and lupus nephritis, glomerulonephritis, Rheumatoid Arthritis, Inflammatory bowel disease (IBD), ulcerative colitis, Crohn's diseases, Psoriasis, and asthma.
62. The method of claim 49 , wherein immunosuppression is provided for transplanted organs or tissues, said immunosuppression being used to prevent transplant rejection and graft-verse-host disease.
63. The method of claim 49 , wherein an inflammatory disorder is treated, said inflammatory disorder being Crohn's disease.
64. The method of claim 49 , wherein cancer is treated, said cancer being selected from the group consisting of neoplastic disorders, hematologic malignances, lymphocytic malignancies, mantel cell lymphoma, leukemia, Waldenstrom Macroglobulinemia, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, metastatic breast cancer, prostate cancer, androgen-dependent and androgen-independent prostate cancer, renal cancer, metastatic renal cell carcinoma, hepatocellular cancer, lung cancer, non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and adenocarcinoma of the lung, ovarian cancer, progressive epithelial or primary peritoneal cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, squamous cell carcinoma of the head and neck, melanoma, neuroendocrine cancer, metastatic neuroendocrine tumors, brain tumors, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma, bone cancer, and soft tissue sarcoma.
65. The method of claim 49 , wherein a neurodegenerative disease or disorder is treated, said neurodegenerative disease or disorder being Amyotrophic Lateral Sclerosis (ALS).
66. The method of claim 49 , wherein a neurodegenerative disease or disorder is treated, said neurodegenerative disease or disorder being Multiple Sclerosis (MS).
67. A method of inhibiting proteasome activity, said method comprising:
contacting a proteasome with a compound of Formula (I):
wherein
R is H or C1-6 alkyl;
R′ is H or C1-6 alkyl;
R1 is H or C1-6 alkyl;
or R and R1 are taken together with the carbon to which they are attached to form a C3-8 cycloalkyl ring;
R2 is independently selected at each occurrence thereof from
or —(CH2)nC(O)NR6R7;
R3 is independently selected at each occurrence thereof from the group consisting of H, C1-12 alkyl, -Boc, —C(O)(CH2)nR5, —(CH2)nC(O)R5, —C(O)OR5, —C(O)(CH2)nNR6R7, —S(O)2R5, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
R4 is H, halogen, NH2, NHCOOC1-12 alkyl, or C1-12 alkyl;
R5 is selected from the group consisting of C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle, wherein C1-12 alkyl, monocyclic or bicyclic C3-10 cycloalkyl, C3-12 cycloalkylalkyl, C1-12 alkoxy, monocyclic and bicyclic aryl, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle can be optionally substituted from 1 to 3 times with R8;
R6, R7 are each independently selected from the group consisting of H, C1-6 alkyl, and arylalkyl;
or R6 and R7 are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, or morpholine ring, wherein piperidine, pyrrolidine, azepane, or morpholine ring can be optionally substituted 1 to 3 times with R9;
R8 is selected independently at each occurrence thereof from the group consisting of halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl, wherein C1-6 alkyl, C3-8 cycloalkyl, aryl, and arylalkyl can be optionally substituted 1 to 3 times with R9;
R9 is selected from the group consisting of H, halogen, C1-6 alkyl, C3-8 cycloalkyl, and aryl, wherein C1-6 alkyl can be optionally substituted 1 to 3 times with halogen;
R10 is H or arylalkyl;
W is CHR2, NR2, or
X is selected from the group consisting of —C(O)—NH—, monocyclic and bicyclic heteroaryl, monocyclic and bicyclic heterocyclyl, and monocyclic and bicyclic non-aromatic heterocycle;
Y is optional and, if present, is —(CH2)m—;
Z is optional and, if present, is aryl or bicyclic heteroaryl;
is the point of attachment to NHR3 moiety;
is the point of attachment to C(O) moiety;
k is 1 or 2;
m is 0, 1, or 2; and
n is 0, 1, 2, 3, or 4,
with the proviso that R2 is not —CH2C(O)NH2, —CH2C(O)NHCH2C(CH3)3, or —(CH2)2C(O)NH2,
or an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof; under conditions effective to inhibit proteasome activity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/521,328 US11732005B2 (en) | 2017-10-11 | 2021-11-08 | Peptidomimetic proteasome inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762571146P | 2017-10-11 | 2017-10-11 | |
PCT/US2018/055482 WO2019075252A1 (en) | 2017-10-11 | 2018-10-11 | Peptidomimetic proteasome inhibitors |
US202016755427A | 2020-04-10 | 2020-04-10 | |
US17/521,328 US11732005B2 (en) | 2017-10-11 | 2021-11-08 | Peptidomimetic proteasome inhibitors |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/755,427 Division US11203613B2 (en) | 2017-10-11 | 2018-10-11 | Peptidomimetic proteasome inhibitors |
PCT/US2018/055482 Division WO2019075252A1 (en) | 2017-10-11 | 2018-10-11 | Peptidomimetic proteasome inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
US20220056073A1 true US20220056073A1 (en) | 2022-02-24 |
US11732005B2 US11732005B2 (en) | 2023-08-22 |
Family
ID=66101028
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/755,427 Active US11203613B2 (en) | 2017-10-11 | 2018-10-11 | Peptidomimetic proteasome inhibitors |
US17/521,328 Active US11732005B2 (en) | 2017-10-11 | 2021-11-08 | Peptidomimetic proteasome inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/755,427 Active US11203613B2 (en) | 2017-10-11 | 2018-10-11 | Peptidomimetic proteasome inhibitors |
Country Status (3)
Country | Link |
---|---|
US (2) | US11203613B2 (en) |
EP (1) | EP3694605A4 (en) |
WO (1) | WO2019075252A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE49816E1 (en) | 2014-01-10 | 2024-01-30 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
US12016896B2 (en) | 2014-08-18 | 2024-06-25 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3362754B1 (en) | 2015-10-15 | 2021-12-22 | Cornell University | Proteasome inhibitors and uses thereof |
WO2019075252A1 (en) | 2017-10-11 | 2019-04-18 | Cornell University | Peptidomimetic proteasome inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW223629B (en) | 1992-03-06 | 1994-05-11 | Hoffmann La Roche | |
US7001921B1 (en) * | 1995-01-23 | 2006-02-21 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
AR011515A1 (en) | 1996-12-25 | 2000-08-30 | Agrogene Ltd | DERIVED FROM AMINOBUTIRIC ACID FOR THE PROTECTION OF PLANTS FROM FUNGAL DISEASES AND A METHOD TO PROTECT A CROP AGAINST FUNGAL DISEASES, FOR EXAMPLE, TOMATOES AND POTATOES AGAINST LATE, EARLY MILK, VINEYARD ELVIO, AND |
US7569724B2 (en) | 2000-09-29 | 2009-08-04 | Topotarget Uk Limited | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors |
US7244743B2 (en) | 2002-06-05 | 2007-07-17 | Solvay Pharmaceuticals Gmbh | Non-peptidic BRS-3 agonists |
KR100973451B1 (en) * | 2002-09-13 | 2010-08-02 | 유겐가이샤 오가 리서치 | Melanin extinguisher |
TWI334868B (en) | 2003-06-03 | 2010-12-21 | Nippon Kayaku Kk | [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof |
EP1770085A4 (en) | 2004-07-21 | 2010-09-22 | Mitsui Chemicals Agro Inc | Diamine derivative, process for producing the same and fungicide containing the derivative as active ingredient |
TW200621223A (en) | 2004-09-07 | 2006-07-01 | Smithkline Beecham Corp | Acyclic 1,3-diamines and uses therefor |
WO2006065826A2 (en) | 2004-12-15 | 2006-06-22 | Merck & Co., Inc. | Process to chiral beta amino acid derivatives by asymmetric hydrogenation |
WO2006099261A2 (en) | 2005-03-11 | 2006-09-21 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
JP2006298785A (en) | 2005-04-18 | 2006-11-02 | Mitsui Chemicals Inc | Diamine derivative, its manufacturing method and bactericide having the same as active ingredient |
WO2007067629A1 (en) | 2005-12-07 | 2007-06-14 | Amgen Inc. | Bradykinin 1 receptor antagonists |
WO2007083394A1 (en) | 2006-01-19 | 2007-07-26 | Mitsui Chemicals, Inc. | Pest control composition containing diamine derivative |
PL2041158T3 (en) | 2006-06-19 | 2013-08-30 | Onyx Therapeutics Inc | Peptide epoxyketones for proteasome inhibition |
DE102007025718A1 (en) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | pyridazinone derivatives |
WO2009035020A1 (en) | 2007-09-11 | 2009-03-19 | Tokyo University Of Science Educational Foundation Administrative Organization | Novel dihydronaphthalene compound and use thereof |
JP5600595B2 (en) | 2007-10-16 | 2014-10-01 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Proteasome inhibitor |
AR075090A1 (en) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. |
WO2010038200A1 (en) * | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
BR112012022060A2 (en) | 2010-03-01 | 2018-05-08 | Onyx Therapeutics Inc | compound for inhibition of immunoproteasome |
JP5933523B2 (en) | 2010-03-31 | 2016-06-08 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
EP2487152A1 (en) | 2010-11-17 | 2012-08-15 | UCB Pharma GmbH | Process for the preparation of Lacosamide including resolution of O-methyl-DL-serine |
CA2828456C (en) * | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | N-benzl-amino-carboxamide inhibitors of the sodium channel |
WO2012129112A2 (en) | 2011-03-18 | 2012-09-27 | Catabasis Pharmaceuticals, Inc. | Use of intracellular enzymes for the release of covalently linked bioactives |
CN102807601B (en) | 2011-06-03 | 2014-02-26 | 首都医科大学 | Aminoacyl-tryptophanyl-5-methoxytryptamine and preparation method and application thereof |
GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
CA2860142C (en) | 2011-12-22 | 2020-10-27 | Ares Trading S.A. | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
JP2014091731A (en) | 2012-11-06 | 2014-05-19 | Kobe Gakuin | Peptide compound from novel somatostatin, and dna polymerase inhibitor, anticancer agent and apoptosis-inducing agent comprising the same |
CA2895150C (en) | 2012-12-21 | 2019-11-26 | F. Hoffmann-La Roche Ag | Peptides as oxytocin agonists |
JP6468562B2 (en) | 2013-11-21 | 2019-02-13 | 国立大学法人北海道大学 | Proteasome inhibitory compounds |
USRE49816E1 (en) | 2014-01-10 | 2024-01-30 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
US11202817B2 (en) | 2014-08-18 | 2021-12-21 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
EP3362754B1 (en) | 2015-10-15 | 2021-12-22 | Cornell University | Proteasome inhibitors and uses thereof |
WO2019075252A1 (en) | 2017-10-11 | 2019-04-18 | Cornell University | Peptidomimetic proteasome inhibitors |
-
2018
- 2018-10-11 WO PCT/US2018/055482 patent/WO2019075252A1/en unknown
- 2018-10-11 US US16/755,427 patent/US11203613B2/en active Active
- 2018-10-11 EP EP18867283.6A patent/EP3694605A4/en active Pending
-
2021
- 2021-11-08 US US17/521,328 patent/US11732005B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE49816E1 (en) | 2014-01-10 | 2024-01-30 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
US12016896B2 (en) | 2014-08-18 | 2024-06-25 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
Also Published As
Publication number | Publication date |
---|---|
WO2019075252A1 (en) | 2019-04-18 |
EP3694605A1 (en) | 2020-08-19 |
US11732005B2 (en) | 2023-08-22 |
EP3694605A4 (en) | 2021-10-27 |
US11203613B2 (en) | 2021-12-21 |
US20200317729A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11732005B2 (en) | Peptidomimetic proteasome inhibitors | |
US11629141B2 (en) | Proteasome inhibitors and uses thereof | |
US20210145832A1 (en) | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | |
US20220153722A1 (en) | Cdk2/5 degraders and uses thereof | |
AU2006226554B2 (en) | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | |
US9988421B2 (en) | Dipeptides as inhibitors of human immunoproteasomes | |
US9994577B2 (en) | Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity | |
US20220080022A1 (en) | Dipeptidomimetics as inhibitors of human immunoproteasomes | |
US20230158157A1 (en) | Potent and selective degraders of alk | |
US20220378919A1 (en) | Erk5 degraders as therapeutics in cancer and inflammatory diseases | |
US20240043470A1 (en) | Macrocyclic compounds as proteasome inhibitors | |
US20150368226A1 (en) | Piperidinylcarbazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction |